WO2016116900A1 - Inhibitors of trka kinase - Google Patents

Inhibitors of trka kinase Download PDF

Info

Publication number
WO2016116900A1
WO2016116900A1 PCT/IB2016/050328 IB2016050328W WO2016116900A1 WO 2016116900 A1 WO2016116900 A1 WO 2016116900A1 IB 2016050328 W IB2016050328 W IB 2016050328W WO 2016116900 A1 WO2016116900 A1 WO 2016116900A1
Authority
WO
WIPO (PCT)
Prior art keywords
urea
methoxyethyl
phenylpyrrolidin
alkyl
methyl
Prior art date
Application number
PCT/IB2016/050328
Other languages
French (fr)
Inventor
Kumaragurubaran NAGASWAMY
Vijaya G TIRUNAGARU
Original Assignee
Gvk Biosciences Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gvk Biosciences Private Limited filed Critical Gvk Biosciences Private Limited
Priority to BR112017015760-8A priority Critical patent/BR112017015760A2/en
Priority to CN201680017646.8A priority patent/CN107531589A/en
Priority to EP16739869.2A priority patent/EP3247692B1/en
Priority to CA2974784A priority patent/CA2974784A1/en
Priority to JP2017557507A priority patent/JP6706630B2/en
Priority to US15/545,061 priority patent/US10336723B2/en
Priority to RU2017129757A priority patent/RU2017129757A/en
Priority to AU2016210544A priority patent/AU2016210544B2/en
Publication of WO2016116900A1 publication Critical patent/WO2016116900A1/en
Priority to AU2020223776A priority patent/AU2020223776A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Definitions

  • the present invention relates to novel compounds that act as inhibitors of the members of Trk family protein kinases. Particularly, the invention discloses compounds possessing inhibitory activity against TrkA.
  • NSAID Non-steroidal anti-inflammatory drugs
  • opioids Most NSAIDs have one or more side effects such as irritation of the gastrointestinal (Gl) tract leading to Nausea/Vomiting, Gastric ulceration/bleeding, Dyspepsia, inflammatory bowel disease, altered renal function, deleterious effects on the cardiovascular system and many more.
  • Opioids result in emetic, constipatory and negative respiratory effects, as well as the potential for addiction.
  • drugs that alleviate pain without the adverse effects caused by the current pain therapies.
  • Trks and neurotrophins are well known for their effects on neuronal growth and survival through their regulation of cell proliferation, differentiation, apoptosis, and survival of neurons in both the central and peripheral nervous systems.
  • Trk kinases, with three highly homologous isoforms, TrkA, TrkB, and TrkC are activated by high affinity growth factors named neurotrophins with Nerve growth factor (NGF), which activates TrkA; brain-derived neurotrophic factor (BDNF) and NT-4/5, which activate TrkB; and NT-3, which activates TrkC.
  • NGF Nerve growth factor
  • BDNF brain-derived neurotrophic factor
  • NT-4/5 which activate TrkB
  • Trk-3 which activates TrkC.
  • Trk kinase The binding of neurotrophins to the extracellular domain of Trks causes the Trk kinase to autophosphorylate at several intracellular tyrosine sites and triggers downstream signal transduction pathways such as PI3K, Ras and PLC- ⁇ pathways (Molecules 2015, 20(6), 10657-10688).
  • NGF signaling via TrkA is recognized to play an important role in pain sensation. Genetic studies in humans with TrkA loss of function mutations have provided evidence of the significant role of NGF signaling in pain sensation (ClinAuton Res 2002; 12 Suppl 1 : 120 -32). Currently, novel pain treatments are highly desired due to low efficacy and/or undesirable gastrointestinal, renal and psychotropic side effects of NSAIDS and opiates. NGF expression is increased in various pain conditions and administration of NGF increases pain sensitivity. Inhibition of NGF signaling via TrkA using a variety of antibody and small molecule based approaches have been shown to be effective in preclinical animal models for pain (Anesthesiology. 201 1 Jul; 115(1):189-204).
  • TrkA inhibition demonstrated equivalent efficacy to nonselective Trk inhibitors. Intermittent TrkA inhibition using a small molecule results in comparable efficacy to NGF antibodies in pain models (Andrews IASP, 2012). NGF mab, Tanezumab demonstrated excellent clinical efficacy in Osteoarthritis, chronic low back pain and diabetic peripheral neuropathy. TrkA selective small molecule inhibitors have therapeutic utility for various pain conditions. Efficacy of Anti- TrkA antibodies and anti-NGF antibodies for treatment of inflammatory and neuropathic pain have been demonstrated in vivo models in WO2006/131952 and WO2005/061540.
  • Trks play key role in malignant transformation, chemotaxis, metastasis, and survival signaling in human tumors (Cancer Lett 2001 ; 169: 107-14). Oncogenic activation of TRKA occurs through genomic rearrangement and the creation of a gene fusion where extracellular domain of TrkA is replaced by fusion with another gene with the kinase domain intactresults in constitutive activation of TrkA pathway.
  • NTRK1 gene fusions have been reported in a variety of cancers such as NSCLC, spitz melanoma, colorectal cancer, cholangiocarcinoma, soft tissue sarcoma, glioblastoma and papillary thyroid carcinoma (Cancer Discovery January 1 , 2015 5; 25) with more new fusions being reported based on the NGS sequencing of patient DNA.
  • Trk inhibitors such as Entrectinib and LOXO-101 have demonstrated significant tumor regression in patients with Trk fusions (Cancer Discov. 2015 Oct;5(10): 1049-57, J Natl Cancer Inst. 2015 Nov 12; 108(1)).
  • TrkA and TrkC wild-type receptors are associated with a positive prognosis in patients with neuroblastoma (excluding expression of the splice variant TRKAIII) (N Engl J Med. 1993 Mar 25;328(12):847-54).
  • TrkA inhibitors have potential for cancers driven by activated TrkA signaling due to molecular alterations or autocrine/paracrine signalling due to increased expression of TrkA and/or NGF.
  • TrkA is expressed in the bone forming area in mouse models of bone fracture (Bone. 2000 Jun; 26(6):625-33) and Trk inhibitors induce apoptosis of proliferating osteoblasts (Cancer Res. 2002 Feb 15; 62(4):986-9) suggesting use of Trk inhibitors for bone remodelling diseases such as bone metastases in cancer patients.
  • NGF and TrkA are expressed in immune cells and a localized increase in NGF at the sites of inflammation is observed during the inflammatory process.
  • Inflammatory cytokines such as IL-1 beta, TNF-alpha and IL-6 are able to modify the basal production of NGF in the organism and induce the synthesis of NGF in a variety of cell types and tissues.
  • TrkA-NGF pathway is also involved in a number of disorders such as Osteoarthritis, Multiple Sclerosis (J Clinlmmunol.
  • TrkA kinase inhibition can be used as a new methodology for the treatment of these diseases.
  • Trk kinases are also involved in skin diseases like atopic dermatitis (Archives of Dermatological Research 2006, 298(1), 31-37), Eczema, Psoriasis (J. Investigative Dermatology 2004, 122(3), 812-819), Pruritis (Acta Derm Venereol 2015; 95: 542-548), restenosis and Atherosclerosis. TrkA inhibition is also implicated for the treatment of fibrotic disorders based on the ability of Connective Tissue Growth Factor (CTGF) to activate TrkA signaling (Fibrogenesis Tissue Repair. 2012 Jun 6; 5(Suppl 1):S24). TrkA inhibitors may also be useful in treatment of endometriosis (Reprod Sci.
  • CTGF Connective Tissue Growth Factor
  • TrkA pathway offers promising approaches for the treatment of a variety of diseases dependent on hyperactivation of TrkA pathway.
  • the invention provides to the compounds of Formula I which are inhibitors of tropomyosin-related kinase A (TrkA):
  • Ra, Rb, Rc, Rd, R1 , R2, L and Het-Ar are as defined herein.
  • the invention further provides for the pharmaceutical compositions which include an effective amount of a compound of formula I , or stereoisomers, tautomers or pharmaceutically acceptable salts, solvates, metabolites, isotopes or prodrugs thereof, and a pharmaceutically acceptable carrier.
  • the invention further provides to the use of pharmaceutical compositions for the treatment and/or prevention of diseases associated with abnormal or deregulated TrkA kinase activity in a patient in need thereof, like Pain, Inflammation or inflammatory diseases, Cancer, Atherosclerosis, Restenosis, Thrombosis, Neurodegenerative diseases like Alzheimer's Disease, Huntington's disease or Progressive supranuclear palsy, Erectile Dysfunction (ED), Skin disorders like Atopic Dermatitis, Eczema, Pruritis or Psoriasis, Autoimmune diseases like Multiple sclerosis, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, Infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth
  • the invention further provides for a method for treating a disease or disorder mediated by the Trk receptors or associated with abnormal or deregulated TrkA kinase activity wherein said disease or disorder is selected from the group consisting of Pain, inflammation or inflammatory diseases, Cancer, atherosclerosis, restenosis, thrombosis, Neurodegenerative diseases, Erectile Dysfunction (ED), Skin disorders, Autoimmune disease, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, Infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk A in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically
  • the invention further provides a method for treating a disease or a disorder modulated by TrkA or in which the NGF receptor TrkA kinases are involved.
  • the method further comprises administering to a patient, in need thereof, a therapeutically effective amount of a compound of this invention or their stereoisomers, tautomers, or pharmaceutically acceptable salts, isotopes, metabolites, solvates or prodrugs.
  • the invention further provides intermediates required for synthesis of the compounds of Formula I.
  • the invention further provides for a method of synthesis, separation, and purification of the compounds of the invention.
  • the invention further provides the use of novel compounds of Formula I which act as TrkA inhibitor and/or antagonist for the preparation of a medicament useful in the treatment of disorders like Pain, Inflammation or inflammatory diseases, Cancer, Atherosclerosis, Restenosis, Thrombosis, Neurodegenerative diseases like Alzheimer's Disease, Parkinson's disease, Huntington's disease or Progressive supranuclear palsy, Erectile Dysfunction (ED), Skin disorders like Atopic Dermatitis, Eczema, Pruritis or Psoriasis, Autoimmune diseases like Multiple sclerosis, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, Infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor
  • alkyl by itself or as part of another substituent, refers to linear or branched alkyl group with 1 to 10 carbon atoms.
  • alkenyl by itself or as part of another substituent, means a straight or branched chain hydrocarbon radical having a single carbon-carbon double bond
  • Alkoxy group refers to an— O(alkyl) group, wherein alkyl group is as defined above.
  • Alkynyl refers to hydrocarbon chain which is straight or branched and contains at least one degree of unsaturation, i.e., at least one carbon-carbon triple bond.
  • Halogen or Halo represents fluorine, chlorine, bromine, or iodine.
  • Haloalkyl means at least one halogen atom is substituted on an alkyl group. Both halogen and alkyl have the meaning as defined above.
  • Hydroxy' or 'Hydroxyl represents— OH.
  • Hydroxyalkyl means at least one hydrogen atom of an alkyl group is replaced by a hydroxyl group. Alkyl group is as defined above.
  • Haloalkoxy means at least one halogen atom is substituted on an alkoxy group, wherein alkoxy and halogen groups are as defined above.
  • 3-10 membered heterocyclic ring refers to a monocyclic or polycyclic ring system, saturated or unsaturated or aromatic; containing one nitrogen atom and optionally 1-3 additional heteroatoms or heterogroups independently selected from O, S, N, CO, SO, or SO2.
  • hetero-aromatic ring or “Het-Ar ring” is understood to encompass any heterocyclic aromatic ring having 5 or 6 atoms, containing one or more independent hetero-atoms selected from nitrogen, oxygen and sulfur. It should be noted that a hetero-atom may be positioned on any position on the fused 5 to 6 membered hetero- aromatic ring formed.
  • cycloalkyl denotes a saturated carbocyclic ring containing 3 to 6 carbon atoms.
  • heteroatom refers to a sulfur, nitrogen, or oxygen atom.
  • aminocarbonyl refers to a monovalent group of formula -(CO)N(R2)2 where each R2 is independently hydrogen or alkyl.
  • Aryl refers to monocyclic or polycyclic aromatic ring system. Exemplary aryl groups include, but are not limited to, phenyl, naphthyl, and the like.
  • heterocyclyl represents a stable 5- to 7-membered monocyclic or stable 8- to 11-membered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, or S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring
  • carbocyclic ring refers to a saturated or non- aromatic unsaturated ring.
  • 3-6-membered carbocyclic ring refers to a carbocyclic ring wherein the number of ring carbon atoms is from 3 to 6.
  • cyano refers to a substituent having a carbon atom joined to a nitrogen atom by a triple bond.
  • nitro refers to the group— N0 2 .
  • amino refers to the group— NH2
  • Carbonyl refers to the divalent group— C(O)-.
  • cyano (1-3Calkyl) denotes an alkyl group as defined above wherein a hydrogen atom of the alkyl group is replaced by a cyano (-CN) group.
  • Ligand denotes a linker molecule or ligand molecule.
  • exemplary Ligand or linker molecules include, but not limited to — O— , — NH— , — S0 2 N(R')— , — C(0)N(R')— ; — N(R')C(0)— , — C(0)N(R')C(0)— , — N(R')S0 2 — , — N(R')S0 2 N(R')— , — NR'C(0)N(R')— , — NR'C(S)N(R')— , or— N(R')C(0)0— .
  • heteroaryl represents a stable 5- to 7-membered monocyclic- or stable 9- to 10- membered fused bicyclic heterocyclic ring system which contains an aromatic ring, any ring of which may be saturated, partially saturated, or unsaturated and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S.
  • substituted alkyl, substituted aryl, substituted heteroaryl, and substituted heterocycle include moieties containing from 1 to 3 substituents in addition to the point of attachment to the rest of the compound.
  • Optionally substituted means that the substitution is optional and therefore it is possible for the designated atom or group to be unsubstituted. When more than one substituent is present on an atom or group, the chosen substituents are independent of each other (i.e. same or different).
  • stereoisomers is a general term used for all isomers of an individual molecule that differ only in the orientation of their atoms in space. It is to be understood that all stereoisomeric forms of the compounds of the invention, including but not limited to, diastereomers, enantiomers and atropsiomers, as well as mixtures thereof such as forms, are included in the scope of the present application.
  • tautomer refers to the coexistence of two (or more) compounds that differ from each other only in the position of one (or more) mobile atoms and in electron distribution, for example, keto-enol tautomers.
  • pharmaceutically acceptable refers to the carrier, diluent, salts, solvates or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the term "metabolite” as used herein refers to the formula of any derivative produced in a subject after administration of a parent compound.
  • the derivatives may be produced from the parent compound by various biochemical transformations in the subject such as, for example, oxidation, reduction, hydrolysis, or conjugation and include, for example, oxides and demethylated derivatives.
  • prodrug refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood as well as the zwitterionic forms of the compounds of the invention
  • the term 'a therapeutically effective amount' refers to the amount of the compound of the present invention that, when administered to a subject, is effective in (i) at least partially alleviating, inhibiting, preventing and/or ameliorating a condition, or a disorder or a disease mediated by TrkA, TrkB and/or TrkC, associated with TrkA, TrkB and/or TrkC activity or characterized by activity (normal or abnormal) of TrkA, TrkB and/or TrkC; (ii) reducing or inhibiting the activity of TrkA, TrkB and/or TrkC; or (iii) reducing or inhibiting the expression of TrkA, TrkB and/or TrkC.
  • fusion refers to a co-linear, covalent linkage of two or more proteins or fragments thereof via their individual peptide backbones, most preferably through genetic expression of a polynucleotide molecule encoding those proteins.
  • TrkA refers to one of Trk's high affinity binding protein kinase receptors that are activated by Neurotrophins (NT), a group of soluble growth factors Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin 3-5 (NT 3-5).
  • the Trk's are made up of three family members TrkA, TrkB and TrkC that bind to and mediate the signal transduction derived from the Neurotrophins. Inhibitors of the Trk/neutrophin pathway have been demonstrated to be highly effective in numerous pre-clinical animal models of pain.
  • the compounds of the invention are modulators of the Trk receptors, particularly TrkA.
  • the present invention relates to novel compounds that act as inhibitors of the members of Trk family protein kinases. Particularly, the present invention discloses compounds possessing inhibitory activity against TrkA.
  • the compounds of the present invention are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of the aforementioned diseases.
  • Ra and Rb are each independently selected from H, alkyl, alkenyl, alkynyl, haloalkyl, halogen, hydroxy, hydroxyalkyl, alkoxy, haloalkoxy, optionally substituted phenyl, optionally substituted 5-6 membered aromatic ring having 1- 3 heteroatoms selected from O, N, and S or Ra and Rb together forms carbonyl group, optionally substituted phenyl which is further optionally substituted with a halogen;
  • Rc and Rd is H, alkyl, alkenyl, alkynyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, optionally substituted phenyl, optionally substituted 5-6 membered aromatic ring having 1-3 heteroatoms selected from O, N, and S or Rc and Rd together to form a ring (4-6 membered) with or without a hetero atom;
  • R1 is H, alkyl, alkenyl, alkynyl, haloalkyi , hydroxy, alkoxy, haloalkoxy, (1-3C alkoxy)(l-3C)alkyl, (1-4C alkoxycarbonyl) (1-6Calkyl), mono, di, tri halo(1-4C alkyl), (1-3C alkyl)aminocarbonyl, Cyano(1-3C alkyl), (1-3C haloalkoxy)(1- 3C)alkyl, optionally substituted phenyl, 3-6 membered carbocyclic or heterocyclic ring with one or more heteroatom selected from O, N or S and optionally substituted with one or more substituents independently selected from H, alkyl, alkenyl, alkynyl, haloalkyi, halogen, hydroxy, alkoxy, haloalkoxy, nitro or amino, a 9-10 membered bicyclic heteroaryl having 1-3 ring nitrogen atoms
  • R2 and R3 are independently selected from H, alkyl, alkenyl, alkynyl, isopropyl, tert butyl, haloalkyi, halogen, hydroxy, alkoxy, haloalkoxy, optionally substituted phenyl, or optionally substituted 5-6 membered aromatic ring having 1-3 heteroatoms selected from O, N or S or R2 and R3 can be combined to form a ring (5/6-membered) with 1-2 hetero atoms.
  • L is a ligand selected from— O— ,— NH— ,— S0 2 N(R')— ,— C(0)N(R')— ;— N(R')C(0)— , — C(0)N(R')C(0)— , — N(R')S0 2 — , — N(R')S0 2 N(R')— , — NR'C(0)N(R')— ,— NR'C(S)N(R')— , or— N(R')C(0)0— ; each R' is independently selected from H or alkyl;
  • Het-Ar ring is selected from H1 or H2;
  • H1 H2 X1-X7 at each occurrence is a bond, -CR5-, -CH2-or an heteroatom selected from N, O or S;
  • R4, R5 and R6 are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, isopropyl, tert. Butyl, haloalkyi, halogen, mono, di, tri halo(1-4C alkyl) hydroxy, alkoxy, haloalkoxy, cyano, cycloalkyl(3-7 carbon), optionally substituted phenyl, optionally substituted 5-6 membered heterocyclic ring having 1-3 heteroatoms selected from O, N, or S or 3-6 membered carbocyclic ring having one or more heteroatom selected from O, N or S,— NH 2 , — N(H)(alkyl), — N(alkyl) 2 , — N(H)C(0)alkyl, — N(alkyl)C(0)alkyl, — N(H)C(0)0 alkyl, — N(alkyl)C(0)Oalkyl, — N(H)
  • H1 is selected from the group consisting of but not limited to:
  • H1 E H1F JU and R4, R5 are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, isopropyl, tert. Butyl, haloalkyl, halogen, mono, di, tri halo(1-4C alkyl) hydroxy, alkoxy, haloalkoxy, cyano,, cycloalkyl(3-7 carbon), optionally substituted phenyl, optionally substituted 5-6 membered heterocyclic ring having 1-3 heteroatoms selected from O, N, or S or 3-6 membered carbocyclic ring having one or more heteroatom selected from O, N or S,— NH 2 ,— N(H)(alkyl),— N(alkyl) 2 ,— N(H)C(0)alkyl,— N(alkyl)C(0)alkyl, — N(H)C(0)0 alkyl, — N(alkyl)C(0)Oalkyl, — N
  • H2 is selected from the group consisting of but not limited to:
  • H2F and each R6 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, isopropyl, tert. Butyl, haloalkyl, halogen, mono, di, tri halo(1-4C alkyl) hydroxy, alkoxy, haloalkoxy, cyano,, cycloalkyl(3-7 carbon), optionally substituted phenyl, optionally substituted 5-6 membered heterocyclic ring having 1-3 heteroatoms selected from O, N, or S or 3-6 membered carbocyclic ring having one or more heteroatom selected from O, N or S, — NH2, — N(H)(alkyl), — N(alkyl) 2 , — N(H)C(0)alkyl, — N(alkyl)C(0)alkyl, — N(H)C(0)0 alkyl, — N(alkyl)C(0)Oalkyl, — N(H)S
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound selected of the Formula I or physiologically acceptable salts thereof, stereoisomers thereof, solvates thereof or the hydrates thereof, or metabolites thereof or isotopes as an active ingredient.
  • the aforementioned pharmaceutical composition is used for preventive and/or therapeutic treatment of diseases caused by abnormal or deregulated TrkA activity.
  • TrkA activity can be one or more of the following but not limited to Pain, inflammation or inflammatory diseases, Cancer, atherosclerosis, restenosis, thrombosis, Neurodegenerative diseases, Erectile Dysfunction (ED), Skin disorders, Autoimmune disease like Multiple sclerosis, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, Infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
  • NGF nerve growth factor
  • a method for the prevention and/or therapeutic treatment of a disease or a disorder selected from the group comprising of Pain, inflammation or inflammatory diseases, Cancer, atherosclerosis, restenosis, thrombosis, Neurodegenerative diseases, Erectile Dysfunction (ED), Skin disorders, Autoimmune disease like Multiple sclerosis, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, Infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk A.
  • NGF nerve growth factor
  • a method for inhibiting tropomyosin receptor kinase A (TrkA) in a patient, by administering a therapeutically effective amount of a compound of the Formula I to the patient.
  • TrkA tropomyosin receptor kinase A
  • a method for the prevention and/or therapeutic treatment of diseases or disorders mentioned above by administering to a patient a therapeutically effective amount of a compound of the Formula I or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier.
  • a medicament which can be used for preventive and/or therapeutic treatment of inflammatory diseases.
  • compounds of the present invention are used for preventive and/or therapeutic treatment of inflammatory diseases selected from the lung diseases, bowel diseases, interstitial cystitis, and painful bladder syndrome.
  • the Inflammatory lung disease is Asthma or Interstitial Cystitis and Inflammatory bowel disease is Ulcerative Colitis, Crohn's disease or urinary incontinence.
  • a method for preventive and/or therapeutic treatment of acute or chronic pain is provided.
  • compounds of the present invention are used for preventive and/or therapeutic treatment of acute pain and chronic pain selected from cancer induced pain, bone fracture pain, inflammatory pain, neuropathic pain, surgery, bone fracture, skeletal pain caused by tumor metastasis, osteoarthritis, psoriatic arthritis, rheumatoid arthritis, interstitial cystitits, chronic pancreatitis, visceral pain, inflammatory pain, migraine, chronic lower back pain, bladder pain syndrome, femur fracture pain, hyperalgesia, repetitive motion pain, dental pain, myofascial pain, dysraennorhea, as well as pain associated with angina.
  • a method for preventive and/or therapeutic treatment of an imbalance of the regulation of bone remodelling is provided.
  • compounds of the present invention are used for preventive and/or therapeutic treatment of osteoporosis, rheumatoid arthritis, and bone metastases, Osteolytic metastases, life- threatening hypercalcemia, spinal cord compression, ankylosing spondylitis, tumor-induced osteolysis, periodontal disease.
  • compounds of the invention may be used to decrease tolerance and/or dependence to opioid treatment of pain, and for treatment of withdrawal syndrome of e.g., alcohol, opioids, and cocaine.
  • a method for preventive and/or therapeutic treatment of abnormal tissue remodelling and fibrotic disorders is provided.
  • compounds of the present invention are used for preventive and/or therapeutic treatment of abnormal tissue remodelling and fibrotic disorders selected from Idiopathic pulmonary fibrosis, Raynaud's syndrome, endometrial fibrosis, atrial fibrosis, myelofibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, scleroderma, systemic sclerosis, atherofibrosis, ocular fibrosis, scarring and cirrhosis.
  • a medicament which can be used for preventive and/or therapeutic treatment of cancer related to dysregulation of TrkA.
  • the dysregulation of TrkA is due to chromosomal rearrangements like one or more chromosome translocations, over-expression, inversions, insertions, deletions or mutationsin the TrkA protein.
  • Non Small cell Lung Cancer colorectal carcinoma, papillary thyroid carcinoma, Glioblastoma, Melanoma, Acute Myeloid Leukemia, Large Cell Neuroendocrine Carcinoma, Gastric Carcinoma, Pancreatic Carcinoma, Prostrate Carcinoma, Head and Neck squamous cell carcinoma.
  • TrkA gene fusion can be LMNA-TrkA, TFG-TrkA, TPM3-TrkA, CD74-TrkA, NFASC- TrkA, MPRIP-TrkA, BCAN-TrkA, TP53-TrkA, RNF213-TrkA, RABGAP1 L-TrkA, IRF2BP2-TrkA, SQSTMI-TrkA, SSBP2-TrkA, or TPR-TrkA.
  • a medicament which can be used for preventive and/or therapeutic treatment of cancer.
  • compounds of the present invention are used for preventive and/or therapeutic treatment of cancer selected from lung adenocarcinomas, breast cancer, thyroid carcinoma, pancreatic cancer, ovarian carcinoma, gastric carcinoma, malignant mesothelioma, prostate carcinoma, neuroblastic tumors, colorectal carcinoma, spitzoid melanoma, salivary adenoid cystic carcinoma, stomach cancer, kidney cancer, urethral cancer, glioblastoma multiforme, oral squamous cell carcinoma, Acute Myeloid Leukemia, cholangiocarcinoma, mastocytosis or extramammary Paget's disease.
  • additional therapeutic agents may be administered together with the compounds of this invention.
  • these additional therapeutic agents are normally administered to treat or prevent the same condition.
  • methotrexate may be combined with the compounds of this invention to treat leukemia.
  • additional therapeutic agent is selected from anti-TNF dugs, or with a circulating receptor fusion protein such as etanercept (Enbrel), targeted kinase inhibitors, these additional therapeutic agents may be administered with Compound of the Formula I or a pharmaceutically acceptable salt thereof as part of the same or separate dosage forms, via the same or different routes of administration, and on the same or different administration schedules according to standard pharmaceutical practice known to one skilled in the art.
  • a circulating receptor fusion protein such as etanercept (Enbrel)
  • targeted kinase inhibitors targeted kinase inhibitors
  • additional therapeutic agent is selected from anti-inflammatory compounds, steroids, analgesics, opioids, calcitonin gene-related peptide receptor antagonists, subtype-selective ion channel modulators, anticonvulsants, dual serotonin-norepinephrine reuptake inhibitors, KSP (kinesin spindle protein) inhibitors, JAK family kinase inhibitors, and tricyclic antidepressants.
  • One or more compounds of Formula I can be supplied in the form of a therapeutic composition that is within the scope of the present application.
  • Table 1 Exemplary compounds from Formula I (Examples 1-202)
  • Example 109 Example 110 Example 111 Example 112
  • the compounds of this invention may be prepared by employing reactions as shown in the following schemes, in addition to other standard manipulations that are known in the literature or exemplified in the experimental procedures. Substituent numbering as shown in the schemes does not necessarily correlate to that used in the claims and often, for clarity, a single substituent is shown attached to the compound where multiple substituents are allowed under the definitions hereinabove. Reactions used to generate the compounds of this invention are prepared by employing reactions as shown in the schemes and examples herein, in addition to other standard manipulations such as ester hydrolysis, cleavage of protecting groups, etc., as may be known in the literature or exemplified in the experimental procedures.
  • Example 1 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(quinolin-3-yl)urea [00101] This compound was synthesized using method 3 as mentioned in the general scheme.
  • Example 2 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(2-phenylquinolin-3-yl)urea. This compound was prepared according to the above mentioned protocol using the intermediate A6 and (3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidine-3-carboxylic acid.
  • Step 1 Preparation of phenyl 2-methylquinolin-3-ylcarbamate: To a solution of 2-methylquinolin-3-amine (Intermediate A7) (0.05 g, 0.31 mmol) and pyridine (0.076 ml_, 0.94 mmol) in THF (5 ml_) at 0°C was added phenylchloroformate (0.076 g, 0.47 mmol) drop-wise, and the resulting mixture was stirred at room temperature for 2 h.
  • Step 2 Preparation of 1-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)-3-(2-methylquinolin-3-yl)urea: To a solution of (3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride (0.18 g, 0.64 mmol) and diisopropylethylamine(0.32 ml_, 1.92 mmol) in DMF (5 ml_) was added phenyl 2-methylquinolin-3-ylcarbamate (0.18 g.
  • Example 4 1-(2-Ethylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 6 1-(2-(Trifluoromethyl)quinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 7 1-(6-Fluoro-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 8 1-(6-Fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 9 1-(5-Fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 10 1-(8-Fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 11 1-(7-Fluoro-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 12 1-(7-Fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 13 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(6-methoxy-2-phenylquinolin-3-yl)urea.
  • Example 14 1-(7-Methoxy-2-phenylquinolin-3-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 15 1-(8-Methoxy-2-phenylquinolin-3-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 16 1-(5-Methoxy-2-phenylquinolin-3-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 17 1-(5-Methoxy-2-methylquinolin-3-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 18 1-(6-Methoxy-2-methylquinolin-3-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 19 1-(7-Methoxy-2-methylquinolin-3-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 20 1-(8-Methoxy-2-methylquinolin-3-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 21 1-(6,7-Dimethoxy-2-phenylquinolin-3-yl)-3-((3S,4R)- 1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 22 1-(6,7-Dimethoxy-2-methylquinolin-3-yl)-3-((3S,4R)- 1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 23 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(6,7-dimethoxyquinolin-3-yl)urea.
  • Example 24 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(6-methyl-2-phenylquinolin-3-yl)urea.
  • Example 25 1-(2,6-Dimethylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 26 1-(2,7-Dimethylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • 1 H NMR (CD 3 OD, 300 MHz): ⁇ 8.38 (s, 1H), 7.68-7.65 (m, 2H), 7.38-7.30 (m, 5H), 7.26-7.21 (m, 1H), 4.43-4.36 (m, 1H), 3.57 (t, J 5.4 Hz, 2H), 3.38-3.31 (m, 1H), 3.36 (s, 3H), 3.25-3.20 (m, 1H), 3.15-3.09 (m, 1H), 2.97-2.92 (m, 1H), 2.90-2.74 (m, 2H), 2.70-2.64 (m, 1H), 2.59 (s, 3H), 2.51 (s, 3H).
  • Example 27 1-(2,5-Dimethylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 28 1-(2,8-Dimethylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 29 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(7-methyl-2-phenylquinolin-3-yl)urea.
  • Example 30 1-(2-Chloroquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • LCMS (M+H): 425.30.
  • Example 31 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(2-(1-methyl-1H-pyrazol-4-yl)quinolin-3-yl)urea.
  • Example 32 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(2-(pyridin-3-yl)quinolin-3-yl)urea.
  • Example 33 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(2-(pyridin-4-yl)quinolin-3-yl)urea.
  • Example 34 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(2-(pyrimidin-5-yl)quinolin-3-yl)urea.
  • Example 35 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(2-morpholinoquinolin-3-yl)urea.
  • Example 36 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(quinolin-4-yl)urea.
  • Example 37 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(quinazolin-4-yl)urea.
  • 1 H NMR (CD 3 OD, 400 MHz): ⁇ 8.80 (s, 1H), 8.36 (d, J 8.0 Hz, 1H), 7.95-7.87 (m, 2H), 7.69-7.65 (m, 1H), 7.45-7.38 (m, 2H), 7.32- 7.29 (m, 2H), 7.23-7.17 (m, 1H), 4.85-4.52 (m, 1H), 3.60-3.58 (m, 2H), 3.46- 3.37 (m, 2H), 3.30 (s, 3H), 3.18-3.13 (m, 1H), 3.08-3.04 (m, 1H), 2.92-2.71 (m, 3H).
  • Example 38 1-(2-Chloro-6,7-dimethoxyquinazolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 39 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(quinoxalin-2-yl)urea.
  • Example 40 1-(2-lsopropylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 41 1-(2-tert-Butylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • 1 H NMR: (CDCb, 300 MHz): 58.14 (s, 1H), 8.01 (d, J 8.7 Hz, 1H), 7.71-7.60 (m, 2H), 7.49-7.44 (m, 1H), 7.35- 7.26 (m, 5H), 6.59 (br s, 1H), 4.58-4.50 (m, 1H), 3.58-3.52 (m, 3H), 3.37-3.31 (m, 1H), 3.31 (s, 3H), 3.23-3.19 (m, 1H), 3.04-3.02 (m, 1H), 2.82-2.79 (m, 2H), 2.63-2.59 (m, 1H), 1.50 (s, 9H).
  • Example 42 1-(6-Methoxy-2-methyl-7-morpholinoquinolin-3-yl)- 3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 43 1-(6-Fluoro-7-methyl-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 44 1-(6-Bromo-8-methoxy-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 45 1-(7-Fluoro-6-methoxy-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 46 1-(7-Fluoro-6-methoxy-2-methylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 47 1-(8-Methoxy-7-methyl-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 48 1-(6-Methoxy-2,7-dimethylquinolin-3-yl)-3-((3S,4R)- 1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 49 1-(7-Fluoro-6-methyl-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 50 1-(7-Fluoro-2,6-dimethylquinolin-3-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 51 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(6-phenyl-[1,3]dioxolo[4,5-g]quinolin-7-yl)urea.
  • Example 52 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(6-methyl-[1,3]dioxolo[4,5-g]quinolin-7-yl)urea.
  • Example 53 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(7-methyl-2,3-dihydro-[1,4]dioxino[2,3-g]quinolin-8-yl)urea.
  • Example 54 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(7-phenyl-2,3-dihydro-[1 ,4]dioxino[2,3-g]quinolin-8-yl)urea.
  • Example 55 1-(6-Amino-7-methoxy-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 56 1-(7-Methoxy-6-(methylamino)-2-phenylquinolin-3- yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 57 N-(7-Methoxy-3-(3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-2-phenylquinolin-6-yl)acetamide.
  • Example 58 N-(7-Methoxy-3-(3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-2-methylquinolin-6-yl)acetamide.
  • Example 59 N-(6-Methoxy-3-(3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-2-phenylquinolin-7-yl)acetamide.
  • Example 60 N-(6-methoxy-3-(3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-2-methylquinolin-7-yl)acetamide.
  • Example 61 1-(8-Methoxy-6-(1-Methyl-1 H-pyrazol-4-yl)-2- phenylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)urea.
  • Example 62 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(2-methyl-8-(1-methyl-1 H-pyrazol-4-yl)quinolin-3-yl)urea.
  • Example 63 1-((3S,4R)-4-(3,4-Difluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(quinolin-3-yl)urea.
  • Example 64 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(naphthalen-2-yl)urea.
  • Example 65 1-((3S,4R)-4-(3,4-Difluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(2-phenylquinolin-3-yl)urea.
  • Example 66 1-((3S,4R)-4-(3,4-Difluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(2-(pyridin-3-yl)quinolin-3-yl)urea.
  • Example 67 1-((3S,4R)-4-(3,4-Difluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(2-methylquinolin-3-yl)urea.
  • Example: 68 1-((3S,4R)-4-(3,4-Difluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(6,7-dimethoxy-2-methylquinolin-3-yl)urea.
  • Example: 69 1-((3S,4R)-4-(3,4-Difluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(6,7-dimethoxyquinolin-3-yl)urea.
  • Example: 70 1-((3S,4R)-4-(3-fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(quinolin-3-yl)urea.
  • Example: 71 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(2-methylquinolin-3-yl)urea.
  • Example: 72 1-(6-Fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-4-(3- fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea.
  • Example: 73 1-(7-Fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-4-(3- fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea.
  • Example: 74 1-(6,7-Dimethoxy-2-phenylquinolin-3-yl)-3- ((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea.
  • Example: 75 1-((3S,4R)-4-(3-fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(6-phenyl-[1,3]dioxolo[4,5-g]quinolin-7-yl)urea.
  • Example: 76 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(6-methyl-[1,3]dioxolo[4,5-g]quinolin-7-yl)urea.
  • Example: 78 1-((3S,4R)-4-(3-Cyanophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(6,7-dimethoxy-2-phenylquinolin-3-yl)urea.
  • Example: 80 1-(6,7-Dimethoxy-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-(pyridin-3-yl)pyrrolidin-3-yl)urea.
  • Example: 82 1-(6,7-Dimethoxy-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-(1-methyl-1H-pyrazol-4-yl)pyrrolidin-3-yl)urea.
  • Example: 83 1-((3S,4R)-1-(2-Methoxyethyl)-4-(1-methyl-1 H- pyrazol-4-yl)pyrrolidin-3-yl)-3-(quinolin-3-yl)urea.
  • Example 84 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(2-phenyl-1 ,8-naphthyridin-3-yl)urea
  • Step 1 Synthesis of ethyl 2-phenyl-1 ,8-naphthyridine-3- carboxylate: To a solution of 2-aminonicotinaldehyde (1.5 g, 12.29 mmol) in piperidine (7.5 ml_) was added ethyl 3-oxo-3-phenylpropanoate (2.59 g, 13.52 mmol) and was stirred at 90 °C for 3h. The reaction mixture was cooled to ambient temperature and poured into cold water. The resulting solid was filtered and washed with ether to get the required compound as an off-white solid.
  • Step 2 Synthesis of 2-phenyl-1 ,8-naphthyridine-3-carboxylic acid: To a solution of ethyl 2-phenyl-1 ,8-naphthyridine-3-carboxylate (1 g, 3.59 mmol) in EtOH (10 ml_) was added H 2 0 (10 ml_) followed by NaOH (0.79 g, 17.9 mmol) . The reaction mixture was then refluxed for 4 hours, cooled to room temperature and solvents were evaporated under reduced pressure.
  • Step 3 Synthesis of 1-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)-3-(2-phenyl-1 ,8-naphthyridin-3-yl)urea: To a solution of 2- phenyl-1 ,8-naphthyridine-3-carboxylic acid (0.2 g, 0.8 mmol) in Toluene (4 ml_) was added DPPA (0.261 g, 0.96 mmol) followed by TEA (0.57 ml_, 4 mmol). The reaction mixture was stirred at room temperature for 16 hours.
  • Example 85 Methyl 2-((3S,4R)-3-(3-(6,7-dimethoxy-2- phenylquinolin-3-yl)ureido)-4-phenylpyrrolidin-1-yl)acetate.
  • Example 86 Methyl 2-((3R,4S)-3-phenyl-4-(3-(quinolin-3- yl)ureido)pyrrolidin-1-yl)acetate.
  • Example 87 1-((3S,4R)-1-(2-Fluoroethyl)-4-phenylpyrrolidin-3- yl)-3-(6,7-dimethoxy-2-phenylquinolin-3-yl)urea.
  • Example 88 1-((3R,4S)-1-(2-Fluoroethyl)-4-phenylpyrrolidin-3- yl)-3-(6,7-dimethoxy-2-phenylquinolin-3-yl)urea.
  • Example 89 1-((3S,4R)-1-(2-Fluoroethyl)-4-phenylpyrrolidin-3- yl)-3-(2-phenylquinolin-3-yl)urea.
  • Example 90 1-((3S,4R)-1-(2-Fluoroethyl)-4-phenylpyrrolidin-3- yl)-3-(quinolin-3-yl)urea.
  • Example 92 1-((3R,4S)-1-(2,2,2-Trifluoroethyl)-4- phenylpyrrolidin-3-yl)-3-(6,7-dimethoxy-2-phenylquinolin-3-yl)urea.
  • Example 93 1-((3S,4R)-1-(2,2,2-Trifluoroethyl)-4- phenylpyrrolidin-3-yl)-3-(quinolin-3-yl)urea.
  • Example 94 1-((3S,4R)-1-(2,2-Difluoroethyl)-4-phenylpyrrolidin- 3-yl)-3-(6,7-dimethoxy-2-phenylquinolin-3-yl)urea.
  • Example 95 1-((3S,4R)-1-(2,2-Difluoroethyl)-4-phenylpyrrolidin- 3-yl)-3-(quinolin-3-yl)urea.
  • Example 96 1-(6,7-Dimethoxy-2-phenylquinolin-3-yl)-3-((3S,4R)- 1-(2-methoxyacetyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 97 1-((3S,4R)-1-(2-Methoxyacetyl)-4-phenylpyrrolidin- 3-yl)-3-(quinolin-3-yl)urea.
  • Example 98 1-(6,7-Dimethoxy-2-phenylquinolin-3-yl)-3-((3S,4R)- 1-(oxetan-3-yl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 99 2-((3S,4R)-3-(3-(6,7-Dimethoxy-2-phenylquinolin-3- yl)ureido)-4-phenylpyrrolidin-1-yl)acetamide.
  • Example 100 1-((3S,4R)-1-(Cyanomethyl)-4-phenylpyrrolidin-3- yl)-3-(6,7-dimethoxy-2-phenylquinolin-3-yl)urea.
  • Example 101 1-((3S,4R)-1-(Cyanomethyl)-4-phenylpyrrolidin-3- yl)-3-(quinolin-3-yl)urea.
  • Example 102 2-((3R,4S)-3-Phenyl-4-(3-(quinolin-3- yl)ureido)pyrrolidin-1-yl)acetamide.
  • Example 103 1-(1-(2-Methoxyethyl)-2-oxo-4-phenylpyrrolidin-3- yl)-3-(quinolin-3-yl)urea.
  • Example 104 1-(Dibenzo[b,d]furan-1-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
  • Step 1 Preparation of phenyl dibenzo[b,d]furan-1-ylcarbamate: To a solution of dibenzo[b,d]furan-1-amine (0.2 g, 1.09 mmol) and pyridine (0.17g, 2.18 mmol) in THF (20 mL) at 0°C was added phenylchloroformate (0.17 g, 1.09 mmol) drop-wise, and the resulting mixture was stirred at room temperature for 2 h. Cold water was added to the reaction mixture and it was extracted with ethyl acetate (2 x 25 mL).
  • Step 2 Preparation of 1-(dibenzo[b,d]furan-1-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea: To a solution of (3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride (0.2g, 0.78 mmol) and diisopropylethylamine (0.30g, 2.34 mmol) in DMF (4 mL) was added phenyl dibenzo[b,d]furan-1-ylcarbamate (0.23g.
  • Example 105 1-(Dibenzo[b,d]furan-1-yl)-3-((3S,4R)-4-(3- fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea.
  • Example 106 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(8-methyldibenzo[b,d]furan-1-yl)urea.
  • Example 108 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(8-fluorodibenzo[b,d]furan-1-yl)urea.
  • Example 109 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(7-methoxydibenzo[b,d]furan-1-yl)urea.
  • Example 110 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(7-fluorodibenzo[b,d]furan-1-yl)urea.
  • Example 111 1-(Dibenzo[b,d]thiophen-1-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 112 1-(5,5-Dioxodibenzo[£»,a]thiophen-1-yl)-3-[1-(2- methoxy-ethyl)-4-phenyl-pyrrolidin-3-yl]-urea.
  • Example 113 1-(4-Methoxydibenzo[b,d]thiophen-1-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 114 1-(4-Methoxy-5,5-Dioxodibenzo[!b,c/]thiophen-1-yl)- 3-[1-(2-methoxy-ethyl)-4-phenyl-pyrrolidin-3-yl]-urea.
  • Example 115 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(9-oxo-9H-fluoren-4-yl)urea.
  • Example 116 1-(6-Methoxydibenzo[b,d]furan-1-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 117 1-(6-Methyldibenzo[b,d]furan-1-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 118 1-(6-Methoxy-7-methyl-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 119 1-(6-Cyano-7-fluoro-2-methylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 120 1-(6-Cyano-7-methoxy-2-methylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 121 1-(7-Cyano-6-fluoro-2-methylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 122 1-(7-Cyano-6-fluoro-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 123 1-(7-Cyano-6-methoxy-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 124 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(2-(thiazol-5-yl)quinolin-3-yl)urea.
  • Example 125 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(2-phenyl-5,6,7,8-tetrahydroquinolin-3-yl)urea.
  • Example 126 1-(6,7-Dimethoxy-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-1 ,3-dimethylurea.
  • Example 127 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-1-methyl-3-(2-phenylquinolin-3-yl)urea.
  • Example 128 1-(6-(Difluoromethoxy)-7-methoxy-2- methylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)urea.
  • Example 129 1-(2,2-Difluoro-6-methyl-[1 ,3]dioxolo[4,5- g]quinolin-7-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 130 1-(6-(Difluoromethyl)-[1 ,3]dioxolo[4,5-g]quinolin-7- yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 131 1-([1 ,3]Dioxolo[4,5-g]quinolin-7-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 132 1-(2-Cyclohexylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 133 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(6-(trifluoromethyl)-[1 ,3]dioxolo[4,5-g]quinolin-7-yl)urea.
  • Example 134 1-(6-(Difluoromethyl)-[1 ,3]dioxolo[4,5-g]quinolin-7- yl)-3-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea.
  • Example 135 1-([1 ,3]Dioxolo[4,5-g]quinolin-7-yl)-3-((3S,4R)-4- (3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea.
  • Example 136 1-(6-Fluoro-2-phenylquinolin-3-yl)-3-((3S,4R)-4-(3- fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea.
  • Example 137 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-5,6,7,8-tetrahydroquinolin-3-yl)urea.
  • Example 138 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(7-methyl-2-phenyl-1 ,8-naphthyridin-3-yl)urea.
  • Example 139 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(2-phenylquinolin-3-yl)urea.
  • Example 140 1-([1 ,3]Dioxolo[4,5-g]quinolin-7-yl)-3-((3S,4R)-4-(3- fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea.
  • Example 141 1-(2-(2,4-Difluorophenyl)quinolin-3-yl)-3-((3S,4R)- 1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 142 1-(2-(3,5-Difluorophenyl)quinolin-3-yl)-3-((3S,4R)- 1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 143 1-(4-(Benzyloxy)-1-(2-methoxyethyl)pyrrolidin-3- yl)-3-(6-methyl-[1,3]dioxolo[4,5-g]quinolin-7-yl)urea.
  • Example 144 1-(1-Chloro-3-methylisoquinolin-4-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 145 1-(1,3-Diphenylisoquinolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 146 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(3-methyl-1-(1-methyl-1H-pyrazol-4- yl)isoquinolin-4-yl)urea.
  • Example 147 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-
  • Example 148 1-(lsoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)-
  • Example 149 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(3-phenylisoquinolin-4-yl)urea.
  • Example 150 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(3-methylisoquinolin-4-yl)urea.
  • Example 151 1-(1-Cyano-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 152 1-(1-Chloro-3-phenylisoquinolin-4-yl)-3-((3S,4R)-4- (3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea.
  • Example 153 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(3-phenylisoquinolin-4-yl)urea.
  • Example 154 1-(1-Cyano-3-phenylisoquinolin-4-yl)-3-((3S,4R)-4- (3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea.
  • Example 155 1-(1-Hydroxy-3-phenylisoquinolin-4-yl)-3-((3S,4R)- 1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 156 1-(1-Amino-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 157 1-(1-Methoxy-3-phenylisoquinolin-4-yl)-3-((3S,4R)- 1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 158 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(1-methyl-3-phenylisoquinolin-4-yl)urea.
  • Example 159 1-(7-Fluoro-1-methyl-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 160 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(1-(1-methyl-1H-pyrazol-4-yl)-3- phenylisoquinolin-4-yl)urea.
  • Example 161 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(3-methyl-1-(1-methyl-1H-pyrazol-4-yl)isoquinolin-4-yl)urea.
  • Example 162 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(1-(1-methyl-1H-pyrazol-4-yl)isoquinolin-4-yl)urea.
  • Example 163 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(1-(1-methyl-1H-pyrazol-4-yl)isoquinolin-4- yl)urea.
  • Example 164 1-(3-(tert-Butyl)-1-(1-methyl-1H-pyrazol-4- yl)isoquinolin-4-yl)-3-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin- 3-yl)urea.
  • Example 165 1-(3-(tert-Butyl)-1-(1-methyl-1H-pyrazol-4- yl)isoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 166 1-(1-Fluoro-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 167 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(1-methyl-3-phenylisoquinolin-4-yl)urea.
  • Example 168 1-(7-Methoxy-1-methyl-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 169 1-(6-Methoxy-1-methyl-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 170 1-(1,6-Dimethyl-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 171 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(3-phenyl-1-(pyridin-3-yl)isoquinolin-4-yl)urea.
  • Example 172 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(1-morpholino-3-phenylisoquinolin-4-yl)urea.
  • Example 173 1-(1-(4-Hydroxypiperidin-1-yl)-3-phenylisoquinolin- 4-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 174 1-(3-(3-Fluorophenyl)-1-methylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 175 1-(3-(2-Fluorophenyl)-1-methylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 176 1-(6,7-Dimethoxy-1-methyl-3-phenylisoquinolin-4- yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 177 1-(6-Fluoro-1-methyl-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 178 1-(1 ,7-Dimethyl-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 179 4-(3-((3S,4R)-1-(2-Methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-3-phenylisoquinoline-1-carboxamide.
  • Example 180 1-(8-Methoxy-1-methyl-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 181 1-(8-Fluoro-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 182 1-(7-Fluoro-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 183 1-(7-fluoro-3-phenylisoquinolin-4-yl)-3-((3S,4R)-4- (3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea.
  • Example 184 1-(5-Methoxy-3-phenylisoquinolin-4-yl)-3-((3S,4R)- 1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 185 1-(7-Fluoro-1-methyl-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea.
  • Example 186 1-(3-Cyanoisoquinolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 187 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(3-phenyl-1-(piperazin-1-yl)isoquinolin-4-yl)urea.
  • Example 188 1-(1-Cyano-7-fluoro-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Step 1 Synthesis of 1-(4-(3-fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(1-formyl-3-phenylisoquinolin-4-yl)urea: To a stirred solution of 1-(4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1- methyl-3-phenylisoquinolin-4-yl)urea (0.1 g, 0.200 mmol) in 1 , 4 dioxane (30 mL) was added selenium dioxide (0.033g, 0.301 mmol) and the reaction mixture was refluxed for 4 h.
  • Step 2 Synthesis of 1-(1-(difluoromethyl)-3-phenylisoquinolin-4- yl)-3-(4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea: Deoxo-Fluor® solution 50% in THF (0.064 g, 0.292 mmol) was added to a solution of 1-(4-(3- fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-formyl-3- phenylisoquinolin-4-yl)urea (0.05 g, 0.097 mmol) in DCM (20 mL) at 0 °C and stirred at rt for 12 h.
  • the reaction mixture was diluted with dichloromethane and washed with water.
  • the separated organic layer was dried over anhydrous Na2S0 4 , filtered and the filtrate was evaporated under reduced pressure.
  • the crude compound was purified by flash chromatography using 5% methanol in dichloromethane as an eluent to afford the title compound (0.01 g, 19%) as an off-white solid.
  • Example 190 7-Fluoro-4-(3-(1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-3-phenylisoquinoline-1-carboxylic acid
  • Example 191 7-Fluoro-4-(3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-3-phenylisoquinoline-1-carboxamide
  • Example 192 4-(3-((3S,4R)-1-(2-Methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)isoquinoline-3-carboxamide.
  • Example 193 Methyl 2-((7-fluoro-4-(3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)ureido)-3-phenylisoquinolin-1- yl)(methyl)amino)acetate.
  • Example 194 2-((7-Fluoro-4-(3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-3-phenylisoquinolin-1-yl)(methyl)amino)acetic acid.
  • Example 195 1-(7-Fluoro-1-((2-hydroxyethyl)(methyl)amino)-3- phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)urea.
  • Example 196 Ethyl 2-((4-(3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-3-phenylisoquinolin-7-yl)oxy)acetate.
  • Example 197 2-((4-(3-((3S,4R)-1-(2-Methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-3-phenylisoquinolin-7-yl)oxy)acetic acid.
  • Example 198 1-(7-(2-hydroxyethoxy)-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 199 1-(4-(Benzyloxy)-1-(2-methoxyethyl)pyrrolidin-3- yl)-3-(7-fluoro-1-methyl-3-phenylisoquinolin-4-yl)urea.
  • Example 200 1-(7-Fluoro-1-methyl-3-phenylisoquinolin-4-yl)-3- (4-hydroxy-1-(2-methoxyethyl)pyrrolidin-3-yl)urea.
  • Example 201 1-(7-Fluoro-1-methyl-3-phenylisoquinolin-4-yl)-3- (4-hydroxy-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.
  • Example 202 1-(4-Fluoro-1-(2-methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(7-fluoro-1-methyl-3-phenylisoquinolin-4-yl)urea.
  • Recombinant AD293 cells overexpressing human TrkA were used to determine TrkA Y490 phosphorylation upon NGF stimulation.
  • 25k cells plated in serum free DMEM medium in a 96 well plate were serum starved for 2 hours at 37°C in 5% C02 incubator.
  • Test compounds were added to the plate at a final concentration of 2.5% DMSO and incubated for 20 min at 37°C. 6nM NGF was added and incubated for 5 min at 37°C. The plate was immediately centrifuged at 2000 rpm for 1 min and media removed.
  • the +++ represents IC50 of ⁇ 100 nM
  • the ++ represents IC50 range between 100 nM to 1000 nM
  • the + represents IC50 of >1000 nM.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

The present invention is directed to the compounds of Formula I which are inhibitors of tropomyosin-related kinase A (TrkA): Formula (I) or steroisomers, tautomers or a pharmaceutically acceptable salts, metabolites, isotopes, solvates or prodrugs thereof, wherein, Ra, Rb, Rc, Rd, R1, R2, L and Het-Ar are as defined herein. These compounds can be used for the preventive and/or therapeutic treatment of diseases or disorders associated with abnormal activities of nerve growth factor (NGF) receptor TrkA such as Pain, inflammation or an inflammatory diseases, Cancer, atherosclerosis, restenosis, thrombosis, Neurodegenerative diseases, Erectile Dysfunction (ED), Skin disorders, Autoimmune disease like Multiple sclerosis, Sjögren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, Infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination.

Description

INHIBITORS OF TrkA KINASE FIELD OF THE INVENTION
[0001] The present invention relates to novel compounds that act as inhibitors of the members of Trk family protein kinases. Particularly, the invention discloses compounds possessing inhibitory activity against TrkA.
BACKGROUND OF THE INVENTION
[0002] The current available therapies for the treatment of pain utilize several classes of compounds like Non-steroidal anti-inflammatory drugs (NSAID's) and opioids. Most NSAIDs have one or more side effects such as irritation of the gastrointestinal (Gl) tract leading to Nausea/Vomiting, Gastric ulceration/bleeding, Dyspepsia, inflammatory bowel disease, altered renal function, deleterious effects on the cardiovascular system and many more. Opioids result in emetic, constipatory and negative respiratory effects, as well as the potential for addiction. Hence, there is a great unmet need for drugs that alleviate pain without the adverse effects caused by the current pain therapies.
[0003] Trks and neurotrophins are well known for their effects on neuronal growth and survival through their regulation of cell proliferation, differentiation, apoptosis, and survival of neurons in both the central and peripheral nervous systems. Trk kinases, with three highly homologous isoforms, TrkA, TrkB, and TrkC are activated by high affinity growth factors named neurotrophins with Nerve growth factor (NGF), which activates TrkA; brain-derived neurotrophic factor (BDNF) and NT-4/5, which activate TrkB; and NT-3, which activates TrkC. The binding of neurotrophins to the extracellular domain of Trks causes the Trk kinase to autophosphorylate at several intracellular tyrosine sites and triggers downstream signal transduction pathways such as PI3K, Ras and PLC-γ pathways (Molecules 2015, 20(6), 10657-10688).
[0004] NGF signaling via TrkA is recognized to play an important role in pain sensation. Genetic studies in humans with TrkA loss of function mutations have provided evidence of the significant role of NGF signaling in pain sensation (ClinAuton Res 2002; 12 Suppl 1 : 120 -32). Currently, novel pain treatments are highly desired due to low efficacy and/or undesirable gastrointestinal, renal and psychotropic side effects of NSAIDS and opiates. NGF expression is increased in various pain conditions and administration of NGF increases pain sensitivity. Inhibition of NGF signaling via TrkA using a variety of antibody and small molecule based approaches have been shown to be effective in preclinical animal models for pain (Anesthesiology. 201 1 Jul; 115(1):189-204). Selective TrkA inhibition demonstrated equivalent efficacy to nonselective Trk inhibitors. Intermittent TrkA inhibition using a small molecule results in comparable efficacy to NGF antibodies in pain models (Andrews IASP, 2012). NGF mab, Tanezumab demonstrated excellent clinical efficacy in Osteoarthritis, chronic low back pain and diabetic peripheral neuropathy. TrkA selective small molecule inhibitors have therapeutic utility for various pain conditions. Efficacy of Anti- TrkA antibodies and anti-NGF antibodies for treatment of inflammatory and neuropathic pain have been demonstrated in vivo models in WO2006/131952 and WO2005/061540.
[0005] Trks play key role in malignant transformation, chemotaxis, metastasis, and survival signaling in human tumors (Cancer Lett 2001 ; 169: 107-14). Oncogenic activation of TRKA occurs through genomic rearrangement and the creation of a gene fusion where extracellular domain of TrkA is replaced by fusion with another gene with the kinase domain intactresults in constitutive activation of TrkA pathway. A number of NTRK1 gene fusions have been reported in a variety of cancers such as NSCLC, spitz melanoma, colorectal cancer, cholangiocarcinoma, soft tissue sarcoma, glioblastoma and papillary thyroid carcinoma (Cancer Discovery January 1 , 2015 5; 25) with more new fusions being reported based on the NGS sequencing of patient DNA. Trk inhibitors such as Entrectinib and LOXO-101 have demonstrated significant tumor regression in patients with Trk fusions (Cancer Discov. 2015 Oct;5(10): 1049-57, J Natl Cancer Inst. 2015 Nov 12; 108(1)). [0006] In addition to gene fusions, molecular alterations such as an in-frame deletion of NTRK1 (ATRKA) in acute myeloid leukemia (AML) and a splice variant of NTRK1 (TRKAIII) in neuroblastoma have been functionally characterized as oncogenic. Autocrine and paracrine signalling by Trk receptors have been implicated as protumorigenic in several different tumor types. An autocrine loop involving TrkA and NGF is associated with protumorigenic activity in both breast and prostate carcinomas (Mol Cell Biol. 2000 Dec; 20(23):8655-66, Clin Cancer Res 2001 ;7:2237-45). Expression of TrkA and TrkC wild-type receptors is associated with a positive prognosis in patients with neuroblastoma (excluding expression of the splice variant TRKAIII) (N Engl J Med. 1993 Mar 25;328(12):847-54). Hence, TrkA inhibitors have potential for cancers driven by activated TrkA signaling due to molecular alterations or autocrine/paracrine signalling due to increased expression of TrkA and/or NGF.
[0007] TrkA is expressed in the bone forming area in mouse models of bone fracture (Bone. 2000 Jun; 26(6):625-33) and Trk inhibitors induce apoptosis of proliferating osteoblasts (Cancer Res. 2002 Feb 15; 62(4):986-9) suggesting use of Trk inhibitors for bone remodelling diseases such as bone metastases in cancer patients.
[0008] NGF and TrkA are expressed in immune cells and a localized increase in NGF at the sites of inflammation is observed during the inflammatory process. Inflammatory cytokines such as IL-1 beta, TNF-alpha and IL-6 are able to modify the basal production of NGF in the organism and induce the synthesis of NGF in a variety of cell types and tissues. TrkA-NGF pathway is also involved in a number of disorders such as Osteoarthritis, Multiple Sclerosis (J Clinlmmunol. Dec 201 1 ; 31 (6): 1010-1020) and in inflammatory diseases including Asthma (Pharmacology &Therapeutics 2008, 1 17(1), 52-76), Interstitial Cystitis (The Journal of Urology 2005, 173(3), 1016-21), inflammatory bowel diseases including Ulcerative Colitis and Crohn's disease (Gut 2000, 46(5), 670-678), neurodegenerative diseases like Alzheimer's disease, Huntington's disease, Progressive Supranuclear Palsy (J Alzheimers Dis. 2014; 40(3): 605-617, ActaNeuropathol. 1998 Nov;96(5):495-501) and Neurogenic Erectile Dysfunction (European Urology, November 2014). Inhibition of Trk pathway has been shown to be effective in preclinical models of inflammatory diseases. Therefore, TrkA kinase inhibition can be used as a new methodology for the treatment of these diseases.
[0009] Trk kinases are also involved in skin diseases like atopic dermatitis (Archives of Dermatological Research 2006, 298(1), 31-37), Eczema, Psoriasis (J. Investigative Dermatology 2004, 122(3), 812-819), Pruritis (Acta Derm Venereol 2015; 95: 542-548), restenosis and Atherosclerosis. TrkA inhibition is also implicated for the treatment of fibrotic disorders based on the ability of Connective Tissue Growth Factor (CTGF) to activate TrkA signaling (Fibrogenesis Tissue Repair. 2012 Jun 6; 5(Suppl 1):S24). TrkA inhibitors may also be useful in treatment of endometriosis (Reprod Sci. 201 1 Dec;18(12): 1202-10, Hum Reprod. 2009 Apr;24(4):827-34), diabetic peripheral neuropathy (Brain Res. 2000 Jun 9;867(1-2):149-56, Diabet Med. 2009 Dec;26(12): 1228-34.), chronic prostatitis/chronic pelvic pain syndrome (Urology. 2002 Apr;59(4):603-8, BJU Int. 2011 Jul;108(2):248-51) and Chagas' disease (Cell Host Microbe. 2007 Jun 14;1 (4):251-61).
[0010] Several classes of small molecule inhibitors of Trk kinases are known to be useful for treating pain or cancer. International Publication No. WO2014/078378, WO2012/125668, Patent publication numbers US20150336970, AU2015200511 and Expert Opinion on Therapeutic Patents (2009) 19, 305-19 and Expert Opinion on Therapeutic Patents (2014), 24(7):731-744 discloses the classes of compounds that are said to be inhibitors of Trk kinases which could be useful for treating diseases such as pain, cancer, restenosis, Psoriasis, thrombosis, atherosclerosis, Inflammatory diseases, neurodegenerative diseases or the like. [0011] Hence, pharmacological inhibition of TrkA pathway offers promising approaches for the treatment of a variety of diseases dependent on hyperactivation of TrkA pathway.
SUMMARY OF THE INVENTION
[0012] The invention provides to the compounds of Formula I which are inhibitors of tropomyosin-related kinase A (TrkA):
Figure imgf000006_0001
Formula I
Where, Ra, Rb, Rc, Rd, R1 , R2, L and Het-Ar are as defined herein.
[0013] The invention further provides for the pharmaceutical compositions which include an effective amount of a compound of formula I , or stereoisomers, tautomers or pharmaceutically acceptable salts, solvates, metabolites, isotopes or prodrugs thereof, and a pharmaceutically acceptable carrier.
[0014] The invention further provides to the use of pharmaceutical compositions for the treatment and/or prevention of diseases associated with abnormal or deregulated TrkA kinase activity in a patient in need thereof, like Pain, Inflammation or inflammatory diseases, Cancer, Atherosclerosis, Restenosis, Thrombosis, Neurodegenerative diseases like Alzheimer's Disease, Huntington's disease or Progressive supranuclear palsy, Erectile Dysfunction (ED), Skin disorders like Atopic Dermatitis, Eczema, Pruritis or Psoriasis, Autoimmune diseases like Multiple sclerosis, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, Infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
[0015] The invention further provides for a method for treating a disease or disorder mediated by the Trk receptors or associated with abnormal or deregulated TrkA kinase activity wherein said disease or disorder is selected from the group consisting of Pain, inflammation or inflammatory diseases, Cancer, atherosclerosis, restenosis, thrombosis, Neurodegenerative diseases, Erectile Dysfunction (ED), Skin disorders, Autoimmune disease, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, Infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk A in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0016] The invention further provides a method for treating a disease or a disorder modulated by TrkA or in which the NGF receptor TrkA kinases are involved. The method further comprises administering to a patient, in need thereof, a therapeutically effective amount of a compound of this invention or their stereoisomers, tautomers, or pharmaceutically acceptable salts, isotopes, metabolites, solvates or prodrugs.
[0017] The invention further provides intermediates required for synthesis of the compounds of Formula I.
[0018] The invention further provides for a method of synthesis, separation, and purification of the compounds of the invention.
[0019] The invention further provides the use of novel compounds of Formula I which act as TrkA inhibitor and/or antagonist for the preparation of a medicament useful in the treatment of disorders like Pain, Inflammation or inflammatory diseases, Cancer, Atherosclerosis, Restenosis, Thrombosis, Neurodegenerative diseases like Alzheimer's Disease, Parkinson's disease, Huntington's disease or Progressive supranuclear palsy, Erectile Dysfunction (ED), Skin disorders like Atopic Dermatitis, Eczema, Pruritis or Psoriasis, Autoimmune diseases like Multiple sclerosis, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, Infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk- A.
[0020] Additional features and advantages of the invention will be apparent from the detailed description which follows, taken in conjunction by way of examples, features of the invention.
DETAILED DESCRIPTION OF THE INVENTION [0021] From the foregoing detailed description of certain embodiments, reference will now be made to the exemplary embodiments and examples, it will be apparent that various modifications, additions and other alternative embodiments, examples are possible without departing from the true scope and spirit of the invention. The embodiments and examples discussed were chosen and described to provide the best illustration of the principles of the invention and its practical application to thereby enable one of ordinary skill in the art to use the invention in various embodiments and with various modifications as are suited to the particular use contemplated. All such modifications and variations are within the scope of the invention. Definitions:
[0022] As used herein, the term "alkyl," by itself or as part of another substituent, refers to linear or branched alkyl group with 1 to 10 carbon atoms.
[0023] As used herein, the term "alkenyl," by itself or as part of another substituent, means a straight or branched chain hydrocarbon radical having a single carbon-carbon double bond
[0024] As used herein, the term "Alkoxy" group refers to an— O(alkyl) group, wherein alkyl group is as defined above. [0025] As used herein, the term "Alkynyl" refers to hydrocarbon chain which is straight or branched and contains at least one degree of unsaturation, i.e., at least one carbon-carbon triple bond.
[0026] As used herein, the term "Halogen or Halo" represents fluorine, chlorine, bromine, or iodine.
[0027] As used herein, the term "Haloalkyl" means at least one halogen atom is substituted on an alkyl group. Both halogen and alkyl have the meaning as defined above.
[0028] As used herein, the term "Hydroxy' or 'Hydroxyl" represents— OH. [0029] As used herein, the term "Hydroxyalkyl" means at least one hydrogen atom of an alkyl group is replaced by a hydroxyl group. Alkyl group is as defined above.
[0030] As used herein, the term "Haloalkoxy" means at least one halogen atom is substituted on an alkoxy group, wherein alkoxy and halogen groups are as defined above.
[0031] As used herein, the term "alkoxycarbonyl" and as used herein denotes a group of formula— C(=0)OR wherein R is alkyl; alkyl as defined herein.
[0032] As used herein, the term "3-10 membered heterocyclic ring" refers to a monocyclic or polycyclic ring system, saturated or unsaturated or aromatic; containing one nitrogen atom and optionally 1-3 additional heteroatoms or heterogroups independently selected from O, S, N, CO, SO, or SO2.
[0033] As used herein, the term "hetero-aromatic ring" or "Het-Ar ring" is understood to encompass any heterocyclic aromatic ring having 5 or 6 atoms, containing one or more independent hetero-atoms selected from nitrogen, oxygen and sulfur. It should be noted that a hetero-atom may be positioned on any position on the fused 5 to 6 membered hetero- aromatic ring formed.
[0034] As used herein, the term "cycloalkyl" denotes a saturated carbocyclic ring containing 3 to 6 carbon atoms. [0035] As used herein, the term "heteroatom" refers to a sulfur, nitrogen, or oxygen atom.
[0036] As used herein, the term "aminocarbonyl" refers to a monovalent group of formula -(CO)N(R2)2 where each R2 is independently hydrogen or alkyl. [0037] As used herein, the term "Aryl" refers to monocyclic or polycyclic aromatic ring system. Exemplary aryl groups include, but are not limited to, phenyl, naphthyl, and the like.
[0038] As used herein, the terms "heterocyclyl", "heterocycle" or "heterocyclic", represents a stable 5- to 7-membered monocyclic or stable 8- to 11-membered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, or S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring
[0039] As used herein, the term "carbocyclic ring" refers to a saturated or non- aromatic unsaturated ring. The term "3-6-membered carbocyclic ring" refers to a carbocyclic ring wherein the number of ring carbon atoms is from 3 to 6.
[0040] As used herein, the term "cyano" refers to a substituent having a carbon atom joined to a nitrogen atom by a triple bond.
[0041] As used herein, the term "nitro" refers to the group— N02. [0042] As used herein, the term "amino" refers to the group— NH2
[0043] As used herein, the term "Carbonyl" refers to the divalent group— C(O)-.
[0044] As used herein, the term "cyano (1-3Calkyl)" denotes an alkyl group as defined above wherein a hydrogen atom of the alkyl group is replaced by a cyano (-CN) group.
[0045] As used herein, the term "Ligand" or "L" denotes a linker molecule or ligand molecule. Exemplary Ligand or linker molecules include, but not limited to — O— , — NH— , — S02N(R')— , — C(0)N(R')— ; — N(R')C(0)— , — C(0)N(R')C(0)— , — N(R')S02— , — N(R')S02N(R')— , — NR'C(0)N(R')— , — NR'C(S)N(R')— , or— N(R')C(0)0— .
[0046] As used herein, the term "heteroaryl", as used herein except where noted, represents a stable 5- to 7-membered monocyclic- or stable 9- to 10- membered fused bicyclic heterocyclic ring system which contains an aromatic ring, any ring of which may be saturated, partially saturated, or unsaturated and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S. [0047] As used herein, unless otherwise specifically defined, substituted alkyl, substituted aryl, substituted heteroaryl, and substituted heterocycle include moieties containing from 1 to 3 substituents in addition to the point of attachment to the rest of the compound.
[0048] As used herein, the term Optionally substituted" means that the substitution is optional and therefore it is possible for the designated atom or group to be unsubstituted. When more than one substituent is present on an atom or group, the chosen substituents are independent of each other (i.e. same or different).
[0049] As used herein, the term "stereoisomers" is a general term used for all isomers of an individual molecule that differ only in the orientation of their atoms in space. It is to be understood that all stereoisomeric forms of the compounds of the invention, including but not limited to, diastereomers, enantiomers and atropsiomers, as well as mixtures thereof such as forms, are included in the scope of the present application. [0050] As used herein, the term "tautomer" refers to the coexistence of two (or more) compounds that differ from each other only in the position of one (or more) mobile atoms and in electron distribution, for example, keto-enol tautomers. [0051] As used herein, the term "pharmaceutically acceptable" refers to the carrier, diluent, salts, solvates or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
[0052] As used herein, the term "metabolite" as used herein refers to the formula of any derivative produced in a subject after administration of a parent compound. The derivatives may be produced from the parent compound by various biochemical transformations in the subject such as, for example, oxidation, reduction, hydrolysis, or conjugation and include, for example, oxides and demethylated derivatives. [0053] As used herein, the term "prodrug" refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood as well as the zwitterionic forms of the compounds of the invention
[0054] As used herein, the term 'a therapeutically effective amount' refers to the amount of the compound of the present invention that, when administered to a subject, is effective in (i) at least partially alleviating, inhibiting, preventing and/or ameliorating a condition, or a disorder or a disease mediated by TrkA, TrkB and/or TrkC, associated with TrkA, TrkB and/or TrkC activity or characterized by activity (normal or abnormal) of TrkA, TrkB and/or TrkC; (ii) reducing or inhibiting the activity of TrkA, TrkB and/or TrkC; or (iii) reducing or inhibiting the expression of TrkA, TrkB and/or TrkC.
[0055] As used herein, the term "fusion" or "fusion protein" refers to a co-linear, covalent linkage of two or more proteins or fragments thereof via their individual peptide backbones, most preferably through genetic expression of a polynucleotide molecule encoding those proteins.
[0056] As used herein, the term "TrkA" refers to one of Trk's high affinity binding protein kinase receptors that are activated by Neurotrophins (NT), a group of soluble growth factors Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin 3-5 (NT 3-5). The Trk's are made up of three family members TrkA, TrkB and TrkC that bind to and mediate the signal transduction derived from the Neurotrophins. Inhibitors of the Trk/neutrophin pathway have been demonstrated to be highly effective in numerous pre-clinical animal models of pain. The compounds of the invention are modulators of the Trk receptors, particularly TrkA. [0057] The present invention relates to novel compounds that act as inhibitors of the members of Trk family protein kinases. Particularly, the present invention discloses compounds possessing inhibitory activity against TrkA. The compounds of the present invention are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of the aforementioned diseases.
[0058] According to an embodiment of the present invention, the compounds are represented by general formula I:
Figure imgf000013_0001
Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates, metabolites, isotopes, or prodrugs thereof, wherein:
Ra and Rb are each independently selected from H, alkyl, alkenyl, alkynyl, haloalkyl, halogen, hydroxy, hydroxyalkyl, alkoxy, haloalkoxy, optionally substituted phenyl, optionally substituted 5-6 membered aromatic ring having 1- 3 heteroatoms selected from O, N, and S or Ra and Rb together forms carbonyl group, optionally substituted phenyl which is further optionally substituted with a halogen;
Rc and Rd is H, alkyl, alkenyl, alkynyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, optionally substituted phenyl, optionally substituted 5-6 membered aromatic ring having 1-3 heteroatoms selected from O, N, and S or Rc and Rd together to form a ring (4-6 membered) with or without a hetero atom;
R1 is H, alkyl, alkenyl, alkynyl, haloalkyi , hydroxy, alkoxy, haloalkoxy, (1-3C alkoxy)(l-3C)alkyl, (1-4C alkoxycarbonyl) (1-6Calkyl), mono, di, tri halo(1-4C alkyl), (1-3C alkyl)aminocarbonyl, Cyano(1-3C alkyl), (1-3C haloalkoxy)(1- 3C)alkyl, optionally substituted phenyl, 3-6 membered carbocyclic or heterocyclic ring with one or more heteroatom selected from O, N or S and optionally substituted with one or more substituents independently selected from H, alkyl, alkenyl, alkynyl, haloalkyi, halogen, hydroxy, alkoxy, haloalkoxy, nitro or amino, a 9-10 membered bicyclic heteroaryl having 1-3 ring nitrogen atoms;
R2 and R3 are independently selected from H, alkyl, alkenyl, alkynyl, isopropyl, tert butyl, haloalkyi, halogen, hydroxy, alkoxy, haloalkoxy, optionally substituted phenyl, or optionally substituted 5-6 membered aromatic ring having 1-3 heteroatoms selected from O, N or S or R2 and R3 can be combined to form a ring (5/6-membered) with 1-2 hetero atoms.
L is a ligand selected from— O— ,— NH— ,— S02N(R')— ,— C(0)N(R')— ;— N(R')C(0)— , — C(0)N(R')C(0)— , — N(R')S02— , — N(R')S02N(R')— , — NR'C(0)N(R')— ,— NR'C(S)N(R')— , or— N(R')C(0)0— ; each R' is independently selected from H or alkyl;
Het-Ar ring is selected from H1 or H2;
Figure imgf000014_0001
H1 H2 X1-X7 at each occurrence is a bond, -CR5-, -CH2-or an heteroatom selected from N, O or S;
X8 is selected from O, S, NH, N-alkyl, SO, S02 or C=0
R4, R5 and R6 are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, isopropyl, tert. Butyl, haloalkyi, halogen, mono, di, tri halo(1-4C alkyl) hydroxy, alkoxy, haloalkoxy, cyano, cycloalkyl(3-7 carbon), optionally substituted phenyl, optionally substituted 5-6 membered heterocyclic ring having 1-3 heteroatoms selected from O, N, or S or 3-6 membered carbocyclic ring having one or more heteroatom selected from O, N or S,— NH2, — N(H)(alkyl), — N(alkyl)2, — N(H)C(0)alkyl, — N(alkyl)C(0)alkyl, — N(H)C(0)0 alkyl, — N(alkyl)C(0)Oalkyl, — N(H)S02(alkyl), — N(alkyl)S02(alkyl),— C(0)alkyl, — C(0)OH, — C(0)Oalkyl, — C(0)NH2, — C(0)N(H)(alkyl), — C(0)N(alkyl)2, — S(alkyl), — S(0)alkyl, — S(0)2alkyl, — S(0)2N(H)2,— S(0)2N(H)(alkyl) and— S(0)2N(alkyl)2.
[0059] In another exemplary embodiment, wherein L is urea or optionally substituted urea.
Figure imgf000015_0001
[0060] In another exemplary embodiment, wherein L is substituted urea and each R' can be joined together to form 5-6 membered ring structure. [0061] According to an exemplary embodiment, wherein the H1 is selected from the group consisting of but not limited to:
Figure imgf000015_0002
Figure imgf000016_0001
H1 E H1F JU and R4, R5 are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, isopropyl, tert. Butyl, haloalkyl, halogen, mono, di, tri halo(1-4C alkyl) hydroxy, alkoxy, haloalkoxy, cyano,, cycloalkyl(3-7 carbon), optionally substituted phenyl, optionally substituted 5-6 membered heterocyclic ring having 1-3 heteroatoms selected from O, N, or S or 3-6 membered carbocyclic ring having one or more heteroatom selected from O, N or S,— NH2,— N(H)(alkyl),— N(alkyl)2,— N(H)C(0)alkyl,— N(alkyl)C(0)alkyl, — N(H)C(0)0 alkyl, — N(alkyl)C(0)Oalkyl, — N(H)S02(alkyl), — N(alkyl)S02(alkyl), — C(0)alkyl, — C(0)OH, — C(0)Oalkyl, — C(0)NH2, — C(0)N(H)(alkyl), — C(0)N(alkyl)2, — S(alkyl), — S(0)alkyl, — S(0)2alkyl, — S(0)2N(H)2,— S(0)2N(H)(alkyl) and— S(0)2N(alkyl)2.
[0062] According to anotherexemplary embodiment, wherein the H2 is selected from the group consisting of but not limited to:
Figure imgf000016_0002
H2F and each R6 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, isopropyl, tert. Butyl, haloalkyl, halogen, mono, di, tri halo(1-4C alkyl) hydroxy, alkoxy, haloalkoxy, cyano,, cycloalkyl(3-7 carbon), optionally substituted phenyl, optionally substituted 5-6 membered heterocyclic ring having 1-3 heteroatoms selected from O, N, or S or 3-6 membered carbocyclic ring having one or more heteroatom selected from O, N or S, — NH2, — N(H)(alkyl), — N(alkyl)2, — N(H)C(0)alkyl, — N(alkyl)C(0)alkyl, — N(H)C(0)0 alkyl, — N(alkyl)C(0)Oalkyl, — N(H)S02(alkyl), — N(alkyl)S02(alkyl), — C(0)alkyl, — C(0)OH, — C(0)Oalkyl, — C(0)NH2, — C(0)N(H)(alkyl), — C(0)N(alkyl)2, — S(alkyl), — S(0)alkyl, — S(0)2alkyl, — S(0)2N(H)2, — S(0)2N(H)(alkyl) and— S(0)2N(alkyl)2.
[0063] According to an embodiment, the invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound selected of the Formula I or physiologically acceptable salts thereof, stereoisomers thereof, solvates thereof or the hydrates thereof, or metabolites thereof or isotopes as an active ingredient. The aforementioned pharmaceutical composition is used for preventive and/or therapeutic treatment of diseases caused by abnormal or deregulated TrkA activity. Diseases involving abnormal TrkA activity can be one or more of the following but not limited to Pain, inflammation or inflammatory diseases, Cancer, atherosclerosis, restenosis, thrombosis, Neurodegenerative diseases, Erectile Dysfunction (ED), Skin disorders, Autoimmune disease like Multiple sclerosis, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, Infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
[0064] According to another embodiment of the invention, a method is provided for the prevention and/or therapeutic treatment of a disease or a disorder selected from the group comprising of Pain, inflammation or inflammatory diseases, Cancer, atherosclerosis, restenosis, thrombosis, Neurodegenerative diseases, Erectile Dysfunction (ED), Skin disorders, Autoimmune disease like Multiple sclerosis, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, Infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk A. [0065] According to another embodiment of the present invention, a method is provided for inhibiting tropomyosin receptor kinase A (TrkA) in a patient, by administering a therapeutically effective amount of a compound of the Formula I to the patient.
[0066] According to yet another embodiment of the present invention, a method is provided for the prevention and/or therapeutic treatment of diseases or disorders mentioned above by administering to a patient a therapeutically effective amount of a compound of the Formula I or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier.
[0067] According to yet another embodiment of the present invention, a medicament is provided which can be used for preventive and/or therapeutic treatment of inflammatory diseases. Specifically, compounds of the present invention are used for preventive and/or therapeutic treatment of inflammatory diseases selected from the lung diseases, bowel diseases, interstitial cystitis, and painful bladder syndrome [0068] The Inflammatory lung disease is Asthma or Interstitial Cystitis and Inflammatory bowel disease is Ulcerative Colitis, Crohn's disease or urinary incontinence.
[0069] According to yet another embodiment of the present invention, a method is provided for preventive and/or therapeutic treatment of acute or chronic pain. Specifically, compounds of the present invention are used for preventive and/or therapeutic treatment of acute pain and chronic pain selected from cancer induced pain, bone fracture pain, inflammatory pain, neuropathic pain, surgery, bone fracture, skeletal pain caused by tumor metastasis, osteoarthritis, psoriatic arthritis, rheumatoid arthritis, interstitial cystitits, chronic pancreatitis, visceral pain, inflammatory pain, migraine, chronic lower back pain, bladder pain syndrome, femur fracture pain, hyperalgesia, repetitive motion pain, dental pain, myofascial pain, dysraennorhea, as well as pain associated with angina.
[0070] According to yet another embodiment of the present invention, a method is provided for preventive and/or therapeutic treatment of an imbalance of the regulation of bone remodelling. Specifically, compounds of the present invention are used for preventive and/or therapeutic treatment of osteoporosis, rheumatoid arthritis, and bone metastases, Osteolytic metastases, life- threatening hypercalcemia, spinal cord compression, ankylosing spondylitis, tumor-induced osteolysis, periodontal disease. [0071] According to yet another embodiment of the present invention, compounds of the invention may be used to decrease tolerance and/or dependence to opioid treatment of pain, and for treatment of withdrawal syndrome of e.g., alcohol, opioids, and cocaine.
[0072] According to yet another embodiment of the present invention, a method is provided for preventive and/or therapeutic treatment of abnormal tissue remodelling and fibrotic disorders. Specifically, compounds of the present invention are used for preventive and/or therapeutic treatment of abnormal tissue remodelling and fibrotic disorders selected from Idiopathic pulmonary fibrosis, Raynaud's syndrome, endometrial fibrosis, atrial fibrosis, myelofibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, scleroderma, systemic sclerosis, atherofibrosis, ocular fibrosis, scarring and cirrhosis.
[0073] According to yet another embodiment of the present invention, a medicament is provided which can be used for preventive and/or therapeutic treatment of cancer related to dysregulation of TrkA. The dysregulation of TrkA is due to chromosomal rearrangements like one or more chromosome translocations, over-expression, inversions, insertions, deletions or mutationsin the TrkA protein. These rearrangements have been shown to be oncogenic driver in a number of cancers like Non Small cell Lung Cancer, colorectal carcinoma, papillary thyroid carcinoma, Glioblastoma, Melanoma, Acute Myeloid Leukemia, Large Cell Neuroendocrine Carcinoma, Gastric Carcinoma, Pancreatic Carcinoma, Prostrate Carcinoma, Head and Neck squamous cell carcinoma.
[0074] The dysregulation of TrkA as a result of one or more chromosome translocations or inversions leads to formation of TrkA gene fusions. The TrkA gene fusion can be LMNA-TrkA, TFG-TrkA, TPM3-TrkA, CD74-TrkA, NFASC- TrkA, MPRIP-TrkA, BCAN-TrkA, TP53-TrkA, RNF213-TrkA, RABGAP1 L-TrkA, IRF2BP2-TrkA, SQSTMI-TrkA, SSBP2-TrkA, or TPR-TrkA.
[0075] According to yet another embodiment of the present invention, a medicament is provided which can be used for preventive and/or therapeutic treatment of cancer. Specifically, compounds of the present invention are used for preventive and/or therapeutic treatment of cancer selected from lung adenocarcinomas, breast cancer, thyroid carcinoma, pancreatic cancer, ovarian carcinoma, gastric carcinoma, malignant mesothelioma, prostate carcinoma, neuroblastic tumors, colorectal carcinoma, spitzoid melanoma, salivary adenoid cystic carcinoma, stomach cancer, kidney cancer, urethral cancer, glioblastoma multiforme, oral squamous cell carcinoma, Acute Myeloid Leukemia, cholangiocarcinoma, mastocytosis or extramammary Paget's disease.
[0076] According to yet another embodiment of the present invention, depending upon the particular conditions to be treated or prevented, additional therapeutic agents may be administered together with the compounds of this invention. In some cases, these additional therapeutic agents are normally administered to treat or prevent the same condition. For example, methotrexate may be combined with the compounds of this invention to treat leukemia.
[0077] According to one embodiment, additional therapeutic agent is selected from anti-TNF dugs, or with a circulating receptor fusion protein such as etanercept (Enbrel), targeted kinase inhibitors, these additional therapeutic agents may be administered with Compound of the Formula I or a pharmaceutically acceptable salt thereof as part of the same or separate dosage forms, via the same or different routes of administration, and on the same or different administration schedules according to standard pharmaceutical practice known to one skilled in the art.
[0078] According to another embodiment, additional therapeutic agent is selected from anti-inflammatory compounds, steroids, analgesics, opioids, calcitonin gene-related peptide receptor antagonists, subtype-selective ion channel modulators, anticonvulsants, dual serotonin-norepinephrine reuptake inhibitors, KSP (kinesin spindle protein) inhibitors, JAK family kinase inhibitors, and tricyclic antidepressants..cabozantinib, crizotinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, pazopanib, pertuzumab, regorafenib, sunitinib, and trastuzumab. sorafenib, trametinib, vemurafenib arsenic trioxide, bleomycin, cabazitaxel, capecitabine, carboplatin, cisplatin, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, doxorubicin, etoposide, fluorouracil, gemcitabine, irinotecan, lomustine, methotrexate, mitomycin C, oxaliplatin, paclitaxel, pemetrexed, temozolomide, vincristine, Aflibercept, bevacizumab, aldesleukin, ipilimumab, lambrolizumab, nivolumab and sipuleucel-T. [0079] One or more compounds of Formula I can be supplied in the form of a therapeutic composition that is within the scope of the present application.
[0080] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art. Examples
Examples of the compounds of the present invention are shown in Table 1. Table 1 : Exemplary compounds from Formula I (Examples 1-202)
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
Example 109 Example 110 Example 111 Example 112
Figure imgf000026_0001
Example 1396-,
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
[0081] The above mentioned compounds are just for exemplary purposes and not to limit the scope of the invention.
[0082] Several methods for preparing the compounds of this invention are illustrated in the followingSchemes and Examples. Starting materials and the requisite intermediates are in some cases commercially available, or can be prepared according to literature procedures or as illustrated herein.
[0083] The compounds of this invention may be prepared by employing reactions as shown in the following schemes, in addition to other standard manipulations that are known in the literature or exemplified in the experimental procedures. Substituent numbering as shown in the schemes does not necessarily correlate to that used in the claims and often, for clarity, a single substituent is shown attached to the compound where multiple substituents are allowed under the definitions hereinabove. Reactions used to generate the compounds of this invention are prepared by employing reactions as shown in the schemes and examples herein, in addition to other standard manipulations such as ester hydrolysis, cleavage of protecting groups, etc., as may be known in the literature or exemplified in the experimental procedures.
[0084] Reaction Schemes: The compounds of the present invention can be prepared readily according to the following Schemes and specific examples, or modifications thereof, using readily available starting materials, reagents and conventional synthetic procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art but are not mentioned in greater detail. The general procedures for making the compounds claimed in this invention can be readily understood and appreciated by one skilled in the art from viewing the following Schemes.
Method 1
I
Figure imgf000030_0001
Step 1
Method 2
Figure imgf000030_0002
Intermediates intermediate B
A or D or I
Method 3
Figure imgf000030_0003
Intermediates Intermediate C
A or D or I
Experimental Section: [0085] All commercially available reagents and solvents were purchased from combi-blocks, Aldrich, Avra etc., and used as received. Reactions using air or moisture sensitive reagents were performed under an atmosphere of nitrogen using freshly opened drySolv solvents. Reaction progress was monitored by TLC and/or LCMS. Flash column chromatography was performed with Grace Purification System or Isco Combi Flash Companion Systems using pre-packed silica gel columns (40-60 μηι particle size RediSep or 20-40 μηι spherical silica gel RediSep Gold columns or reveleris columns or similar columns from other vendors). Specific optical rotation is recorded on Rudolph and melting point on Buchi instrument. Preparative reverse phase HPLC purifications were performed on Agilent or Waters instrument. NMR spectra were measured on Agilent 300 or 400 MHz spectrometer and chemical shifts were reported in ppm downfield from TMS using residual non deuterated solvent as internal standards (CHCI3, 7.26 ppm; DMSO, 2.50 ppm; MeOH, 3.31 ppm). The following abbreviations are used: br = broad signal, s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet. The purity of final compounds was verified by HPLC in all cases using stationary phase and a gradient of water/acetonitrile (5-95% over 10 min, 0.05% TFA in both phases) at a flow rate of 0.4 mL/min.
[0086] List of Intermediates required for synthesis of the compounds of Formula I described below.
Preparation of Intermediates [0087] Certain intermediates were directly purchased from commercial vendors and used as such for the respective synthesis of examples of Formula I. The other intermediates were prepared either by following reported literature procedures or modified as per the requirement or applied the skills in derivatizing with appropriate substitutions. [0088] Intermediate A: Quinoline Intermediates (A1-A72)
Scheme 1 (This scheme was described in Chemistry - A European Journal, 2012, 18, 5530-5535; Tetrahedron, 2004, 60, 2937-2942).
Figure imgf000032_0001
Step 2
Scheme 2 (This scheme was described in J. Org. Chem. 2004, 69, 1565-1570)
Figure imgf000032_0002
Scheme 3 (This scheme was described in WO2014062667 A1)
Figure imgf000032_0003
20 min, MW
Step 1
Scheme 4
Figure imgf000032_0004
Scheme 5 (Part of this scheme was described in US2008/161340 A1)
CN
Figure imgf000032_0005
[0089] Intermediates such as A1-A5 were purchased from commercial vendors and other intermediates A6-A72 were synthesized based on the above general schemes 1-5 and the analytical data are shown below.
Intermediate A1 : Quinolin-3-amine
Intermediate A2: 2-Chloroquinolin-3-amine
Intermediate A3: Quinolin-4-amine Intermediate A4: Quinazolin-4-amine
Intermediate A5: Quinoxalin-2-amine
Intermediate A6: 2-Phenylquinolin-3-amine. LCMS (M+H): 221.10
Intermediate A7: 2-Methylquinolin-3-amine. LCMS (M+H): 158.95.
Intermediate A8: 2-Ethylquinolin-3-amine. LCMS (M+H): 173.12.
Intermediate A9: 2-(Cyclopropyl)-quinolin-3-amine. LCMS (M+H): 185.28.
Intermediate A10: 2-(Trifluoromethyl)-quinolin-3-amine. LCMS(M+H): 213.10.
Intermediate A11 : 6-Fluoro-2-phenylquinolin-3-amine. LCMS (M+H): 238.95.
Intermediate A12: 7-Fluoro-2-phenylquinolin-3-amine. 1 H NMR (DMSO-cfe, 300 MHz): δ 7.77-7.72 (m, 3H), 7.60-7.37 (m, 5H), 7.40-7.30 (m, 1 H), 5.24 (s, 2H).
Intermediate A13: 6-Methoxy-2-phenylquinolin-3-amine. 1 H NMR (DMSO-cfe, 300 MHz): δ 7.72-7.66 (m, 3H), 7.53-7.44 (m, 3H), 7.30 (s, 1 H), 7.03-6.97 (m, 2H), 5.22 (s, 2H), 3.87 (s, 3H).
Intermediate A14: 6,7-Dimethoxy-2-phenylquinolin-3-amine. LCMS (M+H): 281.19.
Intermediate A15: 6,7-Dimethoxy-2-methylquinolin-3-amine. LCMS (M+H): 219.24.
Intermediate A16: 6-Fluoro-2-methylquinolin-3-amine. LCMS (M+H): 177.08. Intermediate A17: 6-Methyl-2-methylquinolin-3-amine. LCMS (M+H): 173.12.
Intermediate A18: 7-Methyl-2-methylquinolin-3-amine. LCMS (M+H): 173.12.
Intermediate A19: 5-Methyl-2-methylquinolin-3-amine. LCMS (M+H): 173.05
Intermediate A20: 5-Fluoro-2-methylquinolin-3-amine. LCMS (M+H): 177.04.
Intermediate A21 : 8-Methyl-2-methylquinolin-3-amine. LCMS (M+H): 173.30. Intermediate A22: 8-Fluoro-2-methylquinolin-3-amine. LCMS (M+H): 177.25.
Intermediate A23: 5-Methoxy-2-methylquinolin-3-amine. LCMS (M+H):
189.29.
Intermediate A24: 6-Methoxy-2-methylquinolin-3-amine. LCMS (M+H):
189.29. Intermediate A25: 7-Methoxy-2-methylquinolin-3-amine. LCMS (M+H):
189.03.
Intermediate A26: 8-Methoxy-2-methylquinolin-3-amine. LCMS (M+H):
189.10.
Intermediate A27: 7-Fluoro-2-methylquinolin-3-amine. LCMS (M+H): 177.08.
Intermediate A28: 6-Methoxy-2-methyl-7-morpholinoquinolin-3-amine. LCMS (M+H): 274.10.
Intermediate A29: 6-Fluoro-7-methyl-2-phenylquinolin-3-amine. LCMS (M+H): 253.31.
Intermediate A30: 6-Bromo-8-methoxy-2-methylquinolin-3-amine.
Intermediate A31 : 8-Methoxy-2,7-dimethylquinolin-3-amine. LCMS (M+H): 265.46.
Intermediate A32: 6-Phenyl-[1 ,3]dioxolo[4,5-g]quinolin-7-amine. LCMS (M+H): 265.25.
Intermediate A33: N-(3-Amino-7-methoxy-2-phenylquinolin-6-yl)acetamide. LCMS (M+H): 308.16.
Intermediate A34: 8-Bromo-2-methylquinolin-3-amine. LCMS (M+H+2H): 238.93.
Intermediate A35: 6-Methyl-[1 ,3]dioxolo[4,5-g]quinolin-7-amine. LCMS (M+H): 203.07.
Intermediate A36: 7-Methyl-2,3-dihydro-[1 ,4]dioxino[2,3-g]quinolin-8-amine. LCMS (M+H): 217.11.
Intermediate A37: 7-Phenyl-2,3-dihydro-[1 ,4]dioxino[2,3-g]quinolin-8-amine. LCMS (M+H): 279.11.
Intermediate A38: N-(3-Amino-6-methoxy-2-phenylquinolin-7-yl)acetamide. LCMS (M+H): 308.16.
Intermediate A39: N-(3-Amino-6-methoxy-2-methylquinolin-7-yl)acetamide. LCMS (M+H): 246.13.
Intermediate A40: 6-Methoxy-7-methyl-2-phenylquinolin-3-amine. LCMS (M+H): 265.16. Intermediate A41 : 3-Amino-7-fluoro-2-methylquinoline-6-carbonitrile. LCMS (M+H): 202.06.
Intermediate A42: 3-Amino-7-methoxy-2-methylquinoline-6-carbonitrile.
Intermediate A43: 3-Amino-6-fluoro-2-methylquinoline-7-carbonitrile. LCMS (M+H): 202.03.
Intermediate A44: 3-Amino-6-fluoro-2-phenylquinoline-7-carbonitrile. LCMS (M+H): 264.13.
Intermediate A45: 3-Amino-6-methoxy-2-phenylquinoline-7-carbonitrile. 1 H NMR (DMSO-cfe, 300 MHz): δ 8.17 (s, 1 H), 7.70-7.67 (m, 2H), 7.55-7.48 (m, 3H), 7.28(d, J = 13.2 Hz, 2H), 5.81 (b s, 2H), 3.97 (s, 3H).
Intermediate A46: 6-(Difluoromethoxy)-7-methoxy-2-methylquinolin-3-amine. LCMS (M+H):255.05.
Intermediate A47: 2,2-Difluoro-6-methyl-[1 ,3]dioxolo[4,5-g]quinolin-7-amine. LCMS (M+H): 239.20.
Intermediate A48: 2-Cyclohexylquinolin-3-amine. LCMS (M+H):227.42.
Intermediate A49: 6-(Trifluoromethyl)-[1 ,3]dioxolo[4,5-g]quinolin-7-amine. LCMS (M+H):257.19.
Intermediate A50: 7-Methyl-2-phenyl-1 ,8-naphthyridin-3-amine. LCMS (M+H): 236.22.
Intermediate A51 : 6,7-Dimethoxyquinolin-3-amine. LCMS (M+H): 205.04.
Intermediate A52: [1 ,3]Dioxolo[4,5-g]quinolin-7-amine. LCMS (M+H): 189.07.
Intermediate A53: 6-Methyl-2-phenylquinolin-3-amine. LCMS (M+H): 235.1.
Intermediate A54: 6-Fluoro-3-amino-2-phenylquinoline. LCMS (M+H):
238.95.
Intermediate A55: 7-Methyl-3-amino-2-phenylquinoline. LCMS - (M+H): 234.99.
Intermediate A56: 7-Methoxy-2-phenylquinolin-3-amine. LCMS (M+H):
251.10.
Intermediate A57: 7-Fluoro-6-methoxy-2-phenylquinolin-3-amine. LCMS (M+H): 269.13. Intermediate A58: 7-Fluoro-6-methyl-2-phenylquinolin-3-amine. LCMS (M+H): 253.08.
Intermediate A59: N-(3-Amino-7-fluoro-2-phenylquinolin-6-yl)acetamide.
Intermediate A60: 6-Methoxy-7-methyl-2-methylquinolin-3-amine. LCMS (M+H): 203.20.
Intermediate A61 : 6-Methoxy-7-fluoro-2-methylquinolin-3-amine. LCMS (M+H): 207.03.
Intermediate A62: Tert-butyl (3-amino-7-methoxy-2-methylquinolin-6- yl)(methyl)carbamate. LCMS (M+H): 380.24.
Intermediate A63: 2-(1-Methyl-1 H-pyrazol-4-yl)quinolin-3-amine. LCMS (M+H): 224.94.
Intermediate A64: 2-(Pyridin-3-yl)quinolin-3-amine. LCMS (M+H): 222.23.
Intermediate A65: 2-(Pyridin-4-yl)quinolin-3-amine. LCMS (M+H): 222.23.
Intermediate A66: 2-(Pyrimidin-5-yl)quinolin-3-amine.LCMS (M+H): 223.12. Intermediate A67: 2-(Thiazol-5-yl)quinolin-3-amine. LCMS (M+H): 228.17.
Intermediate A68: 2-(2,4-Difluorophenyl)quinolin-3-amine. LCMS
(M+H):257.15.
Intermediate A69: 2-(3,5-difluorophenyl)quinolin-3-amine. LCMS
(M+H):257.15.
Intermediate A70: 2-Morpholinoquinolin-3-amine. LCMS (M+H): 230.29.
Intermediate A71 : 2-Phenyl-5,6,7,8-tetrahydroquinolin-3-amine. LCMS:
(M+H): 225.04.
Intermediate A72: 6-(Difluoromethyl)-[1 ,3]dioxolo[4,5-g]quinolin-7-amine. LCMS (M+H): 239.01.
[0090] Intermediate D: Dibenzofuran& Dibenzothiophene Intermediates (D1- D10)
[0091] Intermediates D1-D10 were synthesized based on the Schemes 6-8 and the analytical data for each intermediate are shown below.
Scheme 6 (This scheme was described in Synthesis, 1983, 234 - 235)
Figure imgf000037_0001
Scheme 7 (This scheme was described in J. Med. Chem. 2010, 53, 8498-8507)
Figure imgf000037_0002
Scheme 8 (This scheme was described in J. Am. Chem. Soc, 1954, 76, 2906- 2908)
Figure imgf000037_0003
6. NaN02
H2S04
EtOH
Figure imgf000037_0004
[0092] Analytical data for D1-D10
Intermediate D1 : 6-Methoxydibenzo [b,d]furan-1 -amine. LCMS (M+H):
214.10. Intermediate D2: Dibenzo[b,d]furan-1 -amine. LCMS (M+H): 184.10.
Intermediate D3: 8-Methyldibenzo[b,d]furan-1 -amine. LCMS(M+H): 198.00.
Intermediate D4: 8-Methoxydibenzo[b,d]furan-1 -amine. 1 H NMR (CDCb, 300 MHz): δ 8.44 (s, 1 H), 8.28-8.25 (m, 1 H), 8.03-8.00 (m, 1 H), 7.57-7.54 (m, 1 H), 7.45 (m, 1 H), 7.21 -7.18 (m, 1 H), 3.94 (s, 3H).
Intermediate D5: 8-Fluorodibenzo[b,d]furan-1 -amine. 1 H NMR (CDCb, 300 MHz): δ 7.51 -7.45 (m, 2H), 7.30-7.28 (m, 1 H), 7.15 (dt, J= 2.4, 9.0 Hz, 1 H), 7.01 (d, J = 8.4 Hz, 1 H), 6.63 (d, J = 8.4 Hz, 1 H).
Intermediate D6: 7-Fluorodibenzo[b,d]furan-1-amine. LCMS (M+H): 202.20.
Intermediate D7: 7-Methoxydibenzo[b,d]furan-1 -amine. LCMS (M+H): 214.20.
Intermediate D8: 6-Methyldibenzo[b,d]furan-1-amine.
Intermediate D9: 4-Methoxy-5,5-dioxo-dibenzo[b,<^thiophen-1 -ylamine.
LCMS (M+H): 262.03.
Intermediate D10: 5,5-Dioxo-dibenzo[ib,c/|thiophen-1 -ylamine. LCMS (M+H): 231 .95.
[0093] Intermediate I : Isoquinoline Intermediates (11 -130)
[0094] Intermediates 11-130 were synthesized based on the general Schemes 9- 12 and the analytical data for each intermediate are shown below.
Scheme 9 (Part of the scheme was described in WO 2007/53346 A1 and Chemistry - A European Journal, 2013, 19, 1 1553 - 1 1557)
PhCOCH3
Figure imgf000038_0001
Scheme 10 (This scheme was described inWO 2007/53346 A1)
Figure imgf000039_0001
Scheme 11 (Part of the scheme was described in Org. Lett. 2009, 7 7, 2469
Figure imgf000039_0002
Scheme 12 (Part of the scheme was described in Heterocycles, 2000, 52, 1371 - 1383)
Figure imgf000039_0003
[0095] Analytical data for 11-130 Intermediate 11 : 7-Fluoro-1-methyl-3-phenylisoquinolin-4-amine.LCMS: (M+H)=253.10.
Intermediate I2: 1-(1-Methyl-1 H-pyrazol-4-yl)-3-phenylisoquinolin-4-amine. LCMS (M+H): 301.34.
Intermediate I3: 7-Methoxy-1-methyl-3-phenylisoquinolin-4-amine. LCMS: (M+H)=265.31.
Intermediate I4: 1-Methyl-3-phenylisoquinolin-4-amine. LCMS: (M+H):
235.09.
Intermediate I5: 1 ,7-Dimethyl-3-phenylisoquinolin-4-amine. LCMS: (M+H): 249.41. Intermediate 16: 3-Phenyl-1-(pyridin-3-yl)isoquinolin-4-amine. LCMS: (M+H): 298.41.
Intermediate I7: 8-Methoxy-1-methyl-3-phenylisoquinolin-4-amine. LCMS: (M+H): 265.08.
Intermediate I8: 1 ,3-Diphenylisoquinolin-4-amine.
Intermediate I9: 6-Methoxy-1-methyl-3-phenylisoquinolin-4-amine. LCMS: (M+H): 265.25.
Intermediate 110: 1 ,6-Dimethyl-3-phenylisoquinolin-4-amine. LCMS: (M+H): 249.23.
Intermediate 111 : 6,7-Dimethoxy-1-methyl-3-phenylisoquinolin-4-amine. LCMS: (M+H): 295.39.
Intermediate 112: 6-Fluoro-1-methyl-3-phenylisoquinolin-4-amine. LCMS: (M+H)=295.39.
Intermediate 113: 1-Chloro-3-phenylisoquinolin-4-amine. ESI-MS m/z: 255.34 (M+H)+.
Intermediate 114: 5-Methoxy-3-phenylisoquinolin-4-amine. LCMS: (M+H): 251.07.
Intermediate 115: 8-Fluoro-3-phenylisoquinolin-4-amine. LCMS: (M+H): 239.09.
Intermediate 116: 7-Fluoro-3-phenylisoquinolin-4-amine. LCMS: (M+H) = 239.07.
Intermediate 117: 1-(1-Methyl-1 H-pyrazol-4-yl)isoquinolin-4-amine. LCMS: (M+H) = 225.28.
Intermediate 118: 3-Methyl-1-(1-methyl-1 H-pyrazol-4-yl)isoquinolin-4-amine. ESI-MS m/z: 239.36 (M+H)+.
Intermediate 119: 3-Phenylisoquinolin-4-amine. ESI-MS m/z: 221.08 (M+H)+.
Intermediate I20: 3-Methylisoquinolin-4-amine. ESI-MS m/z: 159.24 (M+H)+.
Intermediate 121 : 4-Aminoisoquinoline-3-carbonitrile. ESI-MS m/z: 170.05 (M+H)+.
Intermediate I22: 3-(3-Fluorophenyl)-1-methylisoquinolin-4-amine. LC- MS(M+H)+:253.23. Intermediate 123: 3-(2-Fluorophenyl)-1-methylisoquinolin-4-amine. LC-MS (M+H): 253.32.
Intermediate I24: 1-Methoxy-3-phenylisoquinolin-4-amine. LCMS: (M+H): 251.03
Intermediate I25: tert-Butyl (4-amino-3-phenylisoquinolin-1-yl)carbamate. LCMS: (M+H): 336.24.
Intermediate I26: 1-Fluoro-3-phenylisoquinolin-4-amine. ESI-MS m/z: 239.29 (M+H)+.
Intermediate I27: 4-Amino-3-phenylisoquinoline-1-carbonitrile. ESI-MS m/z: 246.21 (M+H)+.
Intermediate I28: 1-Morpholino-3-phenylisoquinolin-4-amine. LCMS: (M+H) =306.42.
Intermediate I29: 1-(4-Amino-3-phenylisoquinolin-1-yl)piperidin-4-ol. LCMS: (M+H) =320.26.
Intermediate 130: Methyl 4-amino-7-fluoro-3-phenylisoquinoline-1- carboxylate. LCMS: (M+H) =296.94.
[0096] Intermediate B: Pyrrolidin-3-amines (B1-B21)
[0097] Substituted pyrrolidin-3-amine intermediates were synthesized by using appropriate starting materials based on the reported literature methods (WO2012/125668, WO2014/078378, Expert Opin. Ther. Patents, 2014, 24(7), 731-744, J. Med. Chem. 2012, 55, 8903-8925, WO2011/147951 , J. Chem. Soc, Chem. Commun. 1985, 1566-1567 and Journal of Organic Chemistry, 1992, 57, 4404 - 4414). Herein intermediates B1 - B21 were used for synthesis of examples described in Formula I. Intermediate B1 : (3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3-amine. LCMS (M+H): 221.10.
Intermediate B2: (3S,4R)-4-(3,4-Difluorophenyl)-1-(2-methoxyethyl)pyrrolidin- 3-amine. HCI. LCMS-(M+H): 257.20.
Intermediate B3: (3S,4R)-4-(3-Fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3- amine.HCI. LCMS (M+H): 239.40. Intermediate B4: 3-((3R,4S)-4-amino-1-(2-methoxyethyl)pyrrolidin-3- yl)benzonitrile.HCI. LCMS (M+H): 245.98.
Intermediate B5: (3S,4R)-1-(2-Methoxyethyl)-4-(pyridin-3-yl)pyrrolidin-3- amine.HCI. LCMS (M+H): 221.98.
Intermediate B6: (3S,4R)-1-(2-Methoxyethyl)-4-(1-methyl-1 H-pyrazol-4- yl)pyrrolidin-3-amine.HCI. LCMS (M+H): 225.20.
Intermediate B7: (3S,4R)-4-(tert-butyl)-1-(2-methoxyethyl)pyrrolidin-3- amine.HCI. LCMS (M+H): 201.41
Intermediate B8: Methyl 2-((3S,4R)-3-amino-4-phenylpyrrolidin-1-yl)acetate. LCMS (M+H)+: 235.19.
Intermediate B9: Methyl 2-((3R,4S)-3-Amino-4-phenylpyrrolidin-1-yl)acetate hydrochloride.
Intermediate B10: (3R,4S)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine hydrochloride. 1 HNMR (CD3OD, 300 MHz): δ 7.48-7.39 (m, 5H), 4.29-4.24 (m, 1 H), 4.08-4.05 (m, 2H), 3.78-3.75 (m, 2H), 3.65-3.59 (m, 4H), 3.58 (m, 1 H), 3.43 (s, 3H).
Intermediate B11 : (3S,4R)-1-(2-Fluoroethyl)-4-phenylpyrrolidin-3-amine hydrochloride. LCMS (M+H): 209.10.
Intermediate B12: (3R,4S)-1-(2-Fluoroethyl)-4-phenylpyrrolidin-3-amine hydrochloride. LCMS (M+H): 209.10.
Intermediate B13: 2-((3S,4R)-3-Amino-4-phenylpyrrolidin-1-yl)acetonitrile hydrochloride. LCMS (M+H): 202.31.
Intermediate B14: 2-((3S,4R)-3-Amino-4-phenylpyrrolidin-1-yl)acetamide hydrochloride. LCMS (M+H): 220.00.
Intermediate B15: (3S,4R)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-amine hydrochloride.LCMS (M+H)+: 244.92. Intermediate B16: (3R,4S)-4-Phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-amine hydrochloride. LCMS (M+H): 245.43.
Intermediate B17: (3S,4R)-1-(2,2-Difluoroethyl)-4-phenylpyrrolidin-3-amine hydrochloride. LCMS (M+H): 227.34. Intermediate B18: 1-((3S,4R)-3-amino-4-phenylpyrrolidin-1-yl)-2- methoxyethan-1-one hydrochloride. LCMS (M+H): 235.33.
Intermediate B19: (3S,4R)-1-(Oxetan-3-yl)-4-phenylpyrrolidin-3-amine hydrochloride. 1 HNMR (DMSO-cfc, 300MHz): δ 8.22 (br s, 2H), 7.42-7.31 (m, 5H), 4.67-4.64 (m, 2H), 4.57-4.51 (m, 2H), 4.02 (m, 1 H), 3.92-3.74 (m, 2H), 3.41-3.34 (m, 2H), 3.28-2.96 (m, 2H).
Intermediate B20: 3-Amino-1-(2-methoxyethyl)-4-phenylpyrrolidin-2-one.
Intermediate B21 : 4-Amino-1-(2-methoxyethyl)-3-phenylpyrrolidin-3-ol dihydrochloride. LCMS: (M+1) = 237.17.
[0098] The present invention will now be illustrated in greater detail with reference to Examples, but the present invention should not be interpreted as being restricted thereto.
[0099] Preparation of Examples 1-202
[00100] Example 1 : 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(quinolin-3-yl)urea [00101] This compound was synthesized using method 3 as mentioned in the general scheme.
[00102] To a solution of (3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidine- 3-carboxylic acid (0.15 g, 0.6 mmol) in toluene (10 mL) was added diphenylphosphoryl azide (0.24 g, 0.96 mmol), diisopropylethylamine (0.32 mL, 1.80 mmol) and the resulting mixture was heated to reflux temperature for 1 h. The reaction mixture was then cooled to room temperature followed by 3- aminoquinoline (Intermediate A1) (0.1 g, 0.72 mmol) was added and it was heated to reflux for 24 h. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. The residue thus obtained was diluted with 10% MeOH/dichloromethane, washed with water (10 ml_), brine (10 ml_), dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography by eluting with 2% MeOH/dichloromethane to afford the desired product as a pale brown gummy material. Yield: 0.035 g (6%); (1HNMR CDCb, 300 M Hz): δ 8.69 (br s, 1 H), 8.59 (br s, 1 H), 8.01 (d, J = 8.4 Hz, 1 H), 7.75 (d, J = 8.0 Hz, 1 H), 7.56 (t, J = 7.6 Hz, 1 H), 7.48 (t, J = 7.6 Hz, 1 H), 7.35-7.31 (m, 2H), 7.28-7.24 (m, 3H), 4.22-4.13 (m, 1 H), 3.58 (m, 3H), 3.50-3.45 (m, 1 H), 3.33 (s, 3H), 3.28 - 3.26 (m, 1 H), 2.92-2.84 (m, 2H), 2.79- 2.75 (m, 1 H), 2.46 (t, J= 9.0 Hz, 1 H); LCMS (M+H): 391.20.
[00103] Example 2: 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(2-phenylquinolin-3-yl)urea. This compound was prepared according to the above mentioned protocol using the intermediate A6 and (3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidine-3-carboxylic acid. 1 HNMR (CD3OD, 300 M Hz): δ 8.64 (s, 1 H), 7.98 (d, J= 8.4 Hz, 1 H), 7.87 (d, J = 7.8 Hz, 1 H), 7.68-7.52 (m, 7H), 7.33-7.24 (m, 5H), 4.30-4.26 (m, 1 H), 3.56 (t, J = 5.1 Hz, 2H), 3.35 (s, 3H), 3.19-3.16 (m, 3H), 2.90-2.66 (m, 4H); LCMS (M+H): 467.4. [00104] Example 3: 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(2-methylquinolin-3-yl)urea
[00105] This compound was synthesized using method 1 as mentioned in the general scheme.
[00106] Step 1 : Preparation of phenyl 2-methylquinolin-3-ylcarbamate: To a solution of 2-methylquinolin-3-amine (Intermediate A7) (0.05 g, 0.31 mmol) and pyridine (0.076 ml_, 0.94 mmol) in THF (5 ml_) at 0°C was added phenylchloroformate (0.076 g, 0.47 mmol) drop-wise, and the resulting mixture was stirred at room temperature for 2 h. Ice-cold water was added to the reaction mixture and it was extracted with ethyl acetate (2 x 25 ml_).The combined organic layers were washed with water (10 ml_), brine (10 ml_) and dried over sodium sulphate. The organic layer was filtered and concentrated under reduced pressure to afford the title compound as a pale brown solid. Yield: 0.24 g (29%); LCMS (M+H): 278.91.
[00107] Step 2: Preparation of 1-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)-3-(2-methylquinolin-3-yl)urea: To a solution of (3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride (0.18 g, 0.64 mmol) and diisopropylethylamine(0.32 ml_, 1.92 mmol) in DMF (5 ml_) was added phenyl 2-methylquinolin-3-ylcarbamate (0.18 g. 0.64 mmol) slowly at 0°C, and the resulting mixture was stirred at room temperature for 12 h. The reaction mixture was diluted with water (10 ml_) and extracted with ethyl acetate (25 ml_). The extracts were washed with water (10 ml_), brine (10 ml_) and dried over sodium sulphate. The organic layer was filtered, concentrated under reduced pressure and the residue was purified by flash column chromatography eluting with 2% MeOH/CHC to afford the title compound as an off-white solid. Yield: 0.045 g (10%); 1 HNMR (CD3OD, 400 MHz): δ 8.51 (s, 1 H), 7.90 (d, J = 8.4 Hz, 1 H), 7.80 (d, J = 7.6 Hz, 1 H), 7.62 (dt, J = 0.8 Hz and 6.8 Hz, 1 H), 7.51 (t, J = 6.8 Hz, 1 H), 7.43-7.33 (m, 4H), 7.26 (t, J = 7.2 Hz, 1 H), 4.45-4.40 (m, 1 H), 3.59 (t, J= 5.6 Hz, 2H), 3.37 (s, 3H), 3.36-3.34 (m, 1 H), 3.33-3.23 (m, 1 H), 3.13-2.97 (m, 1 H), 2.96-2.94 (m, 1 H), 2.88-2.77 (m, 2H), 2.70-2.68 (m, 1 H), 2.65 (s, 3H), LCMS (M+H): 404.87.
[00108] The following examples were prepared according to the above mentioned procedure by using appropriate intermediates.
[00109] Example 4: 1-(2-Ethylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR(CD3OD, 400 MHz): δ 8.45 (s, 1 H), 7.91 (d, J = 8.0 Hz, 1 H), 7.77 (d, J = 8.4 Hz, 1 H), 7.60 (dt, J = 1.2 Hz and 8.4 Hz, 1 H), 7.48 (t, J = 7.2 Hz, 1 H), 7.37-7.32 (m, 4H), 7.30-7.23 (m, 1 H), 4.41-4.39 (m, 1 H), 3.57 (t, J= 5.2 Hz, 2H), 3.35 (s, 3H), 3.26-3.21 (m, 1 H), 3.1 1- 3.07 (m, 1 H), 2.99-2.91 (m, 3H), 2.83-2.76 (m, 3H), 2.67 - 2.65 (m, 1 H), 1.30 (t, J = 8.0 Hz, 3H). LCMS (M+H): 419.22. [00110] Example 5: 1-(2-Cyclopropylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR(CD3OD, 300 MHz): δ 8.38 (s, 1 H), 7.83 (d, J = 8.4 Hz, 1 H), 7.72 (d, J = 7.2 Hz, 1 H), 7.56-7.51 (m, 1 H), 7.44-7.29 (m, 5H), 7.25-7.22 (m, 1 H), 4.43-4.38 (m, 1 H), 3.56 (t, J= 5.4 Hz, 2H), 3.35 (s, 3H), 3.23-3.08 (m, 1 H), 3.08-3.05 (m, 1 H), 2.93-2.88 (m, 1 H), 2.83-2.71 (m, 3H), 2.65-2.59 (m, 1 H), 2.23-2.18 (m, 1 H), 1.15-1.09 (m, 2H), 1.07-1.01 (m, 2H). LCMS (M+H): 431.0.
[00111] Example 6: 1-(2-(Trifluoromethyl)quinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR(DMSO-cfe, 400 MHz): δ 8.87 (s, 1 H), 8.05-7.99 (m, 3H), 7.76-7.70 (m, 2H), 7.59 (d, J = 7.6 Hz, 1 H), 7.33-7.30 (m,4H), 7.24-7.22 (m, 1 H), 4.20-4.17 (m, 1 H), 3.47 (t, J= 5.6 Hz, 2H), 3.26 (s, 3H), 3.22-3.18 (m, 1 H), 3.13-3.08 (m, 1 H), 2.93-2.89 (m, 1 H), 2.71-2.60 (m, 3H), 2.45-2.43 (m, 1 H). LCMS (M+H): 459.2.
[00112] Example 7: 1-(6-Fluoro-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR(DMSO-cfe, 300 MHz): δ 8.81 (s, 1 H), 7.96-7.91 (m, 1 H), 7.73-7.70 (m, 1 H), 7.69 - 7.65 (m, 1 H), 7.60- 7.53 (m, 5H), 7.50-7.44 (m, 1 H), 7.39-7.36 (m, 1 H), 7.34-7.31 (m, 4H), 7.23- 7.20 (m, 1 H), 4.18-4.15 (m, 1 H), 3.43 (t, J= 6.0 Hz, 2H), 3.23 (s, 3H), 3.17-3.1 1 (m, 1 H), 3.05-3.00 (m, 1 H), 2.88-2.82 (m, 1 H), 2.62-2.59 (m, 3H), 2.43-2.37 (m, 1 H). LCMS (M+H): 484.86.
[00113] Example 8: 1-(6-Fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR(DMSO-cfe, 300 MHz): δ 8.62 (s, 1 H), 8.32 (br s, 1 H) 7.88-7.83 (m, 1 H), 7.59-7.55 (m, 2H), 7.43-7.32 (m, 6H), 4.52-4.48 (m, 1 H), 4.04-4.01 (m, 1 H), 3.82-3.67 (m, 4H), 3.58-3.45 (m, 4H), 3.31 (s, 3H), 2.57 (s, 3H). LCMS (M+H): 423.25.
[00114] Example 9: 1-(5-Fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR(CD3OD, 400 MHz): δ 8.76 (s, 1 H), 7.70 (d, J = 8.8 Hz, 1 H), 7.56-7.50 (m, 1 H), 7.38-7.31 (m, 4H), 7.25- 7.17 (m, 2H), 4.40-4.39 (m, 1 H), 3.56 (t, J= 6.0 Hz, 2H), 3.36 (s, 3H), 3.34-3.33 (m, 1 H), 3.26-3.22 (m, 1 H), 3.12-3.07 (m, 1 H), 2.95-2.91 (m, 1 H), 2.85-2.74 (m, 2H), 2.74-2.62 (m, 4H). LCMS (M+H): 423.33.
[00115] Example 10: 1-(8-Fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR(DMSO-cfe, 300 MHz): δ 8.74 (s, 1 H), 8.08 (br s, 1 H), 7.59 (d, J= 7.8 Hz, 1 H), 7.43-7.23 (m, 8H), 4.25 - 4.18 (m, 1 H), 3.58 - 3.40 (m, 2H), 3.34-3.33 (m, 1 H), 3.26 (s, 3H), 3.18 - 3.04 (m, 2H), 2.90 - 2.86 (m, 2H), 2.74 - 2.70 (m, 2H), 2.61 (s, 3H). LCMS (M+H): 423.36.
[00116] Example 11 : 1-(7-Fluoro-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR(CD3OD, 400 MHz): δ 8.65 (s, 1 H), 7.96-7.92 (m, 1 H), 7.64-7.60 (m, 3H), 7.59-7.54 (m, 3H), 7.43 (dt, J = 2.8 Hz and 8.8 Hz, 1 H), 7.35-7.30 (m, 4H), 7.26-7.22 (m, 1 H), 4.33-4.29 (m, 1 H), 3.54 (t, J= 5.6 Hz, 2H), 3.33 (s, 3H), 3.24-3.21 (m, 1 H), 3.15-3.08 (m, 1 H), 3.04-2.99 (m, 1 H), 2.82-2.70 (m, 3H), 2.62-2.57 (m, 1 H). LCMS (M+H): 484.80.
[00117] Example 12: 1-(7-Fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR(CD3OD, 300 MHz): δ 8.51 (br s, 1 H), 7.85-7.81 (m, 1 H), 7.53-7.35 (m, 7H), 4.59-4.52 (m, 1 H), 4.08 - 3.65 (m, 5H), 3.64 - 3.56 (m, 2H), 3.44 (s, 3H), 3.38 - 3.35 (m, 1 H), 3.30-3.18 (m, 1 H), 2.61 (s, 3H). LCMS (M+H): 423.11.
[00118] Example 13: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(6-methoxy-2-phenylquinolin-3-yl)urea. 1 HNMR (CD3OD, 300 MHz): δ 8.53 (s, 1 H), 7.84 (d, J = 9.3 Hz, 1 H), 7.56-7.50 (m, 5H), 7.31-7.19 (m, 7H), 4.30-4.28 (m, 1 H), 3.92 (s, 3H), 3.51 (t, J= 5.7 Hz, 2H), 3.23-3.12 (m, 2H), 3.09- 3.02 (m, 2H), 2.98-2.96 (m, 1 H), 2.80-2.65 (m, 4H), 2.59-2.53 (m, 1 H). LCMS (M+H): 496.83.
[00119] Example 14: 1-(7-Methoxy-2-phenylquinolin-3-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (DMSO-d6, 400 MHz): δ 8.60 (s, 1 H), 7.79 (d, J = 9.2 Hz, 1 H), 7.64-7.60 (m, 3H), 7.55-7.50 (m, 3H), 7.33-7.28 (m, 5H), 7.23-7.13 (m, 3H), 4.15-4.10 (m, 1 H), 3.87 (s, 3H), 3.43 (t, J = 6.0 Hz, 2H), 3.23 (s, 3H), 3.14-3.10 (m, 1 H), 3.04-2.98 (m, 1 H), 2.85 (t, J = 8.0 Hz, 1 H), 2.67-2.55 (m, 3H), 2.44-2.40 (m, 1 H). LCMS (M+H): 497.10.
[00120] Example 15: 1-(8-Methoxy-2-phenylquinolin-3-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (DMSO-cfe, 300 MHz): δ 8.72 (s, 1 H), 7.68 (br s, 1 H), 7.56-7.54 (m, 4H), 7.45-7.21 (m, 9H), 7.03 (d, J = 7.8 Hz, 1 H), 4.23 - 4.14 (m, 1 H), 3.91 (s, 3H), 3.49-3.34 (m, 2H), 3.24 (s, 3H), 3.14-3.13 (m, 1 H), 3.03-3.00 (m, 2H), 2.62-2.60 (m, 3H), 2.49-2.48 (m, 1 H). LCMS (M+H): 497.62.
[00121] Example 16: 1-(5-Methoxy-2-phenylquinolin-3-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CD3OD, 300 MHz): δ 8.92 (s, 1 H), 7.60-7.50 (m, 7H), 7.31-7.22 (m, 5H), 6.98 (dd, J= 2.1 Hz and 6.6 Hz, 1 H), 4.31-4.28 (m, 1 H), 4.02 (s, 3H), 3.54-3.50 (m, 2H), 3.31 (s, 3H), 3.23- 3.18 (m, 1 H), 3.11-3.00 (m, 2H), 2.84-2.72 (m, 3H), 2.60 - 2.58 (m, 1 H). LCMS (M+H): 497.55.
[00122] Example 17: 1-(5-Methoxy-2-methylquinolin-3-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CD3OD, 300 MHz): δ 8.77 (s, 1 H), 7.51-7.44 (m, 2H), 7.38-7.21 (m, 5H), 6.92 (d, J = 6.9 Hz, 1 H), 4.40-4.38 (m, 1 H), 3.98 (s, 3H), 3.57 (t, J= 5.4 Hz, 2H), 3.36 (s, 3H), 3.39-3.24 (m, 2H), 3.16-3.10 (m, 1 H), 2.98-2.97 (m, 1 H), 2.86-2.79 (m, 2H), 2.71-2.68 (m, 1 H), 2.59 (s, 3H). LCMS (M+H): 435.39
[00123] Example 18: 1-(6-Methoxy-2-methylquinolin-3-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CD3OD, 400 MHz): δ 8.40 (s, 1 H), 7.75 (d, J= 9.2 Hz, 1 H), 7.37-7.31 (m, 4H), 7.25-7.21 (m, 2H), 7.13 (d, J= 2.4 Hz, 1 H), 4.41-4.40 (m, 1 H), 3.89 (s, 3H), 3.57 (t, J= 6.0 Hz, 2H), 3.36 (s, 3H), 3.34-3.31 (m, 1 H), 3.26-3.22 (m, 1 H), 3.13-3.08 (m, 1 H), 2.95-2.91 (m, 1 H), 2.86-2.72 (m, 2H), 2.68-2.62 (m, 1 H), 2.57 (s, 3H). LCMS (M+H): 435.35.
[00124] Example 19: 1-(7-Methoxy-2-methylquinolin-3-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CD3OD, 400 MHz): δ 8.30 (s, 1 H), 7.69 (d, J= 9.6 Hz, 1 H), 7.38-7.31 (m, 4H), 7.26-7.24 (m, 2H), 7.16 (dd, J= 2.4 Hz and 8.8 Hz, 1 H), 4.41-4.40 (m, 1 H), 3.94 (s, 3H), 3.58 (t, J= 5.6 Hz, 2H), 3.36 (s, 3H), 3.41-3.26 (m, 2H), 3.21-3.17 (m, 1H), 3.01-2.99 (m, 1H), 2.90-2.86 (m, 2H), 2.72-2.70 (m, 1H), 2.58 (s, 3H). LCMS (M+H): 435.39.
[00125] Example 20: 1-(8-Methoxy-2-methylquinolin-3-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (CD3OD, 300 MHz): δ 8.45 (s, 1H), 7.41-7.22 (m, 7H), 7.03 (d, J= 7.2 Hz, 1H), 4.40-4.38 (m, 1H), 4.02 (s, 3H), 3.56 (t, J= 5.7 Hz, 2H), 3.35 (s, 3H), 3.31-3.29 (m, 1H), 3.25-3.20 (m, 1H), 3.10-3.04 (m, 1H), 2.92-2.87 (m, 1H), 2.84-2.71 (m, 2H), 2.62 (s, 3H), 2.61 -2.59 (m, 1H). LCMS (M+H): 435.12.
[00126] Example 21: 1-(6,7-Dimethoxy-2-phenylquinolin-3-yl)-3-((3S,4R)- 1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (DMSO d6, 300 MHz): δ 8.53 (s, 1H), 7.60-7.58 (m, 3H), 7.53-7.47 (m, 3H), 7.31-7.19 (m, 7H), 7.12 (d, J= 7.8 Hz, 1H), 4.17-4.28 (m, 1H), 3.88 (s, 6H), 3.43 (t, J= 6.0 Hz, 2H), 3.24 (s, 3H), 3.09 (t, J= 8.1 Hz, 1 H), 3.02 (q, J= 6.9 Hz, 1 H), 2.85 (t, J= 7.8 Hz, 1 H), 2.60-2.57 (m, 3H), 2.42 (t, J= 8.4 Hz, 1H). LCMS (M+H): 527.72.
[00127] Example 22: 1-(6,7-Dimethoxy-2-methylquinolin-3-yl)-3-((3S,4R)- 1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (CD3OD, 300 MHz): δ 8.24 (s, 1H), 7.37-7.29 (m, 4H), 7.25-7.20 (m, 2H), 7.13 (s, 1H), 4.42-4.37 (m, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 3.55 (t, J= 5.4 Hz, 2H), 3.31 (s, 3H), 3.30-3.19 (m, 2H), 3.09-2.92 (m, 1H), 2.90-2.83 (m, 1H), 2.81-2.70 (m, 2H), 2.62 (t, J = 9.0 Hz, 1H), 2.54 (s, 3H). LCMS (M+H): 464.91.
[00128] Example 23: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(6,7-dimethoxyquinolin-3-yl)urea.1H NMR (CD3OD, 400 MHz): δ 8.51 (d, J= 2.4 Hz, 1H), 8.22 (d, J = 1.6 Hz, 1H), 7.37-7.30 (m, 4H), 7.25-7.23 ( m, 2H ), 7.15 (s, 1H ), 4.43-4.37 ( m, 1H) , 3.95 (s, 6H ), 3.58 (t, J= 5.6 Hz, 2H), 3.40- 3.37 (m, 4H ), 3.31-3.24 (m, 1H), 3.11-3.09 (m, 1H), 2.97-2.95 (m, 1H), 2.87- 2.80 (m, 2H), 2.68-2.65 (m, 1H). LCMS (M+H): 450.81.
[00129] Example 24: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(6-methyl-2-phenylquinolin-3-yl)urea.1HNMR (CD3OD, 300 MHz): δ 8.53 (s, 1H), 7.86 (d, J= 9.0 Hz, 1H), 7.63-7.48 (m, 7H), 7.35-7.22 (m, 5H), 4.31- 4.28 (m, 1H), 3.53 (t, J= 5.4 Hz, 2H), 3.32 (s, 3H), 3.23-2.98 (m, 3H), 2.82-2.71 (m, 3H), 2.61-2.58 (m, 1H), 2.53 (s, 3H). LCMS (M+H): 480.90.
[00130] Example 25: 1-(2,6-Dimethylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (CD3OD, 400 MHz): δ 8.38 (s, 1H), 7.77 (d, J= 8.4 Hz, 1H), 7.54 (s, 1H), 7.45-7.43 (m, 1H), 7.37-7.30 (m, 4H), 7.24-7.21 (m, 1H), 4.42-4.37 (m, 1H), 3.56 (t, J= 5.6 Hz, 2H), 3.35 (s, 3H),
3.24- 3.18 (m, 2H), 3.09-3.04 (m, 1H), 2.90-2.88 (m, 1H), 2.84-2.70 (m, 2H), 2.64-2.62 (m, 1H), 2.59 (s, 3H), 2.48 (s, 3H). LCMS (M+H): 419.33.
[00131] Example 26: 1-(2,7-Dimethylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (CD3OD, 300 MHz): δ 8.38 (s, 1H), 7.68-7.65 (m, 2H), 7.38-7.30 (m, 5H), 7.26-7.21 (m, 1H), 4.43-4.36 (m, 1H), 3.57 (t, J= 5.4 Hz, 2H), 3.38-3.31 (m, 1H), 3.36 (s, 3H), 3.25-3.20 (m, 1H), 3.15-3.09 (m, 1H), 2.97-2.92 (m, 1H), 2.90-2.74 (m, 2H), 2.70-2.64 (m, 1H), 2.59 (s, 3H), 2.51 (s, 3H). LCMS (M+H): 419.37.
[00132] Example 27: 1-(2,5-Dimethylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (CD3OD, 400 MHz): δ 8.68 (s, 1H), 7.73 (d, J= 8.8 Hz, 1H), 7.47 (t, J= 8.4 Hz, 1H), 7.38-7.29 (m, 5H),
7.25- 7.21 (m, 1H), 4.40-4.38 (m, 1H), 3.56 (t, J= 5.2 Hz, 2H), 3.36 (s, 3H), 3.35- 3.33 (m, 1H), 3.26-3.20 (m, 1H), 3.11-3.07 (m, 1H), 2.94-2.90 (m, 1H), 2.85- 2.72 (m, 2H), 2.66-2.64 (m, 1H), 2.62 (s, 6H). LCMS (M+H): 419.33.
[00133] Example 28: 1-(2,8-Dimethylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (DMSO-cfe, 300 MHz): δ 8.62 (s, 1H), 7.97 (br s, 1H), 7.58 (d, J= 7.8 Hz, 1H), 7.38-7.20 (m, 8H), 4.22- 4.18 (m, 1H), 3.47 (t, J= 5.7 Hz, 2H), 3.26 (s, 3H), 3.22-3.19 (m, 1H), 3.14-3.09 (m, 1H), 2.94-2.88 (m, 1H), 2.75-2.67 (m, 3H), 2.64 (s, 3H), 2.60 (s, 3H), 2.44- 2.42 (m, 1H). LCMS (M+H): 419.37.
[00134] Example 29: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(7-methyl-2-phenylquinolin-3-yl)urea. 1H NMR (DMSO-cfc, 300 MHz): δ 8.66 (s, 1H), 7.76 (d, J= 8.7 Hz, 1H), 7.69-7.59 (m, 2H), 7.54-7.52 (m, 5H), 7.38-7.21 (m, 7H), 4.15-4.10 (m, 1H), 3.43 (t, J= 6.0 Hz, 2H), 3.23 (s, 3H), 3.13- 3.10 (m, 1H), 3.02-3.00 (m, 1H), 2.85-2.84 (m, 1H), 2.60-2.59 (m, 3H), 2.50 (s, 3H), 2.44-2.39 (m, 1H). LCMS (M+H): 480.83.
[00135] Example 30: 1-(2-Chloroquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1HNMR (CD3OD 300 MHz): δ 8.81 ( s, 1H ), 7.84-7.79 ( m, 2H ), 7.65-7.51 (m, 2H ), 7.38-7.29 (m, 4H), 7.25-7.22 (m, 1H), 4.39-4.38 (m, 1H ), 3.56 (t, J= 5.4 Hz, 2H), 3.34 (s, 3H), 3.30-3.20 (m, 1H), 3.13-3.08 ( m, 1H), 2.92-2.74 (m, 4H), 2.69-2.63 (m, 1H). LCMS (M+H): 425.30.
[00136] Example 31: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(2-(1-methyl-1H-pyrazol-4-yl)quinolin-3-yl)urea. 1HNMR (CD3OD, 300 MHz): δ 8.38 (s, 1H), 8.08 (s, 1H), 8.00 (s, 1H), 7.96 (d, J= 8.4 Hz, 1H), 7.83 (d, J= 8.4 Hz, 1H), 7.68-7.62 (m, 1H), 7.53-7.49 (m, 1H), 7.32-7.31 (m, 4H), 7.25-7.22 (m, 1H), 4.42-4.35 (m, 1H), 3.94 (s, 3H), 3.54 (t, J= 5.4 Hz, 2H), 3.34 (s, 3H), 3.31-3.30 (m, 1H), 3.23-3.13 (m, 1H), 3.07-3.01 (m, 1H), 2.89-2.84 (m, 1H), 2.80-2.75 (m, 2H), 2.63-2.57 (m, 1H). LCMS (M+H): 470.82.
[00137] Example 32: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(2-(pyridin-3-yl)quinolin-3-yl)urea.1H NMR (CD3OD, 300 MHz): δ 8.83 (s, 1H), 8.64 (d, J= 5.1 Hz, 1H), 8.53 (s, 1H), 8.12-8.09 (m, 1H), 8.03 (d, J= 8.4 Hz, 1H), 7.90 (d, J= 7.8 Hz, 1H), 7.72-7.67 (m, 1H), 7.62-7.53 (m, 2H), 7.34- 7.22 (m, 5H), 4.28-4.26 (m, 1H), 3.52 (t, J= 5.4 Hz, 2H), 3.32 (s, 3H), 3.24-3.21 (m, 1H), 3.11-3.08 (m, 1H), 2.96-2.95 (m, 1H), 2.80-2.71 (m, 3H), 2.56-2.55 (m, 1H). LCMS (M+H): 467.87.
[00138] Example 33: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(2-(pyridin-4-yl)quinolin-3-yl)urea. 1H NMR (CD3OD, 300 MHz): δ 8.67- 8.65 (m, 2H), 8.53 (s, 1H), 8.03 (d, J= 8.4 Hz, 1H), 7.91 (d, J= 8.1 Hz, 1H), 7.74-7.69 (m, 3H), 7.64-7.59 (m, 1 H), 7.36-7.23 (m, 5H), 4.30-4.29 (m, 1 H), 3.56 (t, J= 5.4 Hz, 2H), 3.38-3.37 (m, 1H), 3.35 (s, 3H), 3.24-3.16 (m, 2H), 2.91-2.90 (m, 3H), 2.75-2.74 (m, 1H). LCMS (M-H): 465.85.
[00139] Example 34: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(2-(pyrimidin-5-yl)quinolin-3-yl)urea.1H NMR (CD3OD, 400 MHz): δ 9.22 (s, 1H), 9.11 (s, 2H), 8.44 (s, 1H), 8.05 (d, J= 8.8 Hz, 1H), 7.92 (d, J= 8.4 Hz, 1 H), 7.74-7.71 (m, 1 H), 7.64-7.60 (m, 1 H), 7.32-7.21 (m, 5H), 4.32-4.29 (m, 1 H), 3.53 (t, J= 5.2, 2H), 3.32 (s, 3H), 3.12-3.10 (m, 1H), 2.93-2.91 (m, 1H), 2.76- 2.75 (m, 4H), 2.55-2.54 (m, 1H). LCMS (M+H): 469.60.
[00140] Example 35: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(2-morpholinoquinolin-3-yl)urea. 1H NMR (CD3OD, 300 MHz): δ 8.48 (s, 1H), 7.80 (d, J= 8.4 Hz, 1H), 7.68 (d, J= 8.4 Hz, 1H), 7.53-7.47 (m, 1H), 7.40- 7.29 (m, 5H), 7.25-7.22 (m, 1 H), 4.41-4.40 (m, 1 H), 3.90 (t, J= 4.8 Hz, 4H), 3.56 (t, J= 5.7 Hz, 2H), 3.36 (s, 3H), 3.22-3.16 (m, 5H), 3.12-3.06 (m, 1H), 2.90-2.71 (m, 4H), 2.67-2.61 (m, 1H). LCMS (M+H): 476.21.
[00141] Example 36: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(quinolin-4-yl)urea.1H NMR (DMSO-c , 300MHz): δ 8.98 (s, 1H), 8.62 (d, J= 5.1 Hz, 1H), 8.16-8.13 (m, 2H), 7.94 (d, J= 8.1 Hz, 1H), 7.72 (t, J= 7.2 Hz, 1H), 7.61 (t, J= 7.8 Hz, 1H), 7.39-7.23 (m, 6H), 4.25-4.23 (m, 1H), 3.49-3.47 (m, 2H), 3.31-3.28 (m, 1H), 3.26 (s, 3H), 3.15-3.12 (m, 2H), 2.93-2.91 (m, 1H), 2.72-2.69 (m, 3H). LCMS (M+H): 391.10.
[00142] Example 37: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(quinazolin-4-yl)urea.1H NMR (CD3OD, 400 MHz): δ 8.80 (s, 1H), 8.36 (d, J= 8.0 Hz, 1H), 7.95-7.87 (m, 2H), 7.69-7.65 (m, 1H), 7.45-7.38 (m, 2H), 7.32- 7.29 (m, 2H), 7.23-7.17 (m, 1H), 4.85-4.52 (m, 1H), 3.60-3.58 (m, 2H), 3.46- 3.37 (m, 2H), 3.30 (s, 3H), 3.18-3.13 (m, 1H), 3.08-3.04 (m, 1H), 2.92-2.71 (m, 3H). LCMS (M+H): 391.84.
[00143] Example 38: 1-(2-Chloro-6,7-dimethoxyquinazolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (CD3OD, 300 MHz): δ 7.71 (s, 1H), 7.42-7.40 (m, 2H), 7.34-7.29 (m, 2H), 7.24-7.22 (m, 1H), 7.15 (s, 1H), 4.41-4.39 (m, 1H), 3.99 (s, 3H), 3.97 (s, 3H) 3.58 (t, J =5.1 Hz, 2H), 3.36 (s, 3H), 3.34-3.30 (m, 2H), 3.22-3.16 (m, 1H), 3.02-2.98 (m, 1H), 2.85-2.76 (m, 3H). LCMS (M+H): 485.81.
[00144] Example 39: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(quinoxalin-2-yl)urea.1H NMR: (DMSO-c , 300 MHz): δ 10.05 (s, 1H), 9.07 (d, J= 6.9 Hz, 1H), 8.85 (s, 1H), 7.96 (d, J= 8.4 Hz, 1H), 7.88 (d, J= 8.4 Hz, 1 H), 7.80-7.74 (m, 1 H), 7.65-7.59 (m, 1 H), 7.39-7.29 (m, 4H), 7.24-7.21 (m, 1 H), 4.27-4.25 (m, 1H), 3.49 (t, J= 5.4 Hz, 2H), 3.31 (s, 3H), 3.27-3.25 (m, 2H) 2.99- 2.98 (m, 1H), 2.80-2.69 (m, 3H), 2.50-2.49 (m, 1H). LCMS (M+H): 392.20.
[00145] Example 40: 1-(2-lsopropylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR: (CDCb, 400 MHz): 58.31 (s, 1H), 8.01 (d, J= 8.4 Hz, 1H), 7.72 (d, J= 8.4 Hz, 1H), 7.62-7.57 (m, 1H), 7.46-7.43 (m, 1H), 7.35-7.23 (m, 5H), 5.25 (br s, 1H), 4.43-4.34 (m, 1H), 3.51- 3.48 (m, 2H), 3.47-3.44 (m, 1H), 3.34-3.29 (m, 2H), 3.26 (s, 3H), 3.14-3.12 (m, 1H), 2.91-2.87 (m, 1H), 2.81-2.79 (m, 1H), 2.71-2.70 (m, 1H), 2.49-2.47 (m, 1H), 1.35 (d, J= 2.0 Hz, 3H), 1.33 (d, J= 1.6 Hz, 3H). LCMS (M+H): 433.14.
[00146] Example 41: 1-(2-tert-Butylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR: (CDCb, 300 MHz): 58.14 (s, 1H), 8.01 (d, J= 8.7 Hz, 1H), 7.71-7.60 (m, 2H), 7.49-7.44 (m, 1H), 7.35- 7.26 (m, 5H), 6.59 (br s, 1H), 4.58-4.50 (m, 1H), 3.58-3.52 (m, 3H), 3.37-3.31 (m, 1H), 3.31 (s, 3H), 3.23-3.19 (m, 1H), 3.04-3.02 (m, 1H), 2.82-2.79 (m, 2H), 2.63-2.59 (m, 1H), 1.50 (s, 9H). LCMS (M+H): 447.13.
[00147] Example 42: 1-(6-Methoxy-2-methyl-7-morpholinoquinolin-3-yl)- 3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR: (CDCb, 300 MHz): 58.37 (s, 1 H), 7.36-7.26 (m, 6H), 6.98 (s, 1 H), 6.79 (br s, 1 H), 4.49- 4.42 (m, 1H), 3.95 (s, 3H), 3.92-3.91 (m, 4H), 3.73-3.70 (m, 1H), 3.67 - 3.59 (m, 2H), 3.58-3.49 (m, 1H), 3.35-3.34 (m, 1H), 3.30 (s, 3H), 3.20-3.19 (m, 4H), 3.04-2.91 (m, 3H), 2.74-2.68 (m, 1H), 2.61 (s, 3H). LCMS (M+H): 520.42.
[00148] Example 43: 1-(6-Fluoro-7-methyl-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (CDCb, 300 MHz): 58.76 (s, 1H), 7.86 (d, J= 7.5 Hz, 1H), 7.63-7.60 (m, 2H), 7.56-7.48 (m, 3H), 7.35-7.26 (m, 4H), 7.23-7.22 (m, 2H), 5.16-5.10 (br m, 1H), 4.26-4.23 (m, 1H), 3.44-3.37 (m, 2H), 3.24 (s, 3H), 3.21-3.17 (m, 2H), 3.05-3.02 (m, 1H), 2.73- 2.52 (m, 3H), 2.44 (s, 3H), 2.31-2.25 (m, 1H). LCMS (M+H): 499.44. [00149] Example 44: 1-(6-Bromo-8-methoxy-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CDCI3, 400 MHz): δ 8.51 (s, 1 H), 7.45 (d, J= 1.2 Hz, 1 H), 7.33-7.29 (m, 2H), 7.24-7.22 (m, 3H), 6.98 (d, J = 2.0 Hz, 1 H), 6.04 (br s, 1 H) 4.34-4.31 (m, 1 H), 4.01 (s, 3H), 3.53-3.46 (m, 3H), 3.30-3.20 (m, 5H), 2.90-2.84 (m, 2H), 2.74-2.68 (m, 1 H), 2.63 (s, 3H), 2.49 (t, J = 9.2 Hz, 1 H). LCMS (M+H): 513.33.
[00150] Example 45: 1-(7-Fluoro-6-methoxy-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CDC , 400 MHz): δ 8.76 (s, 1 H), 7.69-7.61 (m, 3H), 7.55-7.48 (m, 3H), 7.34-7.30 (m, 3H), 7.26-7.24 (m, 2H), 7.13 (d, J = 8.8 Hz, 1 H), 5.22 (br s, 1 H), 4.26-4.20 (m, 1 H), 3.99 (s, 3H), 3.44-3.40 (m, 2H), 3.24 (s, 3H), 3.21-3.17 (m, 2H), 3.08-3.04 (m, 1 H), 2.79-2.52 (m, 3H), 2.32-2.28 (m, 1 H). LCMS (M+H): 515.35.
[00151] Example 46: 1-(7-Fluoro-6-methoxy-2-methylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CD3OD, 300 MHz): δ 8.41 (s, 1 H), 7.49 (d, J = 12.0 Hz, 1 H), 7.37-7.23 (m, 6H), 4.42- 4.38 (m, 1 H), 3.97 (s, 3H), 3.56 (t, J= 5.4 Hz, 2H), 3.36 (s, 3H), 3.24 - 3.21 (m, 2H), 3.09-2.94 (m, 1 H), 2.94-2.72 (m, 4H), 2.57 (s, 3H). LCMS (M+H): 453.26.
[00152] Example 47: 1-(8-Methoxy-7-methyl-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CDCb, 400 MHz): δ 8.73 (s, 1 H), 7.70-7.68 (m, 2H), 7.54-7.43 (m, 4H), 7.33-7.29 (m, 3H), 7.23-7.21 (m, 3H), 5.09-5.07 (d, J= 8.0 Hz, 1 H), 4.26-4.20 (m, 1 H), 4.1 1 (s, 3H), 3.41 (t, J= 5.2 Hz, 2H), 3.24 (s, 3H), 3.21-3.17 (m, 2H), 3.03-3.00 (m, 1 H), 2.73- 2.62 (m, 2H), 2.57-2.53 (m, 1 H), 2.45 (s, 3H), 2.28 (t, J = 8.8 Hz, 1 H). LCMS (M+H): 51 1.39.
[00153] Example 48: 1-(6-Methoxy-2,7-dimethylquinolin-3-yl)-3-((3S,4R)- 1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CD3OD, 300 MHz): δ 8.33 (s, 1 H), 7.61 (s, 1 H), 7.38-7.30 (m, 4H), 7.26-7.23 (m, 1 H), 7.08 (s, 1 H), 4.45-4.36 (m, 1 H), 3.93 (s, 3H), 3.57 (t, J= 5.4 Hz, 2H), 3.36 (s, 3H), 3.25-3.09 (m, 2H), 2.96-2.78 (m, 4H), 2.70-2.64 (m, 1 H), 2.55 (s, 3H), 2.34 (s, 3H). LCMS (M+H): 449.26. [00154] Example 49: 1-(7-Fluoro-6-methyl-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (CDCI3, 400 MHz): δ 8.73 (s, 1H), 7.64-7.61 (m, 3H), 7.58-7.46 (m, 4H), 7.33-7.30 (m, 2H), 7.24-7.22 (m, 3H), 5.06 (br s, 1H), 4.25-4.21 (m, 1H), 3.41-3.40 (m, 2H), 3.22 (s, 3H), 3.20-3.17 (m, 2H), 3.05-3.02 (m, 1H), 2.73-2.64 (m, 2H), 2.57-2.48 (m, 1H), 2.45 (s, 3H), 2.29-2.26 (m, 1H). LCMS (M+H): 499.33.
[00155] Example 50: 1-(7-Fluoro-2,6-dimethylquinolin-3-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (DMSO-c/6, 300 MHz): δ 8.62 (s, 1H), 7.97 (s, 1H), 7.71 (d, J= 7.8 Hz, 1H), 7.51 (d, J= 10.8 Hz, 1H), 7.34-7.20 (m, 6H), 4.22-4.16 (m, 1H), 3.47 (t, J= 5.7 Hz„ 2H), 3.25 (s, 3H), 3.21-3.18 (m, 1H), 3.13-3.09 (m, 1H), 2.93-2.87 (m, 1H), 2.72-2.59 (m, 3H), 2.55 (s, 3H), 2.44-2.41 (m, 1H), 2.37 (s, 3H). LCMS (M+H): 437.28.
[00156] Example 51: 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(6-phenyl-[1,3]dioxolo[4,5-g]quinolin-7-yl)urea. 1H NMR (CDC , 300 MHz): δ 8.61 (s, 1H), 7.63-7.60 (m, 2H), 7.54-7.45 (m, 3H), 7.34-7.29 (m, 3H), 7.27-7.22 (m, 3H), 7.04 (s, 1 H), 6.08 (s, 2H), 5.07 (br s, 1 H), 4.24-4.22 (m, 1 H), 3.41 (t, J= 5.4 Hz, 2H), 3.24 (s, 3H), 3.20-3.16 (m, 2H), 3.04-3.01 (m, 1H), 2.74- 2.56 (m, 3H), 2.32-2.26 (m, 1H). LCMS (M+H): 511.39.
[00157] Example 52: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(6-methyl-[1,3]dioxolo[4,5-g]quinolin-7-yl)urea. 1H NMR (CD3OD, 300 MHz): δ 8.23 (s, 1H), 7.39-7.32 (m, 4H), 7.29-7.26 (m, 1H), 7.16 (s, 1H), 7.05 (s, 1H), 6.08 (s, 2H), 4.42-4.39 (m, 1H), 3.61 (t, J= 5.4 Hz, 2H), 3.55-3.49 (m, 1H), 3.38 (s, 3H), 3.36-3.32 (m, 1H), 3.14-3.00 (m, 3H), 2.93-2.80 (m, 2H), 2.51 (s, 3H). LCMS (M+H): 449.36.
[00158] Example 53: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(7-methyl-2,3-dihydro-[1,4]dioxino[2,3-g]quinolin-8-yl)urea. 1H NMR (CD3OD, 400 MHz): δ 8.18 (s, 1H), 7.36-7.30 (m, 4H), 7.27-7.23 (m, 2H), 7.14 (s, 1H), 4.42-4.37 (m, 1H), 4.33 (s, 4H), 3.56 (t, J= 5.6 Hz, 2H), 3.35 (s, 3H), 3.34-3.32 (m, 1H), 3.25-3.21 (m, 1H), 3.09-3.06 (m, 1H), 2.93-2.90 (m, 1H), 2.85-2.75 (m, 2H), 2.65 (t, J= 9.6 Hz, 1H), 2.52 (s, 3H). LCMS M+H): 463.25. [00159] Example 54: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(7-phenyl-2,3-dihydro-[1 ,4]dioxino[2,3-g]quinolin-8-yl)urea. 1 H NMR (CDCb, 400 MHz): δ 8.57 (s, 1 H), 7.61-7.59 (m, 2H), 7.51-7.45 (m, 4H), 7.33- 7.29 (m, 2H), 7.24-7.22 (m, 3H), 7.17 (s, 1 H), 5.22 (br s, 1 H), 4.36 (s, 4H), 4.26- 4.22 (m, 1 H), 3.42-3.36 (m, 2H), 3.24 (s, 3H), 3.19-3.16 (m, 2H), 3.04-3.01 (m, 1 H), 2.75-2.65 (m, 2H), 2.59-2.56 (m, 1 H), 2.32-2.28 (m, 1 H). LCMS (M+H): 525.32.
[00160] Example 55: 1-(6-Amino-7-methoxy-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CDCb, 400 MHz): δ 8.46 (s, 1 H), 7.61-7.59 (m, 2H), 7.52-7.48 (m, 3H), 7.45-7.43 (m, 2H), 7.35-7.23 (m, 4H), 6.88 (s, 1 H), 4.56-4.49 (m, 1 H), 4.19 (br s, 2H), 3.96 (s, 3H), 3.66-3.60 (m, 3H), 3.46-3.44 (m, 2H), 3.32 (s, 3H), 3.16-2.98 (m, 3H), 2.78-2.52 (m, 1 H). LCMS (M+H): 512.32.
[00161] Example 56: 1-(7-Methoxy-6-(methylamino)-2-phenylquinolin-3- yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CD3OD, 400 MHz): δ 8.18 (s, 1 H), 7.55-7.53 (m, 2H), 7.48-7.44 (m, 3H), 7.33- 7.27 (m, 4H), 7.24-7.20 (m, 2H), 6.64 (s, 1 H), 4.29-4.21 (m, 1 H), 3.98 (s, 3H), 3.52 (t, J= 5.6 Hz, 2H), 3.33 (s, 3H), 3.12-2.98 (m, 2H), 2.93 (s, 3H), 2.82-2.72 (m, 4H), 2.62-2.52 (m, 1 H). LCMS (M+H): 526.37.
[00162] Example 57: N-(7-Methoxy-3-(3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-2-phenylquinolin-6-yl)acetamide. 1H NMR (CDCb, 300 MHz): δ 8.78 (s, 1 H), 8.61 (s, 1 H), 7.99 (br s, 1 H), 7.60-7.58 (m, 2H), 7.52- 7.43 (m, 3H), 7.39 (s, 1 H), 7.34-7.29 (m, 2H), 7.23-7.19 (m, 2H), 5.22 (br s, 1 H), 4.29-4.21 (m, 1 H), 4.00 (s, 3H), 3.42 (t, J= 5.7 Hz, 2H), 3.24 (s, 3H), 3.21-3.17 (m, 2H), 3.04-3.02 (m, 1 H), 2.75-2.58 (m, 3H), 2.32-2.28 (m, 1 H), 2.26 (s, 3H). LCMS (M+H): 554.41.
[00163] Example 58: N-(7-Methoxy-3-(3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-2-methylquinolin-6-yl)acetamide. 1 H NMR (CD3OD, 300 MHz): δ 8.71 (s, 1 H), 8.34 (s, 1 H), 7.38-7.31 (m, 4H), 7.27-7.20 (m, 1 H), 7.19 (s, 1 H), 4.44-4.39 (m, 1 H), 4.01 (s, 3H), 3.58 (t, J = 5.4 Hz,, 2H), 3.37 (s, 3H), 3.24-3.13 (m, 2H), 3.00-2.84 (m, 3H), 2.72-2.54 (m, 2H), 2.54 (s, 3H), 2.23 (s, 3H). LCMS (M+H): 492.31.
[00164] Example 59: N-(6-Methoxy-3-(3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-2-phenylquinolin-7-yl)acetamide. 1 H NMR (CD3OD, 400 MHz): δ 8.76 (s, 1 H), 8.45 (s, 1 H), 7.57-7.48 (m, 5H), 7.32-7.23 (m, 6H), 4.29-4.24 (m, 1 H), 4.04 (s, 3H), 3.53 (t, J = 4.8 Hz, 2H), 3.33 (s, 3H), 3.14-3.03 (m, 3H), 2.85-2.61 (m, 4H), 2.23 (s, 3H). LCMS (M+H): 554.30.
[00165] Example 60: N-(6-methoxy-3-(3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-2-methylquinolin-7-yl)acetamide. 1 H NMR (CD3OD, 300 MHz): δ 8.71 (s, 1 H), 8.33 (s, 1 H), 7.39-7.30 (m, 4H), 7.26-7.19 (m, 2H), 4.45-4.38 (m, 1 H), 4.00 (s, 3H), 3.58 (t, J = 5.4 Hz, 2H), 3.36 (s, 3H), 3.24-3.13 (m, 3H), 3.00-2.82 (m, 3H), 2.72-2.54 (m, 1 H), 2.54 (s, 3H), 2.23 (s, 3H). LCMS (M+H): 492.21.
[00166] Example 61 : 1-(8-Methoxy-6-(1-Methyl-1 H-pyrazol-4-yl)-2- phenylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)urea. 1 H NMR (CDCb, 300 MHz): δ 8.51 (s, 1 H), 7.84 (s, 1 H), 7.70 (s, 1 H), 7.39-7.38 (m, 2H), 7.33-7.30 (m, 4H), 7.03-7.00 (m, 1 H), 5.51 (br s, 1 H), 4.36-
4.25 (m, 1 H), 4.10 (s, 3H), 3.98 (s, 3H), 3.68 - 3.64 (m, 1 H), 3.52-3.49 (m, 2H), 3.42-3.33 (m, 1 H), 3.26 (s, 3H), 3.18 - 3.10 (m, 2H), 2.89-2.81 (m, 2H), 2.67 (s, 3H), 2.48-2.42 (m, 1 H). LCMS (M+H): 515.35.
[00167] Example 62: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(2-methyl-8-(1-methyl-1 H-pyrazol-4-yl)quinolin-3-yl)urea. 1 H NMR (CDCb, 300 MHz): δ 8.48 (s, 1 H), 8.42 (s, 1 H), 8.13 (s, 1 H), 7.78 (dd, J = 1.2 Hz and 7.2 Hz, 1 H), 7.61-7.58 (m, 1 H), 7.43 (t, J = 7.2 Hz, 1 H), 7.34-7.28 (m, 6H), 5.66 (br s, 1 H), 4.36-4.32 (m, 1 H), 4.00 (s, 3H), 3.52-3.50 (m, 3H), 3.38-3.26 (m, 1 H),
3.26 (s, 3H), 3.22-3.19 (m, 1 H), 2.92-2.82 (m, 2H), 2.76-2.70 (m, 1 H), 2.67 (s, 3H), 2.57-2.50 (m, 1 H). LCMS (M+H): 485.30.
[00168] Example 63: 1-((3S,4R)-4-(3,4-Difluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(quinolin-3-yl)urea. 1 H NMR: (CD3OD, 300 MHz): δ 8.73 (d, J = 2.4 Hz, 1 H), 8.39 (d, J = 2.1 Hz, 1 H), 7.93 (d, J = 8.4 Hz, 1H), 7.81 (d, J= 7.8 Hz, 1H), 7.63-7.50 (m, 2H), 7.35-7.31 (m, 1H), 7.25-7.16 (m, 2H), 4.39-4.32 ( m, 1H ), 3.58-3.54 (m, 2H), 3.37 (s, 3H), 3.27-3.22 (m, 3H), 3.13-3.07 (m, 1H), 2.85-2.72 (m, 2H), 2.66-2.61 (m, 1H). LCMS: M+H): 426.85.
[00169] Example 64:1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(naphthalen-2-yl)urea.1H NMR (DMSO-cfc, 300 MHz): δ 10.21 (br s, 1H), 8.93-8.85 (m, 1H), 7.96 (s, 1H), 7.78-7.69 (m, 3H), 7.41-7.32 (m, 7H), 6.82-6.80 (m, 1H), 4.56-4.54 (m, 1H), 3.93 (s, 1H), 3.75-3.67 (m, 3H), 3.49-3.47 (m, 4H), 3.34-3.31 (m, 4H). LCMS (M+H): 390.10.
[00170] Example 65: 1-((3S,4R)-4-(3,4-Difluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(2-phenylquinolin-3-yl)urea. 1H NMR (CD3OD 300 MHz): 58.63 (s, 1H), 7.97 (d, J= 8.4 Hz, 1H), 7.87 (d, J= 8.1 Hz, 1H), 7.68- 7.53 (m, 7H), 7.28-7.06 (m, 3H), 4.26-4.22 (m, 1H), 3.51 (t, J= 5.7 Hz, 2H), 3.31 (s, 3H), 3.29-3.05 (m, 3H), 2.79-2.73 (m, 3H), 2.67-2.54 (m, 1H). LCMS (M+H): 502.50.
[00171] Example 66: 1-((3S,4R)-4-(3,4-Difluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(2-(pyridin-3-yl)quinolin-3-yl)urea. 1H NMR (CD3OD, 300 MHz): δ 8.85 (d, J= 1.5 Hz, 1H), 8.65 (dd, J= 1.2 Hz and 5.4 Hz, 1H), 8.52 (s, 1H), 8.15-8.11 (m, 1H), 8.02 (d, J= 8.4 Hz, 1H), 7.91 (d, J= 8.1 Hz, 1H), 7.73-7.67 (m, 1H), 7.62-7.55 (m, 2H), 7.26-7.17 (m, 2H), 7.08-7.05 (m, 1H), 4.21-4.19 (m, 1H), 3.51 (t, J= 5.4 Hz, 2H), 3.30 (s, 3H), 3.21-3.15 (m, 1H), 3.10-2.94 (m, 2H), 2.76-2.65 (m, 3H), 2.58-2.52 (m, 1H). LCMS (M+H): 504.76.
[00172] Example 67: 1-((3S,4R)-4-(3,4-Difluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(2-methylquinolin-3-yl)urea. 1H NMR (CD3OD 300 MHz): 58.49 (s, 1H), 7.89 (d, J= 8.4 Hz, 1H), 7.78 (d, J= 8.1 Hz, 1H), 7.62- 7.57 (m, 1H ), 7.51-7.46 (m, 1H), 7.35-7.29 (m, 1H), 7.22-7.17 (m, 2H), 4.36- 4.32 (m, 1H), 3.55 (t, J= 5.4 Hz, 2H), 3.36 (s, 3H), 3.22-3.17 (m, 3H), 3.13-3.07 (m, 1H), 2.84-2.73 ( m, 3H), 2.63 (s, 3H). LCMS (M+H): 440.90.
[00173] Example: 68: 1-((3S,4R)-4-(3,4-Difluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(6,7-dimethoxy-2-methylquinolin-3-yl)urea. 1H NMR (CD3OD 400 MHz): δ 8.25 (s, 1H), 7.34-7.29 (m, 1H), 7.22-7.14 ( m, 4H), 4.37-4.32 (m, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 3.55 (t, J= 5.2 Hz, 2Η), 3.35 (s, 3Η), 3.25-3.11 (m, 2Η), 3.09-3.07 (m, 1Η), 2.82-2.70 (m, 3Η), 2.65-2.61 (m, 1Η ), 2.55 (s, 3Η). LCMS (M+H): 501.40.
[00174] Example: 69: 1-((3S,4R)-4-(3,4-Difluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(6,7-dimethoxyquinolin-3-yl)urea. 1H NMR (CD3OD, 400 MHz): δ 8.51 (d, J= 2.4 Hz, 1H), 8.23 (d, J= 2.4 Hz, 1H), 7.34- 7.29 (m, 1H), 7.25 (s, 1H), 7.21-7.14 (m, 3H), 4.34-4.32 (m, 1H), 3.95 (s, 6H), 3.56 (t, J= 5.2 Hz, 2H), 3.37 (s, 3H), 3.27-3.19 (m, 2H), 3.09-3.06 (m, 1H), 2.85- 2.72 (m, 3H), 2.63 (t, J= 8.8 Hz, 1H). LCMS (M+H): 487.40.
[00175] Example: 70: 1-((3S,4R)-4-(3-fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(quinolin-3-yl)urea. 1H NMR (DMSO-cfe, 300 MHz): δ 8.86 (s, 1H), 8.71 (d, J= 2.7 Hz, 1H), 8.41 (d, J= 2.7 Hz, 1H), 7.88 (d, J= 7.8 Hz, 1H), 7.80 (d, J= 8.4 Hz, 1H), 7.57-7.47 (m, 2H), 7.40-7.32 (m, 1H), 7.19 (d, J= 7.8 Hz, 2H), 7.07-7.02 (m, 1H), 6.82 (d, J= 8.1 Hz, 1H), 4.21-4.18 (m, 1H), 3.47 (t, J= 5.7 Hz, 2H), 3.26 (s, 3H), 3.22-3.15 (m, 2H), 3.00-2.94 (m, 1H), 2.72-2.64 (m, 3H), 2.50-2.49 (m, 1H). LCMS (M+H): 409.40.
[00176] Example: 71: 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(2-methylquinolin-3-yl)urea. 1H NMR (DMSO- d6, 300 MHz): δ 8.49 (s, 1H), 7.88 (d, J= 8.4 Hz, 1H), 7.78 (d, J= 8.4 Hz, 1H), 7.60 (t, J= 6.9 Hz, 1H), 7.49 (t, J= 7.5 Hz, 1H), 7.40-7.33 (m, 1H), 7.21-7.15 (m, 2H), 7.03-6.97 (m, 1H), 6.70-6.68 (d, J= 7.8 Hz, 1H), 6.61 (d, J= 7.8 Hz, 1H), 4.47-4.40 (m, 1H), 3.74-3.70 (m, 1H), 3.62 (t, J= 5.4 Hz, 2H), 3.55-3.42 (m, 1H), 3.38 (s, 3H), 3.34-3.30 (m, 1H), 3.26-3.18 (m, 1H), 3.12-2.88 (m, 3H), 2.62 (s, 3H). LCMS (M+H): 423.33.
[00177] Example: 72: 1-(6-Fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-4-(3- fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea. 1H NMR (CD3OD, 300 MHz): δ 8.52 (s, 1H), 7.91-7.86 (m, 1H), 7.45-7.29 (m, 3H), 7.19-7.12 (m, 2H), 6.98-6.92 (m, 1H), 4.39-4.37 (m, 1H), 3.56 (t, J= 5.4 Hz, 2H), 3.36 (s, 3H), 3.31- 3.22 (m, 2H), 3.12-3.06 (m, 1H), 2.87-2.64 (m, 4H), 2.62 (s, 3H). LCMS (M+H): 441.05. [00178] Example: 73: 1-(7-Fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-4-(3- fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea. 1H NMR (CD3OD, 400 MHz): 58.49 (s, 1H), 7.85-7.81 (m, 1H), 7.51 (dd, J=2.4 Hz and 10.0 Hz, 1H), 7.36-7.30 (m, 2H), 7.19-7.12 (m, 2H), 6.99-6.94 (m, 1H), 4.39-4.37 (m, 1H), 3.56 (t, J= 5.2 Hz, 2H), 3.36 (s, 3H), 3.27-3.23 (m, 1H), 3.13-3.08 (m, 1H), 2.89-2.73 (m, 4H), 2.68-2.64 (m, 1H), 2.62 (s, 3H). LCMS (M+H): 441.37.
[00179] Example: 74: 1-(6,7-Dimethoxy-2-phenylquinolin-3-yl)-3- ((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea. 1H NMR (DMSO-c , 400 MHz): δ 8.52 (s, 1H), 7.63-7.58 (m, 3H), 7.53-7.45 (m, 3H), 7.38-7.32 (m, 1H), 7.27 (d, J =7.2 Hz, 2H), 7.16-7.11 (m, 3H), 7.06-7.02 (m, 1H), 4.16-4.10 (m, 1H), 3.89 (s, 3H), 3.88 (s, 3H), 3.44 (t, J= 5.6 Hz, 2H), 3.24 (s, 3H), 3.12-3.04 (m, 2H), 2.91-2.87 (m, 1H), 2.62-2.51 (m, 3H), 2.50-2.45 (m, 1H). LCMS (M+H): 545.30.
[00180] Example: 75: 1-((3S,4R)-4-(3-fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(6-phenyl-[1,3]dioxolo[4,5-g]quinolin-7-yl)urea. 1H NMR (CD3OD, 400 MHz): δ 8.37 (s, 1H), 7.57-7.48 (m, 5H), 7.34-7.29 (m, 1H), 7.24 (s, 1H), 7.14-7.04 (m, 3H), 6.98-6.94 (m, 1H), 6.11 (s, 2H), 4.24-4.22 (m, 1H), 3.51 (t, J= 6.0 Hz, 2H), 3.33 (s, 3H), 3.18-3.16 (m, 1H), 3.13-3.07 (m, 1H), 3.02-2.96 (m, 1H), 2.76-2.68 (m, 3H), 2.59-2.57 (m, 1H). LCMS (M+H): 529.29.
[00181] Example: 76: 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(6-methyl-[1,3]dioxolo[4,5-g]quinolin-7-yl)urea. 1H NMR (CD3OD, 300 MHz): δ 8.23 (s, 1H), 7.37-7.29 (m, 1H), 7.18-7.11 (m, 3H), 7.06 (s, 1H), 6.99-6.93 (m, 1H), 6.08 (s, 2H), 4.40-4.34 (m, 1H), 3.55 (t, J = 5.7 Hz, 2H), 3.35 (s, 3H), 3.26-3.18 (m, 2H), 3.10-3.04 (m, 1H), 2.86-2.70 (m, 3H), 2.66-2.60 (m, 1H), 2.53 (s, 3H). LCMS (M+H): 467.30.
[00182] Example: 77: 1-((3S,4R)-4-(3-Cyanophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(quinolin-3-yl)urea.1H NMR (CD3OD, 400 MHz): δ 8.72 (s, 1H), 8.38 (s, 1H), 7.91 (d, J= 8.4 Hz, 1H), 7.81-7.74 (m, 2H), 7.71 (d, J= 7.6 Hz, 1H), 7.61-7.58 (m, 2H), 7.55-7.49 (m, 2H), 4.41-4.38 (m, 1H), 3.58- 3.51 (m, 2H), 3.49-3.45 (m, 1H), 3.39-3.35 (m, 3H), 3.15-3.11 (m, 1H), 2.84- 2.68 (m, 5H). LCMS (M+H): 416.00.
[00183] Example: 78: 1-((3S,4R)-4-(3-Cyanophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(6,7-dimethoxy-2-phenylquinolin-3-yl)urea. 1H NMR (CD3OD, 300 MHz): δ 8.38 (s, 1H), 7.67-7.59 (m, 5H), 7.54-7.47 (m, 4H), 7.33 (s, 1H), 7.23 (s, 1H), 4.25-4.23 (m, 1H), 3.98 (s, 3H), 3.96 (s, 3H), 3.57- 3.50 (m, 2H), 3.37 (s, 3H), 3.25-3.09 (m, 3H), 2.78-2.59 (m, 4H). LCMS (M+H): 551.70.
[00184] Example: 79: 1-((3S,4R)-1-(2-Methoxyethyl)-4-(pyridin-3- yl)pyrrolidin-3-yl)-3-(quinolin-3-yl)urea.1H NMR (CD3OD, 400 MHz): δ 8.73 (d, J= 2.4 Hz, 1H), 8.54 (d, J= 2.0 Hz, 1H), 8.42 (dd, J = 1.6 Hz and 8.4 Hz, 1H), 8.38 (d, J= 2.4 Hz, 1H), 7.94-7.90 (m, 2H), 7.80 (d, J= 7.6 Hz, 1H), 7.62-7.51 (m, 2H), 7.44-7.41 (m, 1H), 4.42-4.41 (m, 1H), 3.58 (t, J= 5.2 Hz, 2H), 3.38 (s, 3H), 3.35-3.31 (m, 2H), 3.21-3.16 (m, 1H), 2.92-2.73 (m, 4H). LCMS (M+H): 392.48.
[00185] Example: 80: 1-(6,7-Dimethoxy-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-(pyridin-3-yl)pyrrolidin-3-yl)urea. 1H NMR (CD3OD, 300 MHz): 58.46 (d, J= 1.5 Hz, 1H), 8.42 (d, J=4.8 Hz, 1H), 8.38 (s, 1H), 7.86-7.83 (m, 1H), 7.59-7.48 (m, 5H), 7.43-7.39 (m, 1H), 7.33 (s, 1H), 7.22 (s,1H), 4.29-4.27 (m, 1H), 3.97 (s, 3H), 3.96 (s, 3H), 3.54-3.51 (m, 2H), 3.34 (s, 3H), 3.24-3.15 (m, 1H), 3.13-3.03 (m, 2H), 2.82-2.62 (m, 4H). LCMS (M+H): 528.55.
[00186] Example: 81: 1-((3S,4R)-4-tert-Butyl-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(quinolin-3-yl)urea.1H NMR (CDCb, 400 MHz): 58.79 (s, 1H), 8.50 (brs, 1H), 8.01 (d, J=8.0Hz, 1H),7.75 (d, J=8.4 Hz, 1H), 7.55-7.47 (m, 2H), 6.86-6.82 (m, 1H), 3.76-3.72 (m, 2H), 3.58-3.42 (m, 4H), 3.35 (s, 3H), 3.02-2.98 (m, 2H), 2.38-2.24 (m, 2H), 0.97 (s, 9H). LCMS (M+H): 371.34.
[00187] Example: 82: 1-(6,7-Dimethoxy-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-(1-methyl-1H-pyrazol-4-yl)pyrrolidin-3-yl)urea. 1 H NMR (CD3OD, 300 MHz): δ 8.43 (s, 1 H), 7.60-7.57 (m, 2H), 7.54-7.48 (m, 4H), 7.38 (s, 1 H), 7.34 (s, 1 H), 7.24 (s, 1 H), 4.18-4.14 (m, 1 H), 3.98 (s, 3H), 3.96 (s, 3H), 3.84 (s, 3H), 3.51 (t, J = 5.4 Hz, 2H), 3.33 (s, 3H), 3.30-3.20 (m, 1 H), 3.07-2.90 (m, 2H), 2.77-2.71 (m, 3H), 2.52-2.49 (m, 1 H). LCMS (M+H): 538.41.
[00188] Example: 83: 1-((3S,4R)-1-(2-Methoxyethyl)-4-(1-methyl-1 H- pyrazol-4-yl)pyrrolidin-3-yl)-3-(quinolin-3-yl)urea. 1 H NMR (CD3OD, 300 MHz): 5 8.75 (d, J= 2.4 Hz, 1 H), 8.42 (d, J= 2.4 Hz, 1 H), 7.93 (d, J= 8.1 Hz, 1 H), 7.82 (d, J = 7.8 Hz, 1 H), 7.63-7.51 (m, 3H), 7.44 (s, 1 H), 4.28-4.26 (m, 1 H), 3.84 (s, 3H), 3.55 (t, J= 5.4 Hz, 2H), 3.36 (s, 3H), 3.22-3.16 (m, 1 H), 3.01-2.95 (m, 1 H), 2.88-2.73 (m, 4H), 2.52 (t, J= 9.0 Hz, 1 H). LCMS (M+H): 395.14.
[00189] Example 84: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3- yl)-3-(2-phenyl-1 ,8-naphthyridin-3-yl)urea
Figure imgf000062_0001
[00190] Step 1 : Synthesis of ethyl 2-phenyl-1 ,8-naphthyridine-3- carboxylate: To a solution of 2-aminonicotinaldehyde (1.5 g, 12.29 mmol) in piperidine (7.5 ml_) was added ethyl 3-oxo-3-phenylpropanoate (2.59 g, 13.52 mmol) and was stirred at 90 °C for 3h. The reaction mixture was cooled to ambient temperature and poured into cold water. The resulting solid was filtered and washed with ether to get the required compound as an off-white solid. Yield: 2.87 g (84%); 1 H NMR (DMSO-cfe, 400 MHz): δ 9.21-9.2 (m, 1 H), 8.95 (s, 1 H), 8.65 (dd, J = 8.4 and 2.0 Hz, 1 H), 7.75-7.72 (m, 2H), 7.65-7.63 (m, 2H), 7.54- 7.52 (m, 2H), 4.21-4.16 (m, 2H), 1.07 (t, J = 6.8 Hz, 3H).
[00191] Step 2: Synthesis of 2-phenyl-1 ,8-naphthyridine-3-carboxylic acid: To a solution of ethyl 2-phenyl-1 ,8-naphthyridine-3-carboxylate (1 g, 3.59 mmol) in EtOH (10 ml_) was added H20 (10 ml_) followed by NaOH (0.79 g, 17.9 mmol) . The reaction mixture was then refluxed for 4 hours, cooled to room temperature and solvents were evaporated under reduced pressure. The residue thus obtained was neutralized with 2N HCI (pH~3 to 4) at 0 °C and the resulting solid was filtered, washed with pentane and dried in vacuum to get the required compound as a white solid. Yield: 0.81 g (89%). 1 H NMR (DMSO-c , 300 MHz): δ 13.5 (s, 1 H), 9.19-9.17 (m, 1 H), 8.62 (dd, J = 8.1 and 1.8 Hz, 1 H), 7.74-7.69 (m, 4H), 7.54-7.5 (m, 3H).
[00192] Step 3: Synthesis of 1-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)-3-(2-phenyl-1 ,8-naphthyridin-3-yl)urea: To a solution of 2- phenyl-1 ,8-naphthyridine-3-carboxylic acid (0.2 g, 0.8 mmol) in Toluene (4 ml_) was added DPPA (0.261 g, 0.96 mmol) followed by TEA (0.57 ml_, 4 mmol). The reaction mixture was stirred at room temperature for 16 hours. Then (3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine (Intermediate B1) (0.22g, 1.03 mmol) was added to the reaction mixture and was refluxed for 2 hours. The reaction mixture was evaporated under vacuum and the resulting residue was extracted twice with EtOAc (2 x 25 ml_). The combined organic layers were washed with water (25 ml_), brine (25 ml_), dried over sodium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography (2% MeOH / DCM) to get the title compound as a colorless semi solid. Yield: 0.033 g. 1 H NMR (DMSO-cfe, 300 MHz): δ 8.97-8.89 (m, 1 H), 8.75 (S, 1 H), 8.35 (dd, J = 1.2 Hz and 8.1 Hz, 1 H), 7.68-7.60 (m, 2H), 7.59-7.47 (m, 5H), 7.37-7.32 (m, 4H), 7.26-7.17 (m, 2H), 4.35-4.33 (m, 1 H), 3.55 (t, J= 5.4 Hz, 2H), 3.37-3.31 (m, 4H),3.22-3.14 (m, 2H), 2.95-2.84 (m, 3H), 2.77-2.70 (m, 1 H). LCMS (M+H): 468.1.
[00193] Example 85: Methyl 2-((3S,4R)-3-(3-(6,7-dimethoxy-2- phenylquinolin-3-yl)ureido)-4-phenylpyrrolidin-1-yl)acetate. 1 H NMR (DMSO- d6, 300 MHz): δ 8.52 (s, 1 H), 7.62-7.57 (m, 3H), 7.53-7.48 (m, 3H), 7.32-7.22 (m, 7H), 7.12 (d, J = 7.5 Hz, 1 H), 4.22-4.18 (m, 1 H), 3.88 (s, 6H), 3.63 (s, 3H), 3.41-3.38 (m, 2H), 3.18-2.98 (m, 3H), 2.72-2.60 (m, 2H). LCMS (M+H)+: 540.71.
[00194] Example 86: Methyl 2-((3R,4S)-3-phenyl-4-(3-(quinolin-3- yl)ureido)pyrrolidin-1-yl)acetate. 1 H NMR (DMSO-cfc, 300 MHz): δ 8.86 (s, 1 H), 8.71 (d, J= 2.4 Hz, 1H), 8.40 (d, J= 2.1 Hz, 1H), 7.88 (d, J= 7.8 Hz, 1H), 7.81 (d, J= 7.5 Hz, 1H), 7.55-7.49 (m, 2H), 7.37-7.30 (m, 4H), 7.24-7.22 (m, 1H), 6.81 (d, J= 7.8 Hz, 1H), 4.28-4.23 (m, 1H), 3.64 (s, 3H), 3.51-3.36 (m, 2H), 3.23-3.19 (m, 2H), 3.11-3.06 (m, 1H), 2.80-2.69 (m, 2H). LCMS (M+H): 405.29.
[00195] Example 87: 1-((3S,4R)-1-(2-Fluoroethyl)-4-phenylpyrrolidin-3- yl)-3-(6,7-dimethoxy-2-phenylquinolin-3-yl)urea. 1H NMR (DMSO- d6, 300 MHz): δ 8.53 (s, 1H), 7.60-7.57 (m, 3H), 7.53-7.49 (m, 3H), 7.32-7.25 (m, 7H),
7.14 (d, J= 7.5 Hz, 1H), 4.62 (t, J= 5.1 Hz, 1H), 4.46 (t, J= 4.8 Hz, 1H), 4.19-
4.15 (m, 1H), 3.89 (s, 3H), 3.88 (s, 3H), 3.31-3.16 (m, 1H), 3.05-3.03 (m, 1H), 2.90-2.88 (m, 1H), 2.81-2.79 (m, 1H), 2.71-2.61 (m, 3H). LCMS (M+H):515.52.
[00196] Example 88: 1-((3R,4S)-1-(2-Fluoroethyl)-4-phenylpyrrolidin-3- yl)-3-(6,7-dimethoxy-2-phenylquinolin-3-yl)urea.1H NMR (DMSO-cfe, 300 MHz): δ 8.53 (s, 1H), 7.61-7.58 (m, 3H), 7.53-7.49 (m, 3H), 7.32-7.22 (m, 7H), 7.14- 7.12 (m, 1H),4.62 (t, J=5.1 Hz, 1H), 4.46 (t, J=5.1 Hz, 1 H), 4.17-4.16 (m, 1H), 3.88 (s, 6H), 3.19-3.13 (m, 1H), 3.08-3.03 (m, 1H), 2.93-2.88 (m, 1H), 2.81-2.79 (m, 1H), 2.71-2.61 (m, 3H). LCMS (M+H): 514.76.
[00197] Example 89: 1-((3S,4R)-1-(2-Fluoroethyl)-4-phenylpyrrolidin-3- yl)-3-(2-phenylquinolin-3-yl)urea.1H NMR (CD3OD, 300 MHz): δ 8.64 (s, 1H), 7.96 (d, J= 8.4 Hz, 1H), 7.86 (d, J= 8.1 Hz, 1H), 7.67-7.52 (m, 7H), 7.31-7.30 (m, 4H), 7.25-7.22 (m, 1H), 4.63 (t, J= 4.8 Hz, 1H), 4.47 (t, J= 5.1 Hz, 1H), 4.32-4.30 (m, 1H), 3.24-3.21 (m, 1H), 3.15-3.04 (m, 2H), 2.91-2.77 (m, 3H), 2.63 (t, J= 9.0 Hz, 1H).SOR: -33.636° (c = 1, MeOH). LCMS (M+H): 454.82.
[00198] Example 90: 1-((3S,4R)-1-(2-Fluoroethyl)-4-phenylpyrrolidin-3- yl)-3-(quinolin-3-yl)urea.1H NMR (CD3OD, 300 MHz): δ 8.72 (d, J= 2.7 Hz, 1 H), 8.38 (d, J= 2.4 Hz, 1H), 7.92 (d, J= 8.4 Hz, 1H), 7.80 (d, J= 8.4 Hz, 1H), 7.62- 7.50 (m, 2H), 7.38-7.29 (m, 4H), 7.24-7.20 (m, 1 H), 4.68 (t, J= 4.8 Hz, 1 H), 4.52 (t, J= 5.1 Hz, 1H), 4.45-4.38 (m, 1H), 3.38-3.35 (m, 1H), 3.26-3.20 (m, 1H), 3.13-3.07 (m, 1H), 2.97-2.81 (m, 3H), 2.67 (t, J= 8.7 Hz, 1H).SOR: -28.000° (c = 1, MeOH). LCMS (M+H): 379.76. [00199] Example 91: 1-((3S,4R)-1-(2,2,2-Trifluoroethyl)-4- phenylpyrrolidin-3-yl)-3-(6,7-dimethoxy-2-phenylquinolin-3-yl)urea. 1 H NMR (DMSO-c , 300 MHz): δ 8.49 (s, 1H), 7.61-7.57 (m, 3H), 7.51-7.47 (m, 3H), 7.33-7.23 (m, 7H), 7.09 (d, J= 7.8 Hz, 1H), 4.24-4.20 (m, 1H), 3.88 (s, 6H), 3.37-3.32 (m, 1H), 3.31-3.22 (m, 2H), 3.14-3.09 (m, 2H), 2.77-2.70 (m, 2H). LCMS (M+H): 550.73.
[00200] Example 92: 1-((3R,4S)-1-(2,2,2-Trifluoroethyl)-4- phenylpyrrolidin-3-yl)-3-(6,7-dimethoxy-2-phenylquinolin-3-yl)urea. 1 H NMR (DMSO-c , 300 MHz): δ 8.50 (s, 1H), 7.61-7.57 (m, 3H), 7.51-7.47 (m, 3H), 7.33-7.23 (m, 7H), 7.09 (d, J= 7.5 Hz, 1H), 4.24-4.20 (m, 1H), 3.89 (s, 3H), 3.88 (s, 3H), 3.37-3.34 (m, 1H), 3.28-3.23 (m, 2H), 3.14-3.09 (m, 2H) 2.77-2.70 (m, 2H). LCMS (M+H): 551.53.
[00201] Example 93: 1-((3S,4R)-1-(2,2,2-Trifluoroethyl)-4- phenylpyrrolidin-3-yl)-3-(quinolin-3-yl)urea. 1H NMR (DMSO-cfe, 300 MHz): δ 8.85 (s, 1H), 8.71 (d, J= 2.4 Hz, 1H), 8.40 (d, J= 2.7 Hz, 1H), 7.88 (d, J= 7.8 Hz, 1H), 7.81 (d, J= 7.8 Hz, 1H), 7.56-7.47 (m, 2H), 7.37-7.30 (m, 4H), 7.26 - 7.21 (m, 1H), 6.81 (d, J= 7.8 Hz, 1H), 4.31 - 4.22 (m, 1H), 3.46 - 3.33 (m, 2H), 3.28 - 3.16 (m, 3H), 2.86 - 2.72 (m, 2H). LCMS (M+H): 415.35.
[00202] Example 94: 1-((3S,4R)-1-(2,2-Difluoroethyl)-4-phenylpyrrolidin- 3-yl)-3-(6,7-dimethoxy-2-phenylquinolin-3-yl)urea.1H NMR (CD3OD, 400 MHz): δ 8.40 (s, 1H), 7.56-7.48 (m, 5H), 7.33-7.30 (m, 5H), 7.28-7.21 (m, 2H), 6.08- 5.80 (m, 1H), 4.30-4.27 (m, 1H), 3.97 (s, 3H), 3.95 (s, 3H), 3.26-3.21 (m, 1H), 3.11-3.06 (m, 2H), 2.97-2.65 (m, 4H). LCMS (M+H): 533.79.
[00203] Example 95: 1-((3S,4R)-1-(2,2-Difluoroethyl)-4-phenylpyrrolidin- 3-yl)-3-(quinolin-3-yl)urea.1H NMR (DMSO-c , 400 MHz): δ 8.85 (s, 1H), 8.71 (d, J= 2.4 Hz, 1H), 8.40 (d, J= 2.4 Hz, 1H), 7.88 (d, J= 7.6 Hz, 1H), 7.82 (dd, J = 1.2 Hz and 8.0 Hz, 1H), 7.56-7.48 (m, 2H), 7.36-7.30 (m, 4H), 7.25 - 7.20 (m, 1H), 6.82 (d, J= 8.0 Hz, 1H), 6.29-6.60 (m, 1H), 4.27-4.20 (m, 1H), 3.26- 3.16 (m, 2H), 3.10 - 3.03 (m, 1H), 3.01-2.83 (m, 2H), 2.79-2.75 (m, 1H), 2.68 - 2.64 (m, 1H). LCMS (M+H): 397.45. [00204] Example 96: 1-(6,7-Dimethoxy-2-phenylquinolin-3-yl)-3-((3S,4R)- 1-(2-methoxyacetyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (DMSO-cfe, 400 MHz): δ 8.46 (br s, 1H), 7.65-7.62 (m, 1H), 7.56-7.54 (m, 2H), 7.46-7.45 (m, 3H), 7.35 - 7.27 (m, 7H), 7.00-6.95 (m, 1H), 4.37 - 4.28 (m, 1H), 4.03 (s, 2H), 3.90 (s, 6H), 3.85-3.80 (m, 2H), 3.37 - 3.35 (m, 1H), 3.31 (s, 3H), 3.20 -3.17 (m, 1H), 3.13-3.10 (m, 1H). LCMS (M+H):540.78.
[00205] Example 97: 1-((3S,4R)-1-(2-Methoxyacetyl)-4-phenylpyrrolidin- 3-yl)-3-(quinolin-3-yl)urea.1H NMR (DMSO-c , 400 MHz): δ 8.91 (d, J= 9.2 Hz, 1H), 8.71-8.69 (m, 1H), 8.41 (brs, 1H),7.88 (d, J=8.4 Hz, 1H), 7.82 (d, J=8.0 Hz, 1H), 7.57-7.49 (m, 2H), 7.40-7.35 (m, 4H), 7.28-7.25 (m, 1H), 6.78-6.72 (m, 1 H), 4.44-4.34 (m, 1 H), 4.05 (s, 2H), 3.99-3.89 (m, 2H), 3.88-3.46 (m, 1 H), 3.36- 3.35 (m, 1H), 3.32 (s, 3H), 3.28-3.17 (m, 1H). LCMS (M+H):405.50.
[00206] Example 98: 1-(6,7-Dimethoxy-2-phenylquinolin-3-yl)-3-((3S,4R)- 1-(oxetan-3-yl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (DMSO-cfe, 300 MHz): δ 8.51 (s, 1H), 7.62-7.58 (m, 3H), 7.53-7.47 (m, 3H), 7.33-7.31 (m, 4H), 7.28-7.22 (m, 3H), 7.14 (d, J= 7.8 Hz, 1H), 4.59 (t, J= 6.3 Hz, 2H), 4.50-4.45 (m, 2H), 4.20-4.18 (m, 1H), 3.88 (s, 6H), 3.66-3.62 (m, 1H), 3.12-3.06 (m, 2H), 2.88-2.82 (m, 1H), 2.55-2.53 (m, 1H), 2.45-2.41 (m, 1H). LCMS (M+H):524.53.
[00207] Example 99: 2-((3S,4R)-3-(3-(6,7-Dimethoxy-2-phenylquinolin-3- yl)ureido)-4-phenylpyrrolidin-1-yl)acetamide.1H NMR (DMSO-cfe, 300 MHz): δ 8.50 (br s, 1H), 7.61-7.58 (m, 3H), 7.51-7.48 (m, 3H), 7.33-7.31 (m, 4H), 7.28 (d, J= 6.0 Hz, 2H), 7.25-7.21 (m, 2H), 7.10-7.07 (m, 2H), 4.20-4.18 (m, 1H), 3.88 (s, 6H), 3.15-2.97 (m, 5H), 2.60-2.57 (m, 2H). LCMS (M+H):526.54.
[00208] Example 100: 1-((3S,4R)-1-(Cyanomethyl)-4-phenylpyrrolidin-3- yl)-3-(6,7-dimethoxy-2-phenylquinolin-3-yl)urea.1H NMR (DMSO-cfe, 400 MHz): δ 8.52 (br s, 1H), 7.62-7.58 (m, 3H), 7.58-7.45 (m, 3H), 7.35-7.22 (m, 7H), 7.15 (d, J= 7.2 Hz, 1H), 4.23-4.19 (m, 1H), 3.88 (s, 6H), 3.40-3.31 (m, 1H), 3.17- 3.08 (m, 3H), 3.05-3.01 (m, 1H) 2.63-2.45 (m, 2H). LCMS (M+H):508.57.
[00209] Example 101: 1-((3S,4R)-1-(Cyanomethyl)-4-phenylpyrrolidin-3- yl)-3-(quinolin-3-yl)urea.1H NMR (DMSO-c , 400 MHz): δ 8.85 (brs, 1H), 8.71 (d, J = 2.4 Hz, 1 H ), 8.40 (d, J= 2.4 Hz, 1 H), 7.88 (d, J= 8.4 Hz, 1 H), 7.82 (dd, 1.2 Hz and 8.0 Hz, 1 H), 7.56-7.48 (m, 2H), 7.34-7.32 (m, 4H), 7.26-7.22 (m, 1 H), 6.88 (d, J= 8.0 Hz, 1 H), 4.23-4.19 (m, 1 H), 3.90 (s, 2H), 3.31-3.17 (m, 2H), 3.13-3.09 (m, 1 H), 2.70 - 2.64 (m, 2H). LCMS (M+H): 371.76. [00210] Example 102: 2-((3R,4S)-3-Phenyl-4-(3-(quinolin-3- yl)ureido)pyrrolidin-1-yl)acetamide. 1 H NMR (DMSO-cfe, 400 MHz): δ 8.85 (br s, 1 H), 8.72 (d, J= 2.8 Hz, 1 H ), 8.40 (d, J= 2.4 Hz, 1 H), 7.88 (d, J= 8.0 Hz, 1 H), 7.81 (d, 8.0 Hz, 1 H), 7.54-7.50 (m, 2H), 7.37-7.22 (m, 6H), 7.16 (br s, 1 H), 6.85 (d, J = 8.0 Hz, 1 H), 4.25-4.24 (m, 1 H), 3.31-3.12 (m, 3H), 3.05-3.00 (m, 2H), 2.73-2.64 (m, 1 H) 2.61-2.55 (m, 1 H). LCMS (M+H): 389.87.
[00211] Example 103: 1-(1-(2-Methoxyethyl)-2-oxo-4-phenylpyrrolidin-3- yl)-3-(quinolin-3-yl)urea. 1 H NMR (CD3OD, 400 MHz): δ 8.74 (d, J= 3.2 Hz, 1 H), 8.40 (d, J= 2.4 Hz, 1 H), 7.92 (d, J= 8.0 Hz, 1 H), 7.80 (d, J= 8.4 Hz, 1 H), 7.62- 7.58 (m, 1 H), 7.55-7.51 (m, 1 H), 7.43-7.41 (m, 2H), 7.37-7.33 (m, 2H), 7.29- 7.25 (m, 1 H), 4.71 (d, J = 10.8 Hz, 1 H), 3.84-3.82 (m, 1 H), 3.73-3.46 (m, 6H), 3.38 (s, 3H). LCMS (M+H): 405.2.
[00212] Example 104: 1-(Dibenzo[b,d]furan-1-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
[00213] Step 1 : Preparation of phenyl dibenzo[b,d]furan-1-ylcarbamate: To a solution of dibenzo[b,d]furan-1-amine (0.2 g, 1.09 mmol) and pyridine (0.17g, 2.18 mmol) in THF (20 mL) at 0°C was added phenylchloroformate (0.17 g, 1.09 mmol) drop-wise, and the resulting mixture was stirred at room temperature for 2 h. Cold water was added to the reaction mixture and it was extracted with ethyl acetate (2 x 25 mL). The combined organic layers were washed with water (10 mL), brine (10 mL) and dried over sodium sulphate. The organic layer was filtered and concentrated under reduced pressure to afford the title compound as a pale brown solid. Yield: 0.2 g (61 %); LCMS (M+H): 304.27.
[00214] Step 2: Preparation of 1-(dibenzo[b,d]furan-1-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea: To a solution of (3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride (0.2g, 0.78 mmol) and diisopropylethylamine (0.30g, 2.34 mmol) in DMF (4 mL) was added phenyl dibenzo[b,d]furan-1-ylcarbamate (0.23g. 0.78 mmol) slowly at 0°C, and the resulting mixture was stirred at room temperature for 12 h. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (25 mL).The organic layers were washed with water (10 mL), brine (10 mL) and dried over sodium sulfate. The organic layers were filtered, concentrated under reduced pressure and the residue was purified by flash column chromatography eluting with 2% MeOH/CHCb to afford the title compound as an off-white solid. Yield: 0.03 g (9%); 1H NMR (CDCI3, 300 MHz): δ 8.01 (d, J= 8.1 Hz, 1H), 7.93 (d, J = 7.2 Hz, 1H), 7.61 (d, J= 8.1 Hz, 1H), 7.51 (d, J= 8.1 Hz, 1H), 7.44 (dt, J= 1.2 and 8.4 Hz, 1H), 7.36 (d, J= 8.4 Hz, 1H), 7.31-7.25 (m, 5H), 7.22-7.20 (m, 1H), 5.35 (d, J= 7.8 Hz, 1H), 4.36-4.32 (m, 1H), 3.52 (t, J= 6.0 Hz, 2H), 3.49-3.46 (m, 1H), 3.38-3.33 (m, 1H), 3.30 (s, 3H), 3.14-3.11 (m, 1H), 2.92-2.70 (m, 3H), 2.46 (t, J = 9.0 Hz, 1 H). (M+H): 430.35.
[00215] The following examples were prepared according to the above mentioned procedure by using appropriate intermediates.
[00216] Example 105: 1-(Dibenzo[b,d]furan-1-yl)-3-((3S,4R)-4-(3- fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea. 1H NMR (DMSO-cfe, 300 MHz): δ 8.68 (br s, 1H), 8.10 (t, J= 7.5 Hz, 2H), 7.70 (d, J= 6.6 Hz, 1H), 7.66 (dd, J= 1.2 and 7.8 Hz, 1H), 7.53 (dt, J= 1.2 and 7.8 Hz, 1H), 7.42 (d, J= 7.2 Hz, 1H),7.40-7.32 (m, 1H), 7.26 (d, J=7.8 Hz, 1H), 7.21-7.17 (m, 3H), 7.09-7.01 (m, 1H), 4.22-4.16 (m, 1H), 3.47 (t, J= 6.0 Hz, 2H), 3.26 (s, 3H), 3.16-3.11 (m, 2H), 2.98 (t, J= 7.5 Hz, 1H), 2.74-2.60 (m, 4H). LCMS (M+H): 448.24. [00217] Example 106: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(8-methyldibenzo[b,d]furan-1-yl)urea. 1H NMR (CD3OD, 300 MHz): δ 7.71 (s, 1H), 7.43 (d, J= 8.4 Hz, 1H), 7.39-7.22 (m, 9H), 4.48-4.40 (m, 1H), 3.95-3.90 (m, 1H), 3.54 (t, J= 5.4 Hz, 2H), 3.34 (s, 3H), 3.25-3.20 (m, 1H), 3.10- 3.05 (m, 1H), 2.98-2.92 (m, 1H), 2.85-2.75 (m, 2H), 2.61 (t, J=9.0Hz, 1H),2.41 (s, 3H). LCMS (M+H): 444.26. [00218] Example"! 07: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(8-methoxydibenzo[b,d]furan-1-yl)urea.1H NMR (CD3OD, 300 MHz): δ 7.46 (d, J= 9.0 Hz, 1H), 7.40-7.35 (m, 3H), 7.31-7.22 (m, 6H), 7.06 (dd, J= 3.0 and 9.0 Hz, 1H), 4.46-4.42 (m, 1H), 3.72 (s, 3H), 3.54 (t, J= 5.4 Hz, 2H), 3.38- 3.36 (m, 1H), 3.34 (s, 3H), 3.24-3.20 (m, 1H), 3.12-3.07 (m, 1H), 3.02-2.96 (m, 1H), 2.87-2.80 (m, 2H), 2.63 (t, J= 9.0 Hz, 1H). LCMS (M+H): 460.28.
[00219] Example 108: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(8-fluorodibenzo[b,d]furan-1-yl)urea.1H NMR (CDCb, 300 MHz): δ 7.58 (dd, J= 2.7 and 8.4 Hz, 1H), 7.46-7.29 (m, 5H), 7.25-7.18 (m, 5H), 7.10 (dt, J =
2.1 and 9.0 Hz, 1H), 5.71 (brs, 1H), 4.45-4.35 (m, 1H), 3.40 (t, J= 5.4 Hz, 2H), 3.37-3.33 (m, 1H), 3.21 (s, 3H), 3.20-3.19 (m, 1H), 3.07 (d, J= 10.2 Hz, 1H), 2.83 (t, J= 7.5 Hz, 1 H), 2.73-2.59 (m, 2H), 2.37 (t, J= 9.6 Hz, 1 H). LCMS (M+H): 448.25.
[00220] Example 109: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(7-methoxydibenzo[b,d]furan-1-yl)urea.1H NMR (CD3OD, 400 MHz): δ 7.66 (d, J= 8.8 Hz, 1H), 7.36-7.22 (m, 8H), 7.13 (d, J= 2.0 Hz, 1H), 6.82 (dd, J = 2.4 and 8.8 Hz, 1H), 4.50-4.40 (m, 1H), 3.88 (s, 3H), 3.53 (t, J= 5.2 Hz, 2H), 3.34 (s, 3H), 3.22-3.18 (m, 1H), 3.03 (t, J= 7.6 Hz, 1H), 2.91-2.87 (m, 1H), 2.80- 2.72 (m, 3H), 2.58 (t, J= 9.2 Hz, 1H). LCMS (M+H): 460.28.
[00221] Example 110: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(7-fluorodibenzo[b,d]furan-1-yl)urea. 1H NMR (DMSO-cfe, 300 MHz): δ 8.24 (brs, 1H), 8.14-8.09 (m, 1H), 7.68-7.63 (m, 2H), 7.40-7.28 (m, 7H), 7.25- 7.20 (m, 2H), 4.32-4.20 (m, 1H), 3.48 (t, J= 5.7 Hz, 2H), 3.26 (s, 3H), 3.22-3.13 (m, 2H), 3.00-2.90 (m, 1 H), 2.80-2.60 (m, 3H), 2.43-2.40 (m, 1 H). LCMS (M+H): 448.29.
[00222] Example 111: 1-(Dibenzo[b,d]thiophen-1-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (DMSO-cfe, 400 MHz): δ 8.32 (d, J= 6.8 Hz, 2H), 8.01 (d, J= 7.2 Hz, 1H), 7.78-7.76 (m, 1H), 7.50 (t, J =
7.2 Hz, 1H), 7.45-7.41 (m, 3H), 7.36-7.29 (m, 4H), 7.23-7.20 (m, 1H), 7.07 (d, J = 7.6 Hz, 1H), 4.25-4.16 (m, 1H), 3.47 (t, J = 6.0 Hz, 2H), 3.26 (s, 3H), 3.19- 3.15 (m, 2H), 2.93 (t, J= 7.6 Hz, 1H), 2.72-2.60 (m, 3H), 2.54-2.50 (m, 1H). LCMS (M+H): 446.20.
[00223] Example 112: 1-(5,5-Dioxodibenzo[£»,a]thiophen-1-yl)-3-[1-(2- methoxy-ethyl)-4-phenyl-pyrrolidin-3-yl]-urea. 1H NMR (CDCI3, 300 MHz): δ 8.07-8.04 (m, 1 H), 7.82-7.79 (m, 1 H), 7.66 (t, J= 7.5 Hz, 2H), 7.48-7.42 (m, 3H), 7.34-7.28 (m, 2H), 7.23-7.20 (m, 3H), 7.05-7.01 (m, 1H), 6.40 (br s, 1H), 4.50- 4.35 (m, 1H), 3.56 (t, J= 8.1 Hz, 2H), 3.48-3.44 (m, 2H), 3.35-3.32 (m, 1H), 3.22 (s, 3H), 2.95 (t, J= 7.8 Hz, 1H), 2.81-2.77 (m, 2H), 2.56 (t, J= 9.6 Hz, 1H). LCMS (M+H): 478.13.
[00224] Example 113: 1-(4-Methoxydibenzo[b,d]thiophen-1-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (DMSO-cfe, 300 MHz): δ 8.29 (d, J= 8.1 Hz, 1H), 8.12 (br s, 1H), 8.02 (d, J= 7.8 Hz, 1H), 7.50 (t, J= 7.2 Hz, 1H), 7.39 (t, J= 7.2 Hz, 1H), 7.32-7.19 (m, 6H), 7.06 (d, J = 8.4 Hz, 1H), 6.84 (d, J= 8.1 Hz, 1H), 4.25-4.15 (m, 1H), 3.97 (s, 3H), 3.46 (t, J = 6.0 Hz, 2H), 3.25 (s, 3H), 3.21-3.11 (m, 2H), 2.93-2.89 (m, 2H), 2.67-2.57 (m, 3H). LCMS (M+H): 476.15.
[00225] Example 114: 1-(4-Methoxy-5,5-Dioxodibenzo[!b,c/]thiophen-1-yl)- 3-[1-(2-methoxy-ethyl)-4-phenyl-pyrrolidin-3-yl]-urea. 1H NMR (DMSO-cfe, 300 MHz): 58.16(brs, 1H), 7.98 ( d, J=8.1 Hz, 1H), 7.91-7.88 (m, 1H), 7.63-7.61 (m, 2H), 7.50 (d, J= 8.7 Hz, 1H), 7.32-7.28 (m, 4H), 7.23 (d,J= 9.0 Hz, 2H), 7.01 (d, J= 7.8 Hz, 1H), 4.20-4.10 (m, 1H), 3.95 (s, 3H), 3.46 ( t, J = 5.1 Hz, 2H), 3.25 (s, 3H), 3.18-3.14 (m, 2H), 2.96-2.85 (m, 1H), 2.70-2.62 (m, 3H), 2.58- 2.54 (m, 1H). LCMS (M+H): 508.26.
[00226] Example 115: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(9-oxo-9H-fluoren-4-yl)urea.1H NMR (DMSO-cfe, 300 MHz): δ 8.13 (brs, 1H), 7.73-7.54 (m, 4H), 7.38-7.21 (m, 9H), 4.22-4.18 (m, 1H), 3.47 (t, J= 6.0 Hz, 2H), 3.26 (s, 3H), 3.21-3.15 (m, 2H), 2.95-2.89 (m, 1H), 2.72-2.61 (m, 3H), 2.43-2.41 (m, 1H). LCMS (M+H): 442.21.
[00227] Example 116: 1-(6-Methoxydibenzo[b,d]furan-1-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (CD3OD, 400 MHz): δ 7.46 (d, J= 8.0 Hz, 1H), 7.42 (d, J= 8.4 Hz, 1H), 7.40-7.30 (m, 6H), 7.26-7.23 (m, 1H), 7.19 (t, J= 8.8 Hz, 1H), 7.08 (d, J= 7.2 Hz, 1H), 4.46-4.43 (m, 1H), 4.02 (s, 3H), 3.54 (t, J= 5.2 Hz, 2H), 3.38-3.36 (m, 1H), 3.35 (s, 3H), 3.26-3.22 (m, 1H), 3.07 (t, J= 8.4 Hz, 1H), 2.95-2.91 (m, 1H), 2.85-2.76 (m, 2H), 2.63 (t, J= 9.2 Hz, 1H). LCMS (M+H): 460.24.
[00228] Example 117: 1-(6-Methyldibenzo[b,d]furan-1-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (CD3OD, 300 MHz): δ 7.71 ( s, 1H), 7.43 (d, J= 8.4 Hz, 1H), 7.39-7.20 (m, 9H), 4.48-4.40 (m, 1H), 3.54 (t, J= 5.4 Hz, 2H), 3.38-3.36 (m, 1H), 3.34 (s, 3H), 3.25-3.20 (m, 1H), 3.08-3.03 (m, 1H), 2.95-2.92 (m, 1H), 2.80-2.74 (m, 2H), 2.59 (t, J= 9.3 Hz, 1H), 2.41 (s, 3H). LCMS (M+H: 444.21.
[00229] The following compounds were synthesized by following the synthetic method 1 and procedure described in Example 3 by using appropriate starting materials.
[00230] Example 118: 1-(6-Methoxy-7-methyl-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (CD3OD, 300 MHz): δ 8.46 (s, 1H), 7.70 (br s, 1H), 7.56-7.49 (m, 5H), 7.31-7.30 (m, 5H), 7.16 (s, 1H), 4.36-4.30 (m, 1H), 3.97 (s, 3H), 3.52 (t, J= 4.8 Hz, 2H), 3.31 (s, 3H), 3.12 - 3.02 (m, 2H), 2.82-2.74 (m, 5H), 2.36 (s, 3H). LCMS (M+H): 511.39.
[00231] Example 119: 1-(6-Cyano-7-fluoro-2-methylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (DMSO d6, 400 MHz): δ 8.85 (s, 1H), 8.60 (d, J=7.6Hz, 1H), 8.13 (s, 1H), 7.84 (d, J= 10.8 Hz, 1H), 7.63-7.52 (m, 1H), 7.38-7.30 ( m, 5H), 7.24-7.21 (m, 1H), 4.25-4.22 (m, 1H), 3.47 (t, J= 6.0 Hz, 2H), 3.26 (s, 3H), 3.23-3.22 (m, 2H), 3.12-3.10 (m, 1H), 2.93-2.90 (m, 1H), 2.72-2.66 (m, 2H), 2.64 (s, 3H), 2.44-2.43 (m, 1H). LCMS (M+H): 448.21.
[00232] Example 120: 1-(6-Cyano-7-methoxy-2-methylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (DMSO d6, 400 MHz): δ 8.67 (s, 1H), 8.39 (s, 1H), 8.03 (s, 1H), 7.43 (s, 1H), 7.35-7.22 (m, 6H), 4.25-4.22 (m, 1H), 3.98 (s, 3H), 3.47 (t, J= 6.4 Hz, 2H), 3.26 (s, 3H), 3.23- 3.21 (m, 1H), 3.14-3.10 (m, 1H), 2.94-2.88 (m, 1H), 2.75 - 2.65 (m, 3H), 2.59 (s, 3H), 2.50-2.49 (m, 1H). LCMS (M+H): 460.25.
[00233] Example 121: 1-(7-Cyano-6-fluoro-2-methylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (CD3OD, 400 MHz): δ 8.73 (s, 1H), 8.26 (d, J= 6.0 Hz, 1H), 7.66 (d, J= 9.6 Hz, 1H), 7.38-7.31 (m, 4H), 7.25-7.23 (m, 1 H), 4.42-4.40 (m, 1H), 3.58 (t, J= 6.4 Hz, 2H), 3.37 (s, 3H), 3.26-3.21 (m, 2H), 3.18-3.13 (m, 1H), 2.98-2.94 (m, 1H), 2.90-2.78 (m, 2H), 2.73 - 2.68 (m, 1 H), 2.65 (s, 3H). LCMS (M+H): 448.29.
[00234] Example 122: 1-(7-Cyano-6-fluoro-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (CD3OD, 400 MHz): δ 8.85 (s, 1H), 8.37 (d, J= 6.0 Hz, 1H), 7.75 (d, J= 10.0 Hz, 1H), 7.62-7.56 (m, 5H), 7.34-7.30 (m, 4H), 7.24-7.20 (m, 1 H), 4.40-4.38 (m, 1 H), 3.53 (t, J= 5.6 Hz, 2H), 3.31 (s, 3H), 3.13-3.05 (m, 2H), 2.84-2.71 (m, 4H), 2.62-2.60 (m, 1H). LCMS (M+H): 510.30.
[00235] Example 123: 1-(7-Cyano-6-methoxy-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (CD3OD, 400 MHz): δ 8.75 (s, 1H), 8.22 (s, 1H), 7.59-7.54 (m, 5H), 7.39 (s, 1H), 7.31- 7.30 (m, 4H), 7.24-7.21 (m, 1H), 4.38-4.36 (m, 1H), 4.05 (s, 3H), 3.53 (t, J= 6.0 Hz, 2H), 3.33 (s, 3H), 3.15-3.07 (m, 2H), 2.84-2.74 (m, 4H), 2.62-2.60 (m, 1H). LCMS (M+H): 522.30.
[00236] Example 124: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(2-(thiazol-5-yl)quinolin-3-yl)urea.1H NMR (CD3OD, 400 MHz) : δ 9.08 (s, 1H), 8.49 (s, 1H), 8.31 (s, 1H), 8.01 (d, J= 8.8 Hz, 1H), 7.86 (d, J= 8.0 Hz, 1 H), 7.73-7.68 (m, 1 H), 7.58-7.54 (m, 1 H), 7.32-7.24 (m, 4H), 7.23-7.21 (m, 1 H), 4.40-4.35 (m, 1H), 3.54 (t, J= 5.6 Hz, 2H), 3.38-3.35 (m, 1H), 3.35 (s, 3H), 3.24-3.13 (m, 1H), 3.12-3.06 (m, 1H), 2.93-2.77 (m, 3H), 2.69-2.64 (m, 1H). LCMS (M+H): 474.37.
[00237] Example 125: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(2-phenyl-5,6,7,8-tetrahydroquinolin-3-yl)urea. 1H NMR (CDCI3, 400 MHz): δ 7.94 (s, 1H), 7.52 (s, 1H), 7.50 (s, 1H), 7.44 (t, J= 7.2 Hz, 2H), 7.39 (d, J = 6.8 Hz, 1 H), 7.32-7.29 (m, 2H), 7.22-7.21 (m,. 3H), 5.32 (br s, 1 H), 4.28 (br s, 1 H), 3.48 -3.44 (m, 2H), 3.31-3.30 (m, 1 H), 3.28 (s, 3H), 3.20-3.18 (m, 1 H), 3.04-3.02 (m, 1 H), 2.90 (t, J = 6.4 Hz, 2H), 2.82-2.61 (m, 5H), 2.35-2.33 (m, 1 H), 1.89-1.88 (m, 2H), 1.82-1.80 (m, 2H). LCMS (M+H): 471.33.
[00238] Example 126: 1-(6,7-Dimethoxy-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-1 ,3-dimethylurea. LCMS (M+H):555.39.
[00239] Example 127:1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-1-methyl-3-(2-phenylquinolin-3-yl)urea. 1 H NMR (CDC , 400 MHz): δ 9.20 (br s, 1 H), 8.71 (s, 1 H), 8.06 (d, J = 8.4 Hz, 1 H), 7.80 (d, J = 8.4 Hz, 1 H), 7.74 (d, J = 7.2 Hz, 2H), 7.60 (t, J = 6.8 Hz, 1 H), 7.53-7.42 (m, 4H), 7.34-7.30 (m, 2H), 7.24-7.19 (m, 2H), 4.28-4.25 (m, 1 H), 3.50 (br s, 1 H), 3.34-3.17 (m, 4H), 2.98 (s, 3H), 2.93 (s, 3H), 2.76-2.74 (m, 1 H), 2.57-2.49 (m, 2H), 2.25-2.22 (m, 1 H), 2.13 (t, J = 10.0 Hz, 1 H). LCMS (M+H): 481.47.
[00240] Example 128: 1-(6-(Difluoromethoxy)-7-methoxy-2- methylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)urea. 1 H NMR (CD3OD, 300 MHz): δ 8.33 (s, 1 H), 7.49 (s, 1 H), 7.37-7.33 (m, 5H), 7.28-7.25 (m, 1 H), 7.10-6.66 (m, 1 H), 4.40-4.39 (m, 1 H), 3.99 (s, 3H), 3.57 (t, J= 5.4 Hz, 2H), 3.38-3.37 (m, 1 H), 3.36 (s, 3H), 3.26-3.23 (m, 1 H), 3.13-3.10 (m, 1 H), 2.98-2.82 (m, 3H), 2.72-2.69 (m, 1 H), 2.58 (s, 3H). LCMS (M+H):501.25
[00241] Example 129: 1-(2,2-Difluoro-6-methyl-[1 ,3]dioxolo[4,5- g]quinolin-7-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (CDCb, 400 MHz): δ 8.48 (s, 1 H), 7.50 (s, 1 H), 7.35-7.31 (m, 5H), 7.25- 7.23 (m, 2H), 5.79-5.78 (m, 1 H), 4.26-4.24 (m, 1 H), 3.53-3.50 (m, 4H), 3.22- 3.20 (m, 1 H), 3.19 (s,3H), 2.86-2.80 (m,2H), 2.70-2.64 (m, 1 H), 2.57 (s, 3H), 2.45-2.40 (m, 1 H). LCMS (M+H): 485.01.
[00242] Example 130: 1-(6-(Difluoromethyl)-[1 ,3]dioxolo[4,5-g]quinolin-7- yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CD3OD, 400 MHz): δ 8.39 (s, 1 H), 7.36-7.20 (m, 6H), 7.12 (s, 1 H), 6.96-6.69 (m, 1 H), 6.13 (s, 2H), 4.37-4.34 (m, 1 H), 3.55 (t, J = 4.4 Hz, 2H), 3.35 (s, 3H), 3.24-3.18 (m, 2H), 3.07-3.03 (m, 1 H), 2.88-2.86 (m, 1 H), 2.85-2.70 (m, 2H), 2.65-2.60 (m, 1 H). LCMS (M+H): 484.94.
[00243] Example 131 : 1-([1 ,3]Dioxolo[4,5-g]quinolin-7-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CDCb, 400 MHz): δ 8.46 (s, 1 H), 8.39 (s, 1 H), 7.35-7.32 (m, 2H), 7.29-7.26 (m, 5H), 6.99 (s, 1 H), 6.07 (s, 2H), 5.48-5.46 (m, 1 H), 4.15-4.12 (m, 1 H), 3.59-3.56 (m, 3H), 3.45-3.42 (m, 1 H), 3.32 (s, 3H), 3.26-3.23 (m, 1 H), 2.89-2.84 (m, 2H), 2.79-2.74 (m, 1 H), 2.49-
2.45 (m, 1 H). LCMS (M+H): 435.39.
[00244] Example 132: 1-(2-Cyclohexylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CD3OD, 400 MHz): δ 8.25 (s, 1 H), 7.96 (d, J= 8.4 Hz, 1 H), 7.75 (d, J= 7.2 Hz, 1 H), 7.60 (t, J= 7.2 Hz 1 H),
7.46 (t, J= 7.2 Hz, 1 H), 7.37-7.29 (m, 4H), 7.25-7.22 (m, 1 H), 4.40-4.39 (m, 1 H), 3.56 (t, J= 5.6 Hz, 2H), 3.35 (s, 3H), 3.12-3.05 (m, 2H), 3.02-2.96 (m, 1 H), 2.84- 2.77 (m, 3H), 2.70-2.69 (m, 1 H), 2.66 (t, J = 8.8 Hz, 1 H), 1.86-1.73 (m, 7H), 1.48-1.35 (m, 3H). LCMS (M+H): 473.45.
[00245] Example 133: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(6-(trifluoromethyl)-[1 ,3]dioxolo[4,5-g]quinolin-7-yl)urea. 1 H NMR (CDCb, 400 MHz): δ 8.57 (s, 1 H), 7.35-7.30 (m, 5H), 7.24-7.22 (m, 1 H), 7.02 (s, 1 H), 6.12 (s, 2H), 5.68-5.66 (m, 1 H), 4.35-4.30 (m, 1 H), 3.53-3.49 (m, 3H), 3.39- 3.27 (m, 1 H) 3.26 (s, 3H), 3.18-3.16 (m, 1 H), 2.88-2.69 (m, 3H), 2.46-2.42 (m, 1 H). LCMS (M+H): 503.35.
[00246] Example 134: 1-(6-(Difluoromethyl)-[1 ,3]dioxolo[4,5-g]quinolin-7- yl)-3-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea. 1 H NMR (DMSO-cfe, 300 MHz): δ 8.58 (s, 1 H), 8.00 (s, 1 H), 7.45-7.31 (m, 4H), 7.21- 7.17 (m, 2H), 7.07-7.02 (m, 2H), 6.21 (s, 2H), 4.19-4.16 (m, 1 H), 3.46 (t, J= 5.7 Hz, 2H), 3.25 (s, 3H), 3.16-3.14 (m, 2H), 2.98-2.92 (m, 1 H), 2.72-2.63 (m, 4H). LCMS (M+H): 503.35.
[00247] Example 135: 1-([1 ,3]Dioxolo[4,5-g]quinolin-7-yl)-3-((3S,4R)-4- (3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea. 1 H NMR (CDCb, 400 MHz): δ 8.51 (s, 1 H), 8.36 (s, 1 H), 7.29 (s, 1 H), 7.14-7.08 (m, 2H), 7.07 - 7.00 (m, 2H), 6.07 (s, 2H), 5.48-5.46 (m, 1 H), 4.15-4.12 (m, 1 H), 3.59-3.56 (m, 2H), 3.45-3.42 (m, 2H), 3.34 (s, 3H), 3.26-3.23 (m, 1 H), 2.91-2.86 (m, 2H), 2.82- 2.78 (m, 1 H), 2.49-2.44 (m, 1 H). LCMS (M+H): 471.34.
[00248] Example 136: 1-(6-Fluoro-2-phenylquinolin-3-yl)-3-((3S,4R)-4-(3- fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea. 1 HNMR (CD3OD, 300 MHz): 8.65 (s, 1 H), 8.00-7.95 (m, 1 H), 7.61-7.41 (m, 7H), 7.35-7.28 (m, 1 H), 7.13-7.05 (m, 2H), 6.99-6.93 (m, 1 H), 4.32-4.26 (m, 1 H), 3.54 (t, J= 5.7 Hz, 2H),
3.32 (s, 3H), 3.23-3.00 (m, 3H), 2.79-2.58 (m, 4H). LCMS (M+H): 503.48.
[00249] Example 137: 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-5,6,7,8-tetrahydroquinolin-3-yl)urea. 1 HNMR (CD3OD, 300 MHz): 7.77 (s, 1 H), 7.48-7.41 (m, 5H), 7.35-7.28 (m, 1 H), 7.10-7.03 (m, 2H), 6.98-6.92 (m, 1 H), 4.27-4.22 (m, 1 H), 3.53 (t, J= 5.7 Hz, 2H),
3.33 (s, 3H), 3.24-3.18 (m, 1 H), 3.12-2.97 (m, 2H), 2.85-2.71 (m, 7H), 2.67-2.57 (m, 1 H), 1.90-1.82 (m, 4H). LCMS (M+H): 489.48.
[00250] Example 138: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(7-methyl-2-phenyl-1 ,8-naphthyridin-3-yl)urea. 1 HNMR (CDC , 300 MHz): δ 8.89-8.88 (m, 1 H), 8.05 (d, J = 8.1 Hz, 1 H), 7.74 (d, J = 6.0 Hz, 2H), 7.54-7.47 (m, 3H), 7.35-7.30 (m, 3H), 7.26-7.24 (m, 3H), 4.30-4.28 (m, 1 H), 3.48-3.44 (m, 2H), 3.33 - 3.28 (m, 1 H), 3.24 (s, 3H), 3.22-3.13 (m, 2H), 2.76 (s, 3H), 2.54-2.50 (m, 3H), 2.48-2.30 (m, 1 H). LCMS (M+H): 482.46.
[00251] Example 139: 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(2-phenylquinolin-3-yl)urea. 1 HNMR (CDCb, 400 MHz): δ 8.85 (s, 1 H), 8.05 (d, J = 8.8 Hz, 1 H), 7.81 (d, J = 8.0 Hz, 1 H), 7.64-7.49 (m, 7H), 7.30-7.26 (m, 1 H), 7.04 (d, J = 8.0 Hz, 1 H), 6.97-6.90 (m, 2H), 5.22-5.21 (m, 1 H), 4.26-4.24 (m, 1 H), 3.47-3.37 (m, 2H), 3.26 (s, 3H), 3.20-3.15 (m, 2H) 3.01-2.98 (m, 1 H), 2.73-2.65 (m, 2H), 2.59-2.56 (m, 1 H), 2.31- 2.37 (m, 1 H). LCMS (M+H): 485.47.
[00252] Example 140: 1-([1 ,3]Dioxolo[4,5-g]quinolin-7-yl)-3-((3S,4R)-4-(3- fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea. 1 HNMR (CDCb, 300 MHz): δ 8.49 (s, 1H), 8.38 (s, 1H), 7.32-7.27 (m, 3H), 7.07 (d, J= 7.5 Hz, 1H), 6.97-6.92 (m, 3H), 6.07 (s, 2H), 5.48-5.46 (m, 1H), 4.18-4.15 (m, 1H), 3.58-3.52 (m, 3H), 3.42-3.40 (m, 1H), 3.33 (s, 3H), 3.21-3.18 (m, 1H), 2.87-2.72 (m, 3H), 2.45-2.39 (m, 1H). LCMS (M+H): 453.38.
[00253] Example 141: 1-(2-(2,4-Difluorophenyl)quinolin-3-yl)-3-((3S,4R)- 1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1HNMR (CDCb, 400 MHz): δ 8.70 (s, 1H), 8.05 (d, J= 8.8 Hz, 1H), 7.82 (d, J= 7.6 Hz, 1H), 7.65-7.51 (m, 3H), 7.34-7.30 (m, 2H), 7.26-7.22 (m, 4H), 7.08-7.04 (m, 1 H), 6.99-6.94 (m, 1 H), 5.32-5.29 (m, 1 H), 4.28-4.25 (m, 1 H), 3.45 (t, J= 4.8 Hz, 2H), 3.36-3.29 (m, 2H), 3.23 (s, 3H), 3.09-3.06 (m, 1H), 2.76-2.69 (m, 2H), 2.63-2.59 (m,1H), 2.36-2.32 (m, 1H). LCMS (M+H): 503.48.
[00254] Example 142: 1-(2-(3,5-Difluorophenyl)quinolin-3-yl)-3-((3S,4R)- 1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1HNMR (CDCb, 300 MHz): δ 8.75 (s, 1H), 8.05 (d, J= 8.4 Hz, 1H), 7.82 (d, J= 8.1 Hz, 1H), 7.65-7.60 (m, 1 H), 7.55-7.50 (m, 1 H), 7.35-7.30 (m, 8H), 6.96-6.90 (m, 1 H), 5.40-5.38 (m, 1 H), 4.19-4.16 (m, 1H), 3.38 (t, J= 5.4 Hz, 2H), 3.24-3.21 (m, 3H), 3.13 (s, 3H), 2.73- 2.67 (m, 2H), 2.60-2.55 (m, 1H), 2.30-2.28 (m, 1H). LCMS (M+H): 502.99.
[00255] Example 143: 1-(4-(Benzyloxy)-1-(2-methoxyethyl)pyrrolidin-3- yl)-3-(6-methyl-[1,3]dioxolo[4,5-g]quinolin-7-yl)urea. 1H NMR (CD3OD, 300 MHz): δ 8.29 (s, 1H), 7.38-7.25 (m, 5H), 7.17 (s, 1H), 7.09 (s, 1H), 6.09 (s, 2H), 4.70 (d, J= 10.4 Hz, 1H), 4.59 (d, J= 12.0 Hz, 1H), 4.28-4.25 (m, 1H), 3.98- 3.94 (m, 1H), 3.52 (t, J= 5.4 Hz, 2H), 3.33 (s, 3H), 3.16-3.10 (m, 1H), 3.04-2.99 (m, 1H), 2.74-2.60 (m, 4H), 2.56 (s, 3H). LCMS (M+H)+:479.15.
[00256] Example 144: 1-(1-Chloro-3-methylisoquinolin-4-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (CD3OD, 400 MHz): δ 8.31 (d, J= 8.4 Hz, 1H), 7.87-7.85 (m, 1H), 7.80-7.77 (m, 1H), 7.72-7.68 (m, 1 H), 7.33-7.32 (m, 4H), 7.26-7.22 (m, 1 H), 4.45-4.41 (m, 1 H), 3.55-3.47 (m, 2H), 3.33 (s, 3H), 3.20-3.06 (m, 2H), 2.90-2.64 (m, 5H), 2.48 (s, 3H). LCMS 439.08.
[00257] Example 145: 1-(1,3-Diphenylisoquinolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (CD3OD, 400 MHz): δ 8.04 (d, J= 8.4 Hz, 2H), 7.78 (t, J= 6.8 Hz, 1H), 7.68-7.67 (m, 4H), 7.62-7.54 (m, 5H), 7.38-7.24 (m, 7H), 4.40-4.36 (m, 1H), 3.50-3.47 (m, 2H), 3.30 (s, 3H), 3.25- 3.24 (m, 1H), 2.80-2.68 (m, 5H), 2.50-2.48 (m, 1H). LCMS (M+H): 543.99.
[00258] Example 146: 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(3-methyl-1-(1-methyl-1H-pyrazol-4- yl)isoquinolin-4-yl)urea.1H NMR (CD3OD, 400 MHz): δ 8.29 (d, J= 8.8 Hz, 1H), 8.12 (s, 1H), 7.93 (s, 1H), 7.89 (d, J=7.6Hz, 1 H), 7.75 -7.71 (m, 1H), 7.62-7.58 (m, 1H), 7.36-7.31 (m, 1H), 7.15-7.09 (m, 2H), 6.99-6.95 (m, 1H), 4.45-4.40 (m, 1H), 4.03 (s, 3H) 3.54-3.51 (m, 3H), 3.33 (s, 3H), 3.12-3.05 (m, 1H), 2.77-2.64 (m, 5H), 2.55 (s, 3H). LCMS (M+H): 503.44.
[00259] Example 147: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-
3- yl)-3-(1-(1-methyl-1H-pyrazol-4-yl)-3-phenylisoquinolin-4-yl)urea. 1H NMR (DMSO cfe, 300 MHz): δ 8.41 (s, 1H), 8.38-8.37 (m, 1H), 8.00 (s, 1H), 7.91 (d, J = 8.1 Hz, 2H), 7.80-7.64 (m, 4H), 7.40-7.39 (m, 3H), 7.34-7.22 (m, 5H), 6.70 (br s, 1H), 4.19-4.11 (m, 1H), 3.96 (s, 3H) 3.46-3.43 (m, 2H), 3.25 (s, 3H), 3.19- 3.12 (m, 2H), 2.91-2.75 (m, 1H), 2.71-2.54 (m, 4H). LCMS (M+H): 547.12.
[00260] Example 148: 1-(lsoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)-
4- phenylpyrrolidin-3-yl)urea.1H NMR (DMSO cfe, 300 MHz): δ 9.07 (d, J= 9.9 Hz 1H), 8.96 (d, J= 6.9 Hz, 1H), 8.54 (br s 1H), 8.25-8.16 (m, 1H), 8.07 (t, J = 9.0 Hz, 2H), 7.84-7.66 (m, 2H), 7.37-7.22 (m, 4H), 7.07 (d, J= 7.5 Hz 1 H), 4.25- 4.20 (m, 1H), 3.48 (t, J= 5.4 Hz, 2H), 3.26 (s, 3H), 3.18-3.08 (m, 2H), 2.98-2.85 (m, 1H), 2.78-2.60 (m, 3H), 2.48-2.39 (m, 1H). LCMS (M+H): 391.47.
[00261] Example 149: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(3-phenylisoquinolin-4-yl)urea.1H NMR (DMSO cfe, 300 MHz): δ 9.29 (s, 1H), 8.15 (d, J= 8.1 Hz, 1H), 7.95 (br s, 1H), 7.86-7.75 (m, 2H), 7.70.-7.65 (m, 3H), 7.41-7.20 (m, 8H), 6.67 (br s, 1H), 4.20-4.08 (m, 1H), 3.44 (t, J= 5.7 Hz, 2H), 3.25 (s, 3H), 3.13-3.06 (m, 2H), 2.84 (t, J= 8.7 Hz, 1H), 2.65-2.58 (m, 3H), 2.46-2.42 (m, 1H). LCMS (M+H): 467.03.
[00262] Example 150: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(3-methylisoquinolin-4-yl)urea.1H NMR (DMSO cfe, 300 MHz): δ 9.09 (s, 1H), 8.08 (s, 1H), 8.05-8.02 (m, 1H), 7.80-7.69 (m, 2H), 7.58 (t, J= 7.8 Hz, 1H), 7.33-7.31 (m, 5H), 7.24-7.23 (m, 1H), 6.70 (d, J= 8.1 Hz, 1H), 4.32-4.11 (m, 1H), 3.48-3.45 (m, 2H), 3.25 (s, 3H), 3.21-3.11 (m, 2H), 2.98-2.91 (m, 1H), 2.68- 2.62 (m, 4H), 2.46 (s, 3H). LCMS (M+H): 405.02.
[00263] Example 151: 1-(1-Cyano-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (DMSO cfe, 300 MHz): δ 8.52-8.39 (m, 1H), 8.27-8.24 (m, 1H), 8.04-8.02 (m, 1H), 7.97-7.91 (m, 2H), 7.65-7.62 (m, 2H), 7.46-7.44 (m, 3H), 7.33-7.19 (m, 5H), 6.88 (d, J= 8.4 Hz, 1H), 4.09-4.07 (m, 1H), 3.45-3.41 (m, 2H), 3.24 (s, 3H), 3.17-3.05 (m, 3H), 2.82- 2.76 (m, 1H), 2.63-2.56 (m, 3H). LCMS (M+H): 492.25.
[00264] Example 152: 1-(1-Chloro-3-phenylisoquinolin-4-yl)-3-((3S,4R)-4- (3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea. 1H NMR (DMSO cfe, 400 MHz): δ 8.30 (d, J= 8.4 Hz, 1H), 8.15-8.02 (m, 1H), 7.95-7.88 (m, 2H), 7.85-7.80 (m, 1H), 7.66-7.65 (m, 2H), 7.42-7.41 (m, 3H), 7.37-7.31 (m, 1H), 7.09-7.02 (m, 3H), 6.78-6.65 (m, 1H), 4.19-4.05 (m, 1H), 3.45-3.41 (m, 2H), 3.24 (s, 3H), 3.17-3.05 (m, 3H), 2.92-2.83 (m, 1H), 2.66-2.56 (m, 3H). LCMS (M+H): 519.38.
[00265] Example 153: 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(3-phenylisoquinolin-4-yl)urea. 1H NMR (CD3OD, 300 MHz): 59.22 (s, 1H), 8.17 (d, J= 8.4 Hz, 1H), 7.98 (d, J= 8.1 Hz, 1 H), 7.84-7.79 (m, 1 H), 7.73-7.67 (m, 1 H), 7.62-7.61 (m, 2H), 7.42-7.40 (m, 3H), 7.36-7.29 (m, 1 H), 7.08-6.95 (m, 3H), 4.22-4.32 (m, 1 H), 3.51-3.48 (m, 2H), 3.29 (s, 3H), 3.22-3.19 (m, 1H), 3.08-3.02 (m, 1H), 2.95-2.85 (m, 1H), 2.72-2.67 (m, 3H), 2.55 - 2.48 (m, 1 H). LCMS (M+H):485.38.
[00266] Example 154: 1-(1-Cyano-3-phenylisoquinolin-4-yl)-3-((3S,4R)-4- (3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea.1H NMR (CD3OD, 400 MHz): δ 8.35-8.32 (m, 1H), 8.09 (d, J= 7.2 Hz, 1H), 7.91-7.87 (m, 2H), 7.67- 7.64 (m, 2H), 7.44 -7.43 (m, 3H), 7.33-7.30 (m, 1H), 7.09-6.97 (m, 3H), 4.32- 4.21 (m, 1H), 3.50-3.47 (m, 2H), 3.30 (s, 3H), 3.22-3.20 (m, 1H), 3.13-3.08 (m, 2H), 2.92-2.90 (m, 1H), 2.74-2.69 (m, 2H), 2.52-2.50 (m, 1H). LCMS (M+H): 510.41.
[00267] Example 155: 1-(1-Hydroxy-3-phenylisoquinolin-4-yl)-3-((3S,4R)- 1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (DMSO cfe, 300 MHz): δ 11.38 (s, 1H), 8.21 (d, J= 9.0 Hz, 1H), 7.72 (t, J= 7.2 Hz, 1H), 7.53-7.48 (m, 4H), 7.42-7.38 (m, 3H), 7.30-7.21 ( m, 6H), 6.50 (br s, 1H), 4.10-4.06 (m, 1H), 3.43-3.39 (m, 2H), 3.23 (s, 3H), 3.08-3.02 (m, 2H), 2.83-2.78 (m, 1H), 2.66-2.52 (m, 3H), 2.47-2.43 (m, 1H). LCMS (M+H): 483.49.
[00268] Example 156: 1-(1-Amino-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (CD3OD, 300 MHz): δ 8.13 (d, J= 8.1 Hz, 1H), 7.77-7.73 (m, 1H), 7.71 -7.64 (m, 1H), 7.62-7.48 (m, 3H), 7.42-7.30 (m, 3H), 7.29-7.18 (m, 5H), 4.34-4.28 (m, 1H), 3.50-3.46 (m, 2H), 3.31 (s, 3H), 3.28-3.22 (m, 1H), 2.94-2.90 (m, 2H), 2.64-2.59 (m, 3H), 2.54-2.48 (m, 1H). LCMS (M+H): 482.07.
[00269] Example 157: 1-(1-Methoxy-3-phenylisoquinolin-4-yl)-3-((3S,4R)- 1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (DMSO cfe, 300 MHz): δ 8.19 (d, J= 8.1 Hz, 1H), 7.75-7.59 (m, 6H), 7.39-7.22 (m, 8H), 6.66 (brs, 1H), 4.22-4.10 (m, 1H), 4.09 (s, 3H), 3.45-3.42 (m, 2H), 3.25 (s, 3H), 3.08-3.06 (m, 2H), 2.84-2.80 (m, 1 H), 2.62 - 2.54 (m, 4H). LCMS (M+H): 497.49.
[00270] Example 158: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(1-methyl-3-phenylisoquinolin-4-yl)urea.1H NMR (CD3OD, 300 MHz): δ 8.25 (d, J= 8.4 Hz, 1H), 7.95 (d, J= 7.8 Hz, 1H), 7.77 (t, J= 8.1 Hz, 1H), 7.68 (t, J= 7.2 Hz, 1H), 7.62-7.56 (m, 2H), 7.42-7.36 (m, 3H), 7.34-7.23 (m, 5H), 4.33-4.28 (m, 1H), 3.49 (t, J= 5.7 Hz, 2H), 3.30 (s, 3H), 3.26-3.23 (m, 1H), 3.10- 3.05 (m, 1H), 2.97 (s, 3H), 2.93-2.90 (m, 1H), 2.74-2.64 (m, 2H), 2.54-2.47 (m, 1H). LCMS (M+H): 481.42.
[00271] Example 159: 1-(7-Fluoro-1-methyl-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (DMSO cfe, 400 MHz): δ 7.95 (dd, J= 2.0 and 9.6 Hz, 1H), 7.92-7.88 (m, 2H), 7.68 (dd, J = 2.4 and 9.2 Hz, 1H ), 7.64-7.62 (m, 2H), 7.39-7.38 (m, 3H), 7.33-7.26 (m, 4H), 7.23 (d, J= 6.8 Hz 1H), 6.65 (br s, 1H), 4.14-4.10 (m, 1H), 3.44 (t, J= 5.6 Hz, 2H), 3.25 (s, 3H), 3.11-3.05 (m, 2H), 2.87 (s, 3H), 2.84-2.82 (m, 1H), 2.65-2.55 (m, 3H), 2.46 (t ,J= 7.2 Hz, 1H). LCMS (M+H): 499.38.
[00272] Example 160: 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(1-(1-methyl-1H-pyrazol-4-yl)-3- phenylisoquinolin-4-yl)urea.1H NMR (CD3OD, 300 MHz): δ 8.41 (d, J= 8.4 Hz, 1H), 8.19 (s, 1H), 8.05-7.98 (m, 2H), 7.79 (t, J= 8.1 Hz 1H), 7.70-7.66 (m, 3H), 7.41-7.28 (m, 4H), 7.03-6.94 (m, 3H), 4.33-4.26 (m, 1H), 4.02 (s, 3H), 3.49 (t, J = 5.4 Hz 2H), 3.29 (s, 3H), 3.22-3.18 (m, 2H), 2.94-2.88 (m, 1H), 2.71-2.64 (m, 3H), 2.53-2.48 (m, 1H). LCMS (M+H): 565.18.
[00273] Example 161: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(3-methyl-1-(1-methyl-1H-pyrazol-4-yl)isoquinolin-4-yl)urea. 1H NMR (CD3OD, 300 MHz): δ 8.29 (d, J= 8.4 Hz, 1H), 8.12 (s, 1H), 7.93 (s, 1H), 7.87 (d, J= 8.1 Hz, 1H), 7.72 (t, J= 8.1 Hz, 1H), 7.59 (t, J= 6.9 Hz, 1H), 7.41-7.32 (m, 4H), 7.27-7.22 (m, 1H), 4.46-4.43 (m, 1H), 4.03 (s, 3H), 3.54 (t, J= 5.1 Hz, 2H), 3.33 (s, 3H), 3.23-3.19 (m, 2H), 3.09-3.06 (m, 1H), 2.95-2.92 (m, 1H), 2.82- 2.78 (m, 2H), 2.54 (s, 3H). LCMS (M+H): 485.20.
[00274] Example 162: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(1-(1-methyl-1H-pyrazol-4-yl)isoquinolin-4-yl)urea.1H NMR (CDCb, 300 MHz): δ 8.60 (s, 1H), 8.37 (d, J= 8.4 Hz, 1H), 7.96-7.90 (m, 3H), 7.70-7.57 (m, 2H), 7.34-7.29 (m, 2H), 7.23-7.21 (m, 3H), 5.57 (br s, 1H), 4.48-4.46 (m, 1H), 4.03 (s, 3H), 3.46 (t, J= 5.4 Hz, 2H), 3.41-3.38 (m, 1H), 3.31-3.27 (m, 1H), 3.24 (s, 3H), 3.14-3.10 (m, 1H), 2.94-2.88 (m, 1H), 2.77-2.70 (m, 2H), 2.47 (t, J= 9.3 Hz,1H). LCMS (M+H): 471.38.
[00275] Example 163: 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(1-(1-methyl-1H-pyrazol-4-yl)isoquinolin-4- yl)urea.1H NMR (CDCb, 400 MHz): δ 8.58 (s, 1H), 8.39 (d, J= 8.8 Hz, 1H), 7.98-7.92 (m, 3H), 7.71 (t, J= 7.2 Hz, 1H), 7.63 (t, J= 7.2 Hz, 1H), 7.29-7.27 (m, 2H), 7.03 (d, J= 8.0 Hz, 1H), 6.95-6.91 (m, 2H), 5.25 (br s, 1H), 4.44-4.41 (m, 1H), 4.04 (s, 3H), 3.43 (t, J= 5.2 Hz, 2H), 3.34 (t, J= 8.8 Hz, 1H), 3.25 (s, 3H), 3.17-3.14 (m, 1H), 2.99-2.97 (m, 1H), 2.86 (t, J= 8.0 Hz, 1H), 2.73-2.62 (m, 2H), 2.40 (t, J= 9.2Hz, 1H). LCMS (M+H): 489.48.
[00276] Example 164: 1-(3-(tert-Butyl)-1-(1-methyl-1H-pyrazol-4- yl)isoquinolin-4-yl)-3-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin- 3-yl)urea.1H NMR (CD3OD 300 MHz): 8.43-8.40 (m, 1H), 8.33 (d, J= 7.5 Hz, 1H), 8.08-8.01 (m, 1H), 7.91-7.78 (m, 1H), 7.72-7.48 (m, 2H), 7.42-7.24 (m, 1H), 7.22-7.14 (m, 1H), 7.08-6.82 (m, 2H), 4.48-4.40 (m, 1H), 4.01 (s, 3H), 3.57 (t, J= 5.7 Hz, 2H), 3.37 (s, 3H), 3.26-3.21 (m, 1H), 3.11-3.05 (m, 1H), 2.94-2.78 (m, 2H), 2.76-2.68 (m, 1H), 2.63-2.59 (m, 1H), 2.48-2.33 (m, 1H), 1.49 (s, 9H). LCMS (M+H): 545.53.
[00277] Example 165: 1-(3-(tert-Butyl)-1-(1-methyl-1H-pyrazol-4- yl)isoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (CD3OD, 300 MHz): δ 8.42-8.01 (m, 3H), 7.79-7.55 (m, 3H), 7.35-7.10 (m, 5H), 4.48-4.44 (m, 1H), 4.01 (s, 3H), 3.57-3.53 (m, 2H), 3.37 (s, 3H), 3.22- 3.08 (m, 2H), 2.83-2.70 (m, 4H), 2.37-2.32 (m, 1H), 1.48 (s, 9H). LCMS (M+H): 527.52.
[00278] Example 166: 1-(1-Fluoro-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (DMSO d6400 MHz): 8.17 (d, J= 8.4 Hz, 1H), 7.96 (br s, 1H), 7.99-7.89 (m, 2H), 7.78 (t, J= 8.0 Hz, 1H), 7.68-7.64 (m, 2H), 7.44-7.39 (m, 3H), 7.33-7.20 (m, 5H), 6.71 (br s, 1H), 4.15-4.10 (m, 1H), 3.44 (t, J= 4.8 Hz, 2H), 3.38-3.34 (m, 1H), 3.24 (s, 3H), 3.14- 3.05 (m, 2H), 2.86-2.80 (m, 1H), 2.69-2.58 (m, 3H). LCMS (M+H): 485.40.
[00279] Example 167: 1-((3S,4R)-4-(3-Fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(1-methyl-3-phenylisoquinolin-4-yl)urea. 1H NMR (CD3OD, 300 MHz): 8.27 (d, J= 8.4 Hz, 1H), 7.96 (d, J= 7.5 Hz, 1H), 7.79 (t, J= 5.1 Hz, 1H), 7.69 (t, J= 7.2 Hz, 1H), 7.62-7.56 (m, 2H), 7.41-7.28 (m, 4H), 7.03-6.94 (m, 3H), 4.29-4.25 (m, 1H), 3.49 (t, J= 5.4 Hz, 2H), 3.34 (s, 3H), 3.28-3.16 (m, 2H), 3.09-3.04 (m, 1H), 2.97 (s, 3H), 2.92-2.86 (m, 1H), 2.68-2.64 (m, 2H), 2.53-2.48 (m, 1H). LCMS (M+H): 499.43. [00280] Example 168: 1-(7-Methoxy-1-methyl-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (CD3OD400 MHz): 7.85 (d, J= 8.4 Hz, 1H), 7.58-7.54 (m, 2H), 7.46 (d, J= 2.0 Hz, 1H), 7.41- 7.37 (m, 4H), 7.31 (d, J= 6.8 Hz, 2H), 7.25 (J= 6.8 Hz, 2H), 7.23-7.19 (m, 1H), 4.31-4.26 (m, 1H), 3.99 (s, 3H), 3.52-3.48 (m, 2H), 3.42-3.38 (m, 1H), 3.30 (s, 3H), 3.28-3.20 (m, 1H), 3.12-3.06 (m, 1H), 2.93 (s, 3H), 2.78-2.74 (m, 3H), 2.58- 2.54 (m, 1H). LCMS (M+H): 511.45.
[00281] Example 169: 1-(6-Methoxy-1-methyl-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (CDCI3, 400 MHz): δ 8.07 (d, J= 9.6 Hz, 1H), 7.65 (d, J= 7.2 Hz, 2H), 7.42-7.35 (m, 3H), 7.28-7.25 (m, 1H), 7.22-7.19 (m, 4H), 7.09 (d, J= 6.8 Hz, 2H), 4.86 (br s, 1H), 4.38-4.33 (m, 1H), 3.78 (s, 3H), 3.37-3.35 (m, 2H), 3.23 (s, 3H), 3.18-3.16 (m, 1H), 2.98 (s, 3H), 2.89-2.87 (m, 1H), 2.82-2.76 (m, 2H), 2.63-2.55 (m, 2H), 2.29 (t, J= 9.6 Hz, 1H). LCMS (M+H): 511.45.
[00282] Example 170: 1-(1,6-Dimethyl-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (CDCb 400 MHz): 8.05 (d, J= 8.4 Hz, 1H), 7.79 (s, 1H), 7.67 (d, J= 7.2 Hz, 2H), 7.46-7.34 (m, 5H), 7.29-7.26 (m, 2H), 7.22 (d, J= 7.2 Hz, 1H), 7.12 (d, J= 7.2 Hz, 2H), 4.85 (br s, 1 H), 4.42-4.28 (m, 1 H), 3.39-3.35 (m, 2H), 3.21 (s, 3H), 2.99 (s, 3H), 2.92-2.85 (m, 1H), 2.83-2.74 (m, 2H), 2.64-2.60 (m, 2H), 2.51 (s, 3H), 2.33-2.29 (m, 2H). LCMS (M+H): 495.47.
[00283] Example 171: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(3-phenyl-1-(pyridin-3-yl)isoquinolin-4-yl)urea.1H NMR (DMSO cfe, 300 MHz): δ 8.91 (d, J= 1.5 Hz, 1H), 8.75 (dd, J= 1.5 and 4.8 Hz, 1H), 8.15 (dt, J = 1.8 and 3.6 Hz, 1H), 8.00-7.96 (m, 3H), 7.83 (t, J= 6.9 Hz, 1H), 7.73-7.59 (m, 4H), 7.42-7.21 (m, 8H), 6.73 (br s, 1H), 4.22-4.13 (m, 1H), 3.45 (t, J= 5.7 Hz, 2H), 3.26 (s, 3H), 3.17-3.12 (m, 2H), 2.86-2.83 (m, 1H), 2.70-2.55 (m, 3H), 2.49- 2.47 (m, 1H). LCMS (M+H): 544.51.
[00284] Example 172: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(1-morpholino-3-phenylisoquinolin-4-yl)urea. 1H NMR (CD3OD, 400 MHz): 8.19 (d, J= 7.6 Hz, 1H), 7.88-7.82 (m, 3H), 7.69 (d, J= 6.4 Hz, 1H), 7.57 (t, J= 7.2 Hz, 1H), 7.36-7.28 (m, 4H), 7.30-7.25 (m, 2H), 7.23 (d, J= 7.2 Hz, 2H), 4.33-4.28 (m, 1H), 3.96 (t, J= 4.4 Hz, 4H), 3.68-3.52 (m, 2H), 3.55 - 3.44 (m, 4H), 3.30 (s, 3H), 3.27-3.18 (m, 2H), 2.96-2.82 (m, 2H), 2.74-2.63 (m, 2H), 2.53-2.48 (m, 1H). LCMS (M+H): 552.52.
[00285] Example 173: 1-(1-(4-Hydroxypiperidin-1-yl)-3-phenylisoquinolin- 4-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (CDsOD 400 MHz): 8.13 (d, J= 8.0 Hz, 1H), 7.88-7.82 (m, 1H), 7.74-7.63 (m, 3H), 7.56 (t, J= 8.4 Hz, 1H), 7.42-7.28 (m, 5H), 7.25-7.19 (m, 3H), 4.33-4.29 (m, 1H), 3.86-3.79 (m, 3H), 3.52-3.46 (m, 2H), 3.30 (s, 3H), 3.15 (t, J= 9.6 Hz, 4H), 2.96-2.88 (m, 2H), 2.74-2.65 (m, 2H), 2.53-2.47 (m, 1H), 2.07-2.05 (m, 2H), 1.86-1.79 (m, 2H). LCMS (M+H): 566.56.
[00286] Example 174: 1-(3-(3-Fluorophenyl)-1-methylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (CD3OD, 400 MHz): 58.27 (d, J=8.4Hz, 1H), 7.97-7.95 (m, 1H), 7.79 (t, J=7.2 Hz, 1H), 7.70 (t, J= 8.0 Hz, 1H), 7.44-7.38 (m, 3H), 7.32-7.20 (m, 5H), 7.12 (t, J= 6.8 Hz, 1H), 4.31-4.26 (m, 1H), 3.52-3.47 (m, 2H), 3.30 (s, 3H), 3.25-3.14 (m, 2H), 2.98 (s, 3H), 2.88-2.82 (m, 1H), 2.78-2.62 (m, 3H), 2.52-2.47 (m, 1H). LCMS (M+H): 499.47.
[00287] Example 175: 1-(3-(2-Fluorophenyl)-1-methylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (CDC , 400 MHz): δ 8.18 (d, J= 8.4 Hz, 1H), 8.03 (d, J= 8.4 Hz, 1H), 7.73-7.64 (m, 2H), 7.57-7.51 (m, 1H), 7.39-7.35 (m, 1H), 7.29-7.28 (m, 2H), 7.23-7.20 (m, 2H), 7.16-7.08 (m, 3H), 4.82 (br s, 1H), 4.25-4.22 (m, 1H), 3.41-3.43 (m, 2H), 3.28- 3.26 (m, 1H), 3.21 (s, 3H), 3.03 (s, 3H), 2.94-2.90 (m, 2H), 2.71-2.54 (m, 3H), 2.33-2.30 (m, 1H). LCMS (M+H): 499.47.
[00288] Example 176: 1-(6,7-Dimethoxy-1-methyl-3-phenylisoquinolin-4- yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (CDCb, 300 MHz): δ 7.63 (d, J= 6.9 Hz, 2H), 7.42-7.32 (m, 5H), 7.23-7.19 (m, 3H), 7.09 (d, J = 6.6 Hz, 2H), 4.85 (br s, 1 H), 4.45-4.37 (m, 1 H), 4.08 (s, 3H), 3.83 (s, 3H), 3.40-3.36 (m, 2H), 3.24 (s, 3H), 3.23-3.22 (m, 1 H), 2.96 (s, 3H), 2.87-2.77 (m, 3H), 2.61-2.56 (m, 2H), 2.30 (t, J = 8.4 Hz, 1 H). LCMS (M+H): 541.50.
[00289] Example 177: 1-(6-Fluoro-1-methyl-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CD3OD, 400 MHz): δ 8.36-8.32 (m, 1 H), 7.57-7.45 (m, 4H), 7.39-7.38 (m, 3H), 7.33-7.22 (m, 5H), 4.30-4.28 (m, 1 H), 3.52-3.51 (m, 2H), 3.31 (s, 3H), 3.31-3.30 (m, 2H), 3.1 1-3.09 (m, 1 H), 2.96 (s, 3H), 2.79-2.73 (m, 3H), 2.57-2.55 (m, 1 H). LCMS (M+H): 499.51.
[00290] Example 178: 1-(1 ,7-Dimethyl-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CD3OD, 400 MHz): δ 8.03 (s, 1 H), 7.84 (d, J= 8.0 Hz, 1 H), 7.62 (d, J= 8.8 Hz 1 H), 7.58- 7.56 (m, 2H), 7.39-7.36 (m, 3H), 7.33-7.29 (m, 2H), 7.25-7.21 (m, 3H), 4.32- 4.27 (m, 1 H), 3.52-3.48 (m, 2H), 3.30 (s, 3H), 3.24-3.22 (m, 1 H), 3.12-2.99 (m, 1 H), 2.95 - 2.93 (m, 1 H), 2.92 (s, 3H), 2.80-2.70 (m, 3H), 2.59 (s, 3H), 2.53- 2.48 (m, 1 H). LCMS (M+H): 495.55.
[00291] Example 179: 4-(3-((3S,4R)-1-(2-Methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-3-phenylisoquinoline-1-carboxamide. 1 H NMR CDsOD, 300 MHz): δ 8.95 (dd, J= 2.7 Hz and 10.8 Hz, 1 H), 8.08-8.03 (m, 1 H), 7.71-7.69 (m, 3H), 7.63-7.56 (m, 2H), 7.41-7.33 (m, 5H), 7.31-7.25 (m, 2H), 4.32-4.27 (m, 1 H), 3.52 (t, J= 4.5 Hz, 2H), 3.31 (s, 3H), 3.17-3.11 (m, 2H), 2.97 (t, J = 8.1 Hz, 1 H), 2.82-2.74 (m, 3H), 2.59 (t, J = 9.3 Hz, 1 H). LCMS (M+H):510.54.
[00292] Example 180: 1-(8-Methoxy-1-methyl-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CD3OD, 400 MHz): 6 8.00 (d, J= 8.4 Hz, 2H), 7.91 (s, 1 H), 7.60 (d, J= 8.4 Hz, 1 H), 7.49- 7.42 (m, 3H), 7.29-7.26 (m, 3H), 7.23 (d, J = 8.0 Hz, 1 H), 7.20 (d, J = 6.8 Hz 1 H), 7.03 (d, J = 8.4 Hz 1 H), 4.44-4.39 (m, 1 H), 4.02 (s, 3H), 3.54 (t, J = 5.6 Hz, 2H), 3.48-3.46 (m, 1 H), 3.33 (s, 3H), 3.14 (s, 3H), 3.08-3.02 (m, 1 H), 2.91-2.87 (m, 3H), 2.80-2.71 (m, 2H). LCMS (M+H):510.94. [00293] Example 181: 1-(8-Fluoro-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (CD3OD, 400 MHz): δ 9.22 (s, 1H), 8.15 (d, J= 8.0 Hz, 1H), 7.98-7.86 (m, 1H), 7.82-7.78 (m, 1H), 7.70-7.68 (m, 1H), 7.62-7.58 (m, 1H), 7.45-7.39 (m, 3H), 7.34-7.29 (m, 1H), 7.26-7.15 (m, 3H) 7.02-6.94 (m, 1H), 4.35-4.22 (m, 1H), 3.50 (t, J= 4.4 Hz, 2H), 3.37-3.35 (m, 1H), 3.30 (s, 3H), 3.26-3.22 (m, 1H), 3.12-3.08 (m, 1H), 2.95-2.92 (m, 1H), 2.78-2.66 (m, 2H), 2.56 (t, J= 7.6 Hz, 1H). LCMS (M+H):485.35.
[00294] Example 182: 1-(7-Fluoro-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1H NMR (CD3OD, 300 MHz): δ 9.20 (s, 1 H), 8.01-7.96 (m, 1 H), 7.84 (dd, J= 2.4 and 9.0 Hz, 1 H), 7.64-7.57 (m, 3H), 7.41-7.39 (m, 3H), 7.35-7.23 (m, 5H), 4.32-4.28 (m, 1H), 3.53-3.50 (m, 2H), 3.33 (s, 3H), 3.24-3.22 (m, 1H), 3.12-3.07 (m, 1H), 2.98-2.94 (m, 1H), 2.80- 2.74 (m, 3H), 2.56-2.54 (m, 1H). LCMS (M+H):484.88.
[00295] Example 183: 1-(7-fluoro-3-phenylisoquinolin-4-yl)-3-((3S,4R)-4- (3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea.1H NMR (CD3OD, 300 MHz): δ 9.21 (s, 1H), 8.04-7.99 (m, 1H),7.84 (dd, J=2.4 and 9.0 Hz, 1H), 7.65- 7.58 (m, 3H), 7.42-7.29 (m, 4H), 7.09-6.95 (m, 3H), 4.32-4.28 (m, 1H), 3.50 (t, J= 5.7 Hz, 2H), 3.31 (s, 3H), 3.24-3.19 (m, 1H), 3.10-3.07 (m, 1H), 2.95-2.90 (m, 1H), 2.79-2.65 (m, 3H), 2.56-2.54 (m, 1H).). LCMS (M+H):502.82.
[00296] Example 184: 1-(5-Methoxy-3-phenylisoquinolin-4-yl)-3-((3S,4R)- 1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea.1H NMR (CD3OD, 400 MHz): δ 8.99 (s, 1H), 7.58 (d, J= 8.0 Hz, 1H), 7.53-7.52 (m, 2H), 7.48 (d, J= 8.0 Hz, 1H), 7.28-7.26 (m, 3H), 7.19 (d, J= 7.2 Hz, 2H), 7.15-7.10 (m, 4H), 4.07-4.09 (m, 1H), 3.69 (s, 3H), 3.42-3.41 (m, 2H), 3.31-3.29 (m, 1H), 3.21 (s, 3H), 3.04- 3.02 (m, 1H), 2.86-2.82 (m, 1H), 2.72-2.64 (m, 3H), 2.50-2.48 (m, 1H). LCMS (M+H):497.39.
[00297] Example 185: 1-(7-Fluoro-1-methyl-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea. 1H NMR (CDsOD, 300 MHz): δ 8.03-7.98 (m, 1H), 7.91 (dd, J= 2.4 and 9.9 Hz, 1H), 7.61-7.57 (m, 3H), 7.40-7.28 (m, 4H), 7.07-6.94 (m, 3H), 4.27-4.24 (m, 1H), 3.49 (m, J= 5.1 Hz, 2H), 3.31 (s, 3H), 3.29-3.21 (m, 2H), 3.20-3.05 (m, 1 H), 2.93 (s, 3H), 2.75-2.65 (m, 3H), 2.54-2.50 (m, 1 H). LCMS (M+H):517.10.
[00298] Example 186: 1-(3-Cyanoisoquinolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CD3OD, 300 MHz): δ 8.83 (s, 1 H), 8.68-8.65 (m, 1 H), 8.06-8.03 (m, 1 H), 7.84-7.80 (m, 2H), 7.37-7.19 (m, 4H), 6.46-6.41 (m, 1 H), 3.90-3.84 (m, 1 H), 3.82-3.76 (m, 1 H), 3.64 (t, J = 5.1 Hz, 2H), 3.56 (d„ J= 8.7 Hz 1 H), 3.42 (s, 3H), 3.35-3.31 (m, 1 H), 3.07-2.94 (m, 2H), 2.87-2.79 (m, 1 H), 2.58 (t, J = 9.6 Hz, 1 H). LCMS (M+H):415.91.
[00299] Example 187: 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(3-phenyl-1-(piperazin-1-yl)isoquinolin-4-yl)urea. 1 H NMR (CD3OD, 400 MHz): δ 8.16 (d, J = 8.0 Hz, 1 H), 7.89-7.85 (m, 1 H), 7.70-7.66 (m, 3H), 7.58 (t, J = 8.0 Hz, 1 H), 7.33-7.22 (m, 8H), 4.33-4.29 (m, 1 H), 3.52-3.49 (m, 6H), 3.35- 3.50 (m, 4H), 3.25-3.12 (m, 5H), 2.91-2.68 (m, 5H). LCMS (M+H):551.39.
[00300] Example 188: 1-(1-Cyano-7-fluoro-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (DMSO cfe, 400 MHz): δ 8.40 (br s, 1 H), 8.12-8.09 (m, 1 H), 7.93-7.85 (m, 2H), 7.63-7.61 (m, 2H), 7.52-7.45 (m, 3H), 7.33-7.20 (m, 5H), 6.90 (d, J = 8.0 Hz, 1 H), 4.09- 4.04 (m, 1 H), 3.43 (t, J = 5.6 Hz, 2H), 3.24 (s, 3H), 3.13-3.04 (m, 2H), 2.80 (t, J = 8.0 Hz, 1 H), 2.65-2.55 (m, 3H), 2.44 (t, J= 8.4 Hz, 1 H). LCMS (M+H):510.36. [00301] Example 189: 1-(1-(Difluoromethyl)-3-phenylisoquinolin-4-yl)-3- (4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea
[00302] Step 1 : Synthesis of 1-(4-(3-fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)-3-(1-formyl-3-phenylisoquinolin-4-yl)urea: To a stirred solution of 1-(4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1- methyl-3-phenylisoquinolin-4-yl)urea (0.1 g, 0.200 mmol) in 1 , 4 dioxane (30 mL) was added selenium dioxide (0.033g, 0.301 mmol) and the reaction mixture was refluxed for 4 h. The reaction mixture was allowed to room temperature, concentrated under reduced pressure and the resultant crude compound was purified by flash chromatography using 5% methanol in dichloromethane as an eluent to afford intermediate 1-(4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin- 3-yl)-3-(1-formyl-3-phenylisoquinolin-4-yl)urea (0.05 g, 49%) as a white solid. ESI-MS m/z: 513.47 (M+H)+.
[00303] Step 2: Synthesis of 1-(1-(difluoromethyl)-3-phenylisoquinolin-4- yl)-3-(4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea: Deoxo-Fluor® solution 50% in THF (0.064 g, 0.292 mmol) was added to a solution of 1-(4-(3- fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-formyl-3- phenylisoquinolin-4-yl)urea (0.05 g, 0.097 mmol) in DCM (20 mL) at 0 °C and stirred at rt for 12 h. The reaction mixture was diluted with dichloromethane and washed with water. The separated organic layer was dried over anhydrous Na2S04, filtered and the filtrate was evaporated under reduced pressure. The crude compound was purified by flash chromatography using 5% methanol in dichloromethane as an eluent to afford the title compound (0.01 g, 19%) as an off-white solid. 1 H NMR (DMSO cfc 300 MHz): 8.41 (d, J = 8.4 Hz, 1 H), 8.17 (br s, 1 H), 8.00 (d, J= 7.5 Hz, 1 H), 7.90-7.77 (m, 2H), 7.69-7.65 (m, 2H), 7.58-7.38 (m, 4H), 7.35-7.31 (m, 1 H), 7.1 1-7.01 (m, 3H), 6.79 (d, J =7.8 Hz, 1 H), 4.15- 4.03 (m, 1 H), 3.44 (t, J = 5.7 Hz, 2H), 3.24 (s, 3H), 3.09-3.05 (m, 2H), 2.86 (t, J = 7.5 Hz, 1 H), 2.74-2.71 (m, 1 H), 2.66-2.57 (m, 2H), 2.28-2.24 (m, 1 H). ESI-MS m/z: 535.49 (M+H)+.
[00304] Example 190: 7-Fluoro-4-(3-(1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-3-phenylisoquinoline-1-carboxylic acid
[00305] To a stirred solution of methyl 7-fluoro-4-(3-(1-(2-methoxyethyl)- 4-phenylpyrrolidin-3-yl)ureido)-3-phenylisoquinoline-1-carboxylate (0.02 g, 0.036 mmol) in THF:MeOH (1 :1) (6 mL) was added LiOH.H20 (0.003g 0.073 mmol) and the reaction mixture was stirred for 2 h at rt. Then, it was concentrated under vacuum and the resulting residue was neutralized with 2N HCI, the formed solid was filtered and dried under reduced pressure to get the title compound as grey solid. Yield: 0.010 g (53%). 1 H NMR (CD3OD, 400 MHz): δ 8.22-8.14 (m, 1 H), 8.02-7.94 (m, 1 H), 7.65-7.53 (m, 3H), 7.36-7.29 (m, 8H), 4.42-4.36 (m, 1 H), 3.89-3.85 (m, 1 H), 3.66-3.63 (m, 2H), 3.59-3.47 (m, 2H), 3.38 (s, 3H), 3.35-3.31 (m, 3H), 3.28-3.21 (m, 1 H). LC-MS (M+H): 529.69. [00306] Example 191 : 7-Fluoro-4-(3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-3-phenylisoquinoline-1-carboxamide
[00307] To a stirred solution of 7-fluoro-4-(3-(1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-3-phenylisoquinoline-1-carboxylic acid (Example 190,0.075 g, 0.142 mmol) in DMF (5 mL) were added HATU (0.081 g 0.213 mmol), DIPEA (0.075mL, 0.426 mmol) and THF solution of ammonia ( 5 mL) and was stirred for 1 h at rt. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (2x20 mL). The combined organic layers were washed with water (10 mL), brine (10 mL) and dried over sodium sulphate. The solvents were filtered, concentrated under reduced pressure and the residue was purified by flash column chromatography eluting with 3% methanol/dichloromethane to afford the title compound as a yellow solid. Yield: 0.008 g (1 1 %). 1 H NMR (CD3OD, 300 MHz): δ 8.95 (dd, J= 2.7 Hz and 10.8 Hz, 1 H), 8.08-8.03 (m, 1 H), 7.71-7.69 (m, 2H), 7.63-7.56 (m, 2H), 7.41-7.33 (m, 5H), 7.31-7.25 (m, 2H), 4.32-4.27 (m, 1 H), 3.52 (t, J= 4.5 Hz, 2H), 3.31 (s, 3H), 3.17- 3.11 (m, 2H), 2.97 (t, J= 8.1 Hz, 1 H), 2.82-2.74 (m, 3H), 2.59 (t, J= 9.3 Hz, 1 H). LC-MS (M+H): 528.38.
[00308] Example 192: 4-(3-((3S,4R)-1-(2-Methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)isoquinoline-3-carboxamide. 1 H NMR (CD3OD, 400 MHz): δ 8.98 (s,1 H), 8.65 (d, J = 8.0 Hz 1 H), 7.80 (d, J = 8.4 Hz, 1 H), 7.72- 7.64 (m, 2H), 7.40-7.33 (m, 4H), 7.25 (t, J= 6.8 Hz, 1 H), 4.44-4.38 (m, 1 H), 3.58 (t, J = 5.4 Hz 2H), 3.37 (s, 3H), 3.35-3.34 (m, 2H), 3.18 (t, J = 9.2 Hz, 1 H), 2.99-2.95 (m, 1 H), 2.91-2.80 (m, 3H). LC-MS (M+H): 434.24.
[00309] Example 193: Methyl 2-((7-fluoro-4-(3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)ureido)-3-phenylisoquinolin-1- yl)(methyl)amino)acetate. 1 H NMR (DMSO-c , 300 MHz): δ 7.84 (dd, J = 2.4, 10.2 Hz, 1 H), 7.80-7.78 (m, 1 H), 7.73-7.68 (m, 1 H), 7.65-7.58 (m, 3H), 7.36- 7.21 (m, 8H), 6.63 (br s, 1 H), 4.21-4.16 (m, 1 H), 4.13 (s, 2H), 3.64 (s, 3H), 3.44 (t, J = 5.4Hz, 2H), 3.31 (s, 3H), 3.25 (s, 3H), 3.11-3.04 (m, 2H), 2.88-2.85 (m, 1 H), 2.67-2.58 (m, 3H), 2.49 (t, J = 1.8 Hz, 1 H).LC-MS(M+H): 586.08. [00310] Example 194: 2-((7-Fluoro-4-(3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-3-phenylisoquinolin-1-yl)(methyl)amino)acetic acid. 1 H NMR (DMSO-c , 300 MHz): δ 7.85-7.82 (m, 1 H), 7.78 (d, J = 8.0 Hz, 1 H), 7.62-7.55 (m, 3H), 7.34-7.32 (m, 9H), 6.62 (br s, 1 H), 4.16-4.10 (m, 1 H), 4.04 (s, 2H), 3.44 (t, J = 5.7 Hz, 2H), 3.32 (s, 3H), 3.24 (s, 3H), 3.13-3.02 (m, 2H), 2.88-2.85 (m, 1 H), 2.66-2.55 (m, 3H).LC-MS(M+H): 572.35.
[00311] Example 195: 1-(7-Fluoro-1-((2-hydroxyethyl)(methyl)amino)-3- phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)urea. 1 H NMR (CD3OD, 400 MHz): δ 8.06 (d, J = 9.6 Hz, 1 H), 7.93-7.88 (m, 1 H), 7.86-7.79 (m, 1 H), 7.66-7.60 (m, 2H), 7.48-7.42 (m, 1 H), 7.36-7.28 (m, 7H), 4.68-4.59 (m, 1 H), 3.92-3.89 (m, 4H), 3.78-3.72 (m, 1 H), 3.70-3.61 (m, 3H), 3.59 (s, 3H), 3.52-3.45 (m, 2H), 3.38-3.34 (m, 3H), 3.12 (s, 3H).LC-MS(M+H): 558.45.
[00312] Example 196: Ethyl 2-((4-(3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-3-phenylisoquinolin-7-yl)oxy)acetate. 1 H NMR (CD3OD, 400 MHz): δ 9.10 (s, 1 H), 7.87 (d, J= 9.2 Hz, 1 H), 7.57-7.56 (m, 2H), 7.48 (d, J= 9.6 Hz, 2H), 7.39-7.21 (m, 8H), 4.91 (s, 2H), 4.35-4.32 (m, 1 H) 4.28 (q, J = 7.2 Hz, 2H), 3.50 (t, J = 10.8 Hz, 2H), 3.30 (s, 3H), 3.24-3.19 (m, 1 H), 3.12-3.04 (m, 1 H), 2.92-2.90 (m, 1 H), 2.76-2.70 (m, 3H), 2.53 (t, J = 10.8 Hz, 1 H), 1.30 (t, J = 6.8 Hz, 3H).LC-MS: (M+H):569.31.
[00313] Example 197: 2-((4-(3-((3S,4R)-1-(2-Methoxyethyl)-4- phenylpyrrolidin-3-yl)ureido)-3-phenylisoquinolin-7-yl)oxy)acetic acid. 1 H NMR (CD3OD, 300 MHz): δ 9.09 (s, 1 H), 7.82-7.76 (m, 1 H), 7.60-7.54 (m, 1 H), 7.50- 7.45 (m, 3H), 7.42-7.36 (m, 5H), 7.32-7.28 (m, 3H), 4.58 (s, 2H), 4.42-4.34 (m, 1 H), 3.75-3.71 (m, 1 H), 3.62 (t, J= 4.8 Hz, 2H), 3.52-3.44 (m, 2H), 3.38 (s, 3H), 3.23-3.18 (m, 1 H), 3.12-3.05 (m, 3H).LC-MS(M+H):541.35.
[00314] Example 198: 1-(7-(2-hydroxyethoxy)-3-phenylisoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (CD3OD, 300 MHz): 9.10 (s, 1 H), 7.84 (d, J= 9.3 Hz, 1 H), 7.57-7.51 (m, 3H), 7.47 (dd, J = 2.4 and 9.3 Hz, 1 H), 7.39-7.24 (m, 8H), 4.32-4.28 (m, 1 H), 4.24 (t, J= 4.2 Hz, 2H), 3.96 (t, J= 4.8 Hz, 2H), 3.50 (t, J= 5.4 Hz, 2H), 3.31 (s, 3H), 3.26-3.22 (m, 1 H), 3.12-3.05 (m, 1 H), 2.93 (t, J = 6.9 Hz, 1 H), 2.76-2.71 (m, 3H), 2.54 (t, J = 9.3 Hz, 1 H).LC-MS (M+H):527.46.
[00315] Example 199: 1-(4-(Benzyloxy)-1-(2-methoxyethyl)pyrrolidin-3- yl)-3-(7-fluoro-1-methyl-3-phenylisoquinolin-4-yl)urea. 1 H NMR (CD3OD, 400 MHz): δ 8.13-8.09 (m, 1 H), 7.94 (dd, J= 2.4 and 9.6 Hz, 1 H), 7.64-7.59 (m, 3H), 7.42-7.33 (m, 3H), 7.28-7.25 (m, 5H), 4.57-4.54 (m, 1 H), 4.44-4.40 (m, 1 H), 4.34-4.10 (m, 1 H), 3.78-3.60 (m, 2H), 3.44 (s, 3H), 3.30-3.25 (m, 1 H), 3.10-2.98 (m, 1 H), 2.94 (s, 3H), 2.87-2.78 (m, 1 H), 2.68-2.57 (m, 2H), 2.49-2.42 (m, 2H). LCMS (M+H): 529.08.
[00316] Example 200: 1-(7-Fluoro-1-methyl-3-phenylisoquinolin-4-yl)-3- (4-hydroxy-1-(2-methoxyethyl)pyrrolidin-3-yl)urea. 1 H NMR (DMSO-cfe, 400 MHz): δ 8.50-7.79 (m, 2H), 7.76-7.67 (m, 3H), 7.45 (t,= 7.2 Hz, 2H), 7.39 (t, J= 7.6 Hz, 1 H), 6.54-6.48 (m, 2H), 4.00-3.89 (m, 1 H), 3.87-3.79 (m, 2H), 3.51-3.42 (m, 3H), 3.25 (s, 3H), 3.23-3.20 (m, 1 H), 3.10-3.00 (m, 2H), 2.89 (s, 3H), 2.64- 2.58 (m, 1 H). LCMS (M+H): 439.25.
[00317] Example 201 : 1-(7-Fluoro-1-methyl-3-phenylisoquinolin-4-yl)-3- (4-hydroxy-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea. 1 H NMR (DMSO- d6, 300 MHz): 5 7.91 (dd, J = 2.1 and 9.9 Hz, 1 H), 7.69 (br s, 1 H), 7.53-7.50 (m, 5H), 7.41-7.35 (m, 7H), 6.28 (br s, 1 H ), 5.44 (br s, 1 H), 4.30-4.23 (m, 1 H), 3.51- 3.47 (m, 2H), 3.28 (s, 3H), 3.24-3.15 (m, 3H), 2.84 (s, 3H), 2.80-2.75 (m, 3H), 2.61-2.58 (m, 1 H). LCMS (M+H): 515.35.
[00318] Example 202: 1-(4-Fluoro-1-(2-methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(7-fluoro-1-methyl-3-phenylisoquinolin-4-yl)urea. 1 H NMR (CDCb, 300 MHz): δ 7.67 (d, J = 7.5 Hz, 2H), 7.50-7.42 (m, 4H), 7.40-7.33 (m, 5H), 7.22- 7.17 (m, 3H), 5.91 (br s, 1 H), 4.63-4.53 (m, 1 H), 3.46 (t, J = 5.4 Hz, 2H), 3.32 (s, 3H), 3.16-3.06 (m, 2H), 3.01-2.97 (m, 1 H), 2.93 (s, 3H), 2.75-2.73 (m, 2H), 2.63-2.61 (m, 1 H). LCMS (M+H): 517.33.
[00319] Biological Activity Example A: TrkA cell based phosphorylation assay
Recombinant AD293 cells overexpressing human TrkA were used to determine TrkA Y490 phosphorylation upon NGF stimulation. 25k cells plated in serum free DMEM medium in a 96 well plate were serum starved for 2 hours at 37°C in 5% C02 incubator. Test compounds were added to the plate at a final concentration of 2.5% DMSO and incubated for 20 min at 37°C. 6nM NGF was added and incubated for 5 min at 37°C. The plate was immediately centrifuged at 2000 rpm for 1 min and media removed. Lysis buffer containing 1 % NP-40 Substitute, 20 mMTris (pH 8.0), 137 mMNaCI final concentrations was added, mixed for one minute and kept on ice for 15 min with shaking every 5 minutes. 100 ul of the cell lysate was added to the PathScan® Phospho-TrkA (Tyr490) Sandwich ELISA plate with precoated wells and ELISA performed according to the manufacturer's instructions for color development. IC50 was generated in Graph Pad Prism software in non linear regression format. IC50 for representative compounds of this invention are provided below in Table 2.
Table 2: TrkA Cell based activity for representative compounds
Figure imgf000091_0001
[00320] The +++ represents IC50 of <100 nM, the ++ represents IC50 range between 100 nM to 1000 nM and the + represents IC50 of >1000 nM.

Claims

CLAIMS We claim:
1. A compound of Formula I :
Figure imgf000092_0001
Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, isotopes, solvates, prodrugs or metabolites thereof, wherein:
Ra and Rb are each independently selected from H, alkyl, alkenyl, alkynyl, haloalkyi, halogen, hydroxy, hydroxyalkyi, alkox, haloalkoxy, optionally substituted phenyl, optionally substituted 5-6 membered aromatic ring having 1- 3 heteroatoms selected from O, N, and S or Ra and Rb together forms carbonyl group, optionally substituted phenyl which is further optionally substituted with a halogen;
Rc and Rd is H, alkyl, alkenyl, alkynyl, haloalkyi, hydroxy, alkoxy, haloalkoxy, optionally substituted phenyl, optionally substituted 5-6 membered aromatic ring having 1-3 heteroatoms selected from O, N, or S or Rc and Rd together form a ring (4-6 membered) with or without a hetero atom;
R1 is H, alkyl, alkenyl, alkynyl, haloalkyi , hydroxy, alkoxy, haloalkoxy, (1-3C alkoxy) (l-3C)alkyl, (1-4C alkoxycarbonyl) (1-6Calkyl), mono, di, tri halo(1-4C alkyl), (1-3C alkyl)aminocarbonyl, Cyano(1-3C alkyl), (1-3C haloalkoxy)(1-3C)alkyl, optionally substituted phenyl, 3-6 membered carbocyclic or heterocyclic ring with one or more heteroatom selected from O, N orS and optionally substituted with one or more substituents independently selected from H, alkyl, alkenyl, alkynyl, haloalkyi, halogen, hydroxy, alkoxy, haloalkoxy, nitro or amino, a 9-10 membered bicyclic heteroaryl having 1-3 ring nitrogen atoms; R2 and R3 are independently selected from H, alkyi, alkenyl, alkynyl, isopropyl, tert butyl, haloalkyi, halogen, hydroxy, alkoxy, haloalkoxy, optionally substituted phenyl, or optionally substituted 5-6 membered aromatic ring having 1-3 heteroatoms selected from O, N or S or R2 and R3 can be combined to form a ring (5/6-membered) with 1-
2 hetero atoms;
L is a ligand selected from— O— , — NH— , — S02N(R')— , — C(0)N(R')— ; — N(R')C(0)— , — C(0)N(R')C(0)— , — N(R')S02— , — N(R')S02N(R')— , — NR'C(0)N(R')— , — NR'C(S)N(R')— , or — N(R')C(0)0— ;each R' is independently selected from H or alkyi;
Het-Ar ring is selected from H1 or H2;
Figure imgf000093_0001
X1-X7 at each occurrence is a bond, -CR5-, -CH2, or an heteroatom selected from N, O or S; X8 is selected from O, S, NH, N-alkyl, SO, S02 or C=0;
R4, R5 and R6 are each independently selected from the group consisting of H, alkyi, alkenyl, alkynyl, isopropyl, tert. Butyl, haloalkyi, halogen, mono, di, tri halo(1-4C alkyi) hydroxy, alkoxy, haloalkoxy, cyano, cycloalkyl(3-7 carbon), optionally substituted phenyl, optionally substituted 5-6 membered heterocyclic ring having 1-3 heteroatoms selected from O, N, or S or 3-6 membered carbocyclic ring having one or more heteroatom selected from O, N or S,— NH2,— N(H)(alkyl),— N(alkyl)2,— N(H)C(0)alkyl,— N(alkyl)C(0)alkyl, — N(H)C(0)0 alkyl, — N(alkyl)C(0)Oalkyl, — N(H)S02(alkyl), —
N(alkyl)S02(alkyl),— C(0)alkyl, — C(0)OH, — C(0)Oalkyl, — C(0)NH2, —
C(0)N(H)(alkyl), — C(0)N(alkyl)2, — S(alkyl), — S(0)alkyl, — S(0)2alkyl, — S(0)2N(H)2,— S(0)2N(H)(alkyl) and— S(0)2N(alkyl)2. 2. The compound according to claim 1 , wherein L is selected from urea or optionally substituted urea.
3. The compound according to claim 1 , wherein H1 is selected from the group consisting of:
Figure imgf000094_0001
H1 E H1 F and R4, R5 are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, isopropyl, tert. Butyl, haloalkyl, halogen, mono, di, tri halo(1-4C alkyl) hydroxy, alkoxy, haloalkoxy, cyano, cycloalkyl(3-7 carbon), optionally substituted phenyl, optionally substituted 5-6 membered heterocyclic ring having 1-3 heteroatoms selected from O, N, or S or 3-6 membered carbocyclic ring having one or more heteroatom selected from O, N or S, — NH2, — N(H)(alkyl), — N(alkyl)2, — N(H)C(0)alkyl, — N(alkyl)C(0)alkyl,— N(H)C(0)0 alkyl,— N(alkyl)C(0)Oalkyl,— N(H)S02(alkyl), — N(alkyl)S02(alkyl), — C(0)alkyl, — C(0)OH, — C(0)Oalkyl, — C(0)NH2, — C(0)N(H)(alkyl), — C(0)N(alkyl)2, — S(alkyl), — S(0)alkyl, — S(0)2alkyl, — S(0)2N(H)2,— S(0)2N(H)(alkyl) and— S(0)2N(alkyl)2.
4. The compound according to claim 1 , wherein H2 is selected from the group consisting of:
Figure imgf000095_0001
H2A H2B H2C
Figure imgf000095_0002
H2D H2E and each R6 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, isopropyl, tert. Butyl, haloalkyi, halogen, mono, di, tri halo(1-4C alkyl) hydroxy, alkoxy, haloalkoxy, cyano,, cycloalkyl (3-7 carbon), optionally substituted phenyl, optionally substituted 5-6 membered heterocyclic ring having 1-3 heteroatoms selected from O, N, or S or 3-6 membered carbocyclic ring having one or more heteroatom selected from O, N or S, — NH2, — N(H)(alkyl), — N(alkyl)2, — N(H)C(0)alkyl, — N(alkyl)C(0)alkyl, — N(H)C(0)Oalkyl,— N(alkyl)C(0)Oalkyl,— N(H)S02(alkyl),— N(alkyl)S02(alkyl), — C(0)alkyl, — C(0)OH, — C(0)Oalkyl, — C(0)NH2, — C(0)N(H)(alkyl), — C(0)N(alkyl)2, — S(alkyl), — S(0)alkyl, — S(0)2alkyl, — S(0)2N(H)2, — S(0)2N(H)(alkyl) and— S(0)2N(alkyl)2. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I in claim 1 or a pharmaceutically acceptable salt thereof.
The pharmaceutical composition of claim 5, wherein the composition is used for treating or preventing a disorder or disease caused by abnormal or deregulated TrkA activity.
The pharmaceutical composition of claim 6, wherein said disease or disorder is selected from the group consisting of Pain, inflammation or inflammatory diseases, Cancer, atherosclerosis, restenosis, thrombosis, Neurodegenerative diseases, Erectile Dysfunction (ED), Skin disorders, Autoimmune disease, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, Infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
A method for treating a disease or disorder mediated by the Trk receptors or associated with abnormal or deregulated TrkA kinase activity wherein said disease or disorder is selected from the group consisting of Pain, inflammation or inflammatory diseases, Cancer, atherosclerosis, restenosis, thrombosis, Neurodegenerative diseases, Erectile Dysfunction (ED), Skin disorders, Autoimmune disease, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, Infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk- A in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The method of claim 8, wherein the inflammatory disease is selected from the group consisting of lung diseases, bowel diseases, interstitial cystitis or painful bladder syndrome.
The method of claim 8, wherein the pain includes chronic and acute pain. The method of claim 10, wherein the pain is related to cancer induced pain, bone fracture pain, inflammatory pain, neuropathic pain, surgery, bone fracture, skeletal pain caused by tumor metastasis, osteoarthritis, psoriatic arthritis, rheumatoid arthritis, interstitial cystitits, chronic pancreatitis, visceral pain, inflammatory pain, migraine, chronic lower back pain, bladder pain syndrome.
The method of claim 8, wherein the diseases resulting from abnormal tissue remodelling and fibrotic disorders is selected from the group comprising of Idiopathic pulmonary fibrosis, Raynaud's syndrome, endometrial fibrosis, atrial fibrosis, myelofibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, scleroderma, systemic sclerosis, atherofibrosis, ocular fibrosis, scarring and cirrhosis
The method of claim 8, wherein the cancer is related to dysregulation of TrkA.
The method of claim 13, wherein the dysregulation of TrkA comprises one or more chromosome translocations or inversions resulting in TrkA gene fusions.
The method of claim 14, wherein the TrkA gene fusion is LMNA-TrkA, TFG-TrkA, TPM3-TrkA, CD74-TrkA, NFASC-TrkA, MPRIP-TrkA, BCAN- TrkA, TP53-TrkA, RNF213-TrkA, RABGAP1 L-TrkA, IRF2BP2-TrkA, SQSTMI-TrkA, SSBP2-TrkA, or TPR-TrkA.
The method of claim 8 and 13, wherein the dysregulation of TrkA comprises one or more deletions, insertions or mutations in the TrkA protein.
The method of claim 8, wherein the cancer is selected from the group comprising of lung adenocarcinomas, breast cancer, thyroid carcinoma, pancreatic cancer, papillary thyroid carcinoma, ovarian carcinoma, gastric carcinoma, malignant mesothelioma, prostate carcinoma, neuroblastic tumors, colorectal carcinoma, spitzoid melanoma, salivary adenoid cystic carcinoma glioblastoma multiforme, stomach cancer, kidney cancer, urethral cancer, oral squamous cell carcinoma, mastocytosis, extramammary Paget's disease, Acute Myeloid Leukemia, cholangiocarcinomaor sarcoma.
A compound which is:
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(quinolin-3- yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2- phenylquinolin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2- methylquinolin-3-yl)urea
• 1-(2-Ethylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(2-Cyclopropylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(2-(Trifluoromethyl)quinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(6-Fluoro-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(6-Fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(5-fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(8-fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(7-fluoro-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea • 1-(7-fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(6-methoxy-2- phenylquinolin-3-yl)urea
• 1 -(7-methoxy-2-phenylquinolin-3-yl) -3-((3S,4R)-1- 2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1 -(8-methoxy-2-phenylquinolin-3-yl) -3-((3S,4R)-1- 2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1 -(5-methoxy-2-phenylquinolin-3-yl) -3-((3S,4R)-1- 2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(5-methoxy-2-methylquinolin-3-yl) -3-((3S,4R)-1- 2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(6-methoxy-2-methylquinolin-3-yl) -3-((3S,4R)-1- 2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(7-methoxy-2-methylquinolin-3-yl) -3-((3S,4R)-1- 2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(8-methoxy-2-methylquinolin-3-yl) -3-((3S,4R)-1- 2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(6,7-dimethoxy-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)- 4-phenylpyrrolidin-3-yl)urea
• 1-(6,7-dimethoxy-2-methylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)- 4-phenylpyrrolidin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(6,7- dimethoxyquinolin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(6-methyl-2- phenylquinolin-3-yl)urea
• 1-(2,6-dimethylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(2,7-dimethylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea • 1-(2,5-dimethylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(2,8-dimethylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(7-methyl-2- phenylquinolin-3-yl)urea
• 1-(2-chloroquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-(1-methyl- 1 H-pyrazol-4-yl)quinolin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-(pyridin-3- yl)quinolin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-(pyridin-4- yl)quinolin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-(pyrimidin- 5-yl)quinolin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2- morpholinoquinolin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(quinolin-4- yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(quinazolin-4- yl)urea
• 1-(2-chloro-6,7-dimethoxyquinazolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(quinoxalin-2- yl)urea
• 1-(2-isopropylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(2-tert-butylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea • 1-(6-methoxy-2-methyl-7-morpholinoquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(6-fluoro-7-methyl-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(6-bromo-8-methoxy-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(7-fluoro-6-methoxy-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(7-fluoro-6-methoxy-2-methylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(8-methoxy-7-methyl-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(6-methoxy-2,7-dimethylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)- 4-phenylpyrrolidin-3-yl)urea
• 1-(7-fluoro-6-methyl-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(7-fluoro-2,6-dimethylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(6-phenyl- [1 ,3]dioxolo[4,5-g]quinolin-7-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(6-methyl- [1 ,3]dioxolo[4,5-g]quinolin-7-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(7-methyl-2,3- dihydro-[1 ,4]dioxino[2,3-g]quinolin-8-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(7-phenyl-2,3- dihydro-[1 ,4]dioxino[2,3-g]quinolin-8-yl)urea
• 1-(6-amino-7-methoxy-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(7-methoxy-6-(methylamino)-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea • N-(7-methoxy-3-(3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)ureido)-2-phenylquinolin-6-yl)acetamide
• N-(7-methoxy-3-(3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)ureido)-2-methylquinolin-6-yl)acetamide
• N-(6-methoxy-3-(3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)ureido)-2-phenylquinolin-7-yl)acetamide
• N-(6-methoxy-3-(3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)ureido)-2-methylquinolin-7-yl)acetamide
• 1-(8-methoxy-6-(1-methyl-1 H-pyrazol-4-yl)-2-phenylquinolin-3-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-methyl-8-(1- methyl-1 H-pyrazol-4-yl)quinolin-3-yl)urea
• 1-((3S,4R)-4-(3,4-Difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3- (quinolin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(naphthalen-2- yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(naphthalen-2- yl)urea
• 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3- (2-(pyridin-3-yl)quinolin-3-yl)urea
• 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3- (2-methylquinolin-3-yl)urea
• 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3- (6,7-dimethoxy-2-methylquinolin-3-yl)urea
• 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3- (6,7-dimethoxyquinolin-3-yl)urea
• 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3- (quinolin-3-yl)urea
• 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2- methylquinolin-3-yl)urea • 1-(6-fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-4-(3-fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)urea
• 1-(7-fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-4-(3-fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)urea
• 1-(6,7-Dimethoxy-2-phenylquinolin-3-yl)-3-((3S,4R)-4-(3-fluorophenyl)- 1-(2-methoxyethyl)pyrrolidin-3-yl)urea
• 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(6- phenyl-[1 ,3]dioxolo[4,5-g]quinolin-7-yl)urea
• 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(6- methyl-[1 ,3]dioxolo[4,5-g]quinolin-7-yl)urea
• 1-((3S,4R)-4-(3-Cyanophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3- (quinolin-3-yl)urea
• 1-((3S,4R)-4-(3-cyanophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(6,7- dimethoxy-2-phenylquinolin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-(pyridin-3-yl)pyrrolidin-3-yl)-3-(quinolin-
3- yl)urea
• 1-(6,7-dimethoxy-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-
4- (pyridin-3-yl)pyrrolidin-3-yl)urea
• 1-((3S,4R)-4-tert-butyl-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(quinolin-3- yl)urea
• 1-(6,7-dimethoxy-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)- 4-(1 -methyl- 1 H-pyrazol-4-yl)pyrrolidin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-(1-methyl-1 H-pyrazol-4-yl)pyrrolidin-3- yl)-3-(quinolin-3-yl)urea
• 1-((3S,4R)-1-(2-Methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-1 ,8- naphthyridin-3-yl)urea
• Methyl 2-((3S,4R)-3-(3-(6,7-dimethoxy-2-phenylquinolin-3-yl)ureido)-4- phenylpyrrolidin-1-yl)acetate
• Methyl 2-((3R,4S)-3-phenyl-4-(3-(quinolin-3-yl)ureido)pyrrolidin-1- yl)acetate • 1-((3S,4R)-1-(2-fluoroethyl)-4-phenylpyrrolidin-3-yl)-3-(6,7-dimethoxy-2- phenylquinolin-3-yl)urea
• 1-((3R,4S)-1-(2-fluoroethyl)-4-phenylpyrrolidin-3-yl)-3-(6,7-dimethoxy-2- phenylquinolin-3-yl)urea
• 1-((3S,4R)-1-(2-fluoroethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenylquinolin- 3-yl)urea
• 1-((3S,4R)-1-(2-fluoroethyl)-4-phenylpyrrolidin-3-yl)-3-(quinolin-3- yl)urea
• 1-((3S,4R)-1-(2,2,2-trifluoroethyl)-4-phenylpyrrolidin-3-yl)-3-(6,7- dimethoxy-2-phenylquinolin-3-yl)urea
• 1-((3R,4S)-1-(2,2,2-trifluoroethyl)-4-phenylpyrrolidin-3-yl)-3-(6,7- dimethoxy-2-phenylquinolin-3-yl)urea
• 1-((3S,4R)-1-(2,2,2-trifluoroethyl)-4-phenylpyrrolidin-3-yl)-3-(quinolin-3- yl)urea
• 1-((3S,4R)-1-(2,2-difluoroethyl)-4-phenylpyrrolidin-3-yl)-3-(6,7- dimethoxy-2-phenylquinolin-3-yl)urea
• 1-((3S,4R)-1-(2,2-difluoroethyl)-4-phenylpyrrolidin-3-yl)-3-(quinolin-3- yl)urea
• 1-(6,7-dimethoxy-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyacetyl)-4-phenylpyrrolidin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyacetyl)-4-phenylpyrrolidin-3-yl)-3-(quinolin-3- yl)urea
• 1-(6,7-dimethoxy-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(oxetan-3-yl)-4- phenylpyrrolidin-3-yl)urea
• 2-((3S,4R)-3-(3-(6,7-dimethoxy-2-phenylquinolin-3-yl)ureido)-4- phenylpyrrolidin-1-yl)acetamide
• 1-((3S,4R)-1-(cyanomethyl)-4-phenylpyrrolidin-3-yl)-3-(6,7-dimethoxy-2- phenylquinolin-3-yl)urea
• 1-((3S,4R)-1-(cyanomethyl)-4-phenylpyrrolidin-3-yl)-3-(quinolin-3- yl)urea
• 2-((3R,4S)-3-phenyl-4-(3-(quinolin-3-yl)ureido)pyrrolidin-1-yl)acetamide • 1-(1-(2-Methoxyethyl)-2-oxo-4-phenylpyrrolidin-3-yl)-3-(quinolin-3- yl)urea
• 1-(dibenzo[b,d]furan-1-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(dibenzo[b,d]furan-1-yl)-3-((3S,4R)-4-(3-fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(8- methyldibenzo[b,d]furan-1-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(8- methoxydibenzo[b,d]furan-1-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(8- fluorodibenzo[b,d]furan-1-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(7- methoxydibenzo[b,d]furan-1-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(7- fluorodibenzo[b,d]furan-1-yl)urea
• 1-(dibenzo[b,d]thiophen-1-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(5,5-Dioxodibenzo[b,d]thiophen-1-yl)-3-[1-(2-methoxy-ethyl)-4-phenyl- pyrrolidin-3-yl]-urea
• 1-(4-methoxydibenzo[b,d]thiophen-1-yl)-3-((3S,4R)-1-(2-methoxyethyl)- 4-phenylpyrrolidin-3-yl)urea
• 1-(4-methoxy-5,5-Dioxodibenzo[b,d]thiophen-1-yl)-3-[1-(2-methoxy- ethyl)-4-phenyl-pyrrolidin-3-yl]-urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(9-oxo-9H- fluoren-4-yl)urea
• 1-(6-methoxydibenzo[b,d]furan-1-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(6-methyldibenzo[b,d]furan-1-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea • 1-(6-methoxy-7-methyl-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(6-cyano-7-fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(6-cyano-7-methoxy-2-methylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(7-cyano-6-fluoro-2-methylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(7-cyano-6-fluoro-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(7-cyano-6-methoxy-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-(thiazol-5- yl)quinolin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl- 5,6,7,8-tetrahydroquinolin-3-yl)urea
• 1-(6,7-dimethoxy-2-phenylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)- 4-phenylpyrrolidin-3-yl)-1 ,3-dimethylurea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-1-methyl-3-(2- phenylquinolin-3-yl)urea
• 1-(6-(difluoromethoxy)-7-methoxy-2-methylquinolin-3-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(2,2-difluoro-6-methyl-[1 ,3]dioxolo[4,5-g]quinolin-7-yl)-3-((3S,4R)-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(6-(difluoromethyl)-[1 ,3]dioxolo[4,5-g]quinolin-7-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-([1 ,3]dioxolo[4,5-g]quinolin-7-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(2-cyclohexylquinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea • 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(6- (trifluoromethyl)-[1 ,3]dioxolo[4,5-g]quinolin-7-yl)urea
• 1 -(6-(difluoromethyl)-[1 ,3]dioxolo[4,5-g]quinolin-7-yl)-3-((3S,4R)-4-(3- fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea
• 1-([1 ,3]dioxolo[4,5-g]quinolin-7-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1- (2-methoxyethyl)pyrrolidin-3-yl)urea
• 1-(6-fluoro-2-phenylquinolin-3-yl)-3-((3S,4R)-4-(3-fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)urea
• 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2- phenyl-5,6,7,8-tetrahydroquinolin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(7-methyl-2- phenyl-1 ,8-naphthyridin-3-yl)urea
• 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2- phenylquinolin-3-yl)urea
• 1-([1 ,3]dioxolo[4,5-g]quinolin-7-yl)-3-((3S,4R)-4-(3-fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)urea
• 1-(2-(2,4-difluorophenyl)quinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4 phenylpyrrolidin-3-yl)urea
• 1-(2-(3,5-difluorophenyl)quinolin-3-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4 phenylpyrrolidin-3-yl)urea
• 1-(4-(benzyloxy)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(6-methyl- [1 ,3]dioxolo[4,5-g]quinolin-7-yl)urea
• 1-(1-chloro-3-methylisoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(1 ,3-diphenylisoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3- methyl-1-(1-methyl-1 H-pyrazol-4-yl)isoquinolin-4-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(1-(1-methyl- 1 H-pyrazol-4-yl)-3-phenylisoquinolin-4-yl)urea • 1-(isoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(3- phenylisoquinolin-4-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(3- methylisoquinolin-4-yl)urea
• 1-(1-cyano-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(1-chloro-3-phenylisoquinolin-4-yl)-3-((3S,4R)-4-(3-fluorophenyl)-1-(2 methoxyethyl)pyrrolidin-3-yl)urea
• 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3- phenylisoquinolin-4-yl)urea
• 1-(1-cyano-3-phenylisoquinolin-4-yl)-3-((3S,4R)-4-(3-fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)urea
• 1-(1-Hydroxy-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)- 4-phenylpyrrolidin-3-yl)urea
• 1-(1-amino-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(1-methoxy-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)- 4-phenylpyrrolidin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(1-methyl-3- phenylisoquinolin-4-yl)urea
• 1-(7-fluoro-1-methyl-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-(1- methyl-1 H-pyrazol-4-yl)-3-phenylisoquinolin-4-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(3-methyl-1-(1 methyl-1 H-pyrazol-4-yl)isoquinolin-4-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(1-(1-methyl- 1 H-pyrazol-4-yl)isoquinolin-4-yl)urea • 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-(1- methyl-1 H-pyrazol-4-yl)isoquinolin-4-yl)urea
• 1-(3-(tert-butyl)-1-(1-methyl-1 H-pyrazol-4-yl)isoquinolin-4-yl)-3- ((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea
• 1-(3-(tert-butyl)-1-(1-methyl-1 H-pyrazol-4-yl)isoquinolin-4-yl)-3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(1-fluoro-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1- methyl-3-phenylisoquinolin-4-yl)urea
• 1-(7-methoxy-1-methyl-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(6-methoxy-1-methyl-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(1 ,6-dimethyl-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(3-phenyl-1- (pyridin-3-yl)isoquinolin-4-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(1-morpholino- 3-phenylisoquinolin-4-yl)urea
• 1-(1-(4-hydroxypiperidin-1-yl)-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(3-(3-fluorophenyl)-1-methylisoquinolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(3-(2-fluorophenyl)-1-methylisoquinolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(6,7-dimethoxy-1-methyl-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(6-fluoro-1-methyl-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea • 1-(1 ,7-dimethyl-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 4-(3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)ureido)-3- phenylisoquinoline-1-carboxamide
• 1-(8-methoxy-1-methyl-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1-(8-fluoro-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(7-fluoro-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-(7-fluoro-3-phenylisoquinolin-4-yl)-3-((3S,4R)-4-(3-fluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3-yl)urea
• 1-(5-methoxy-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)- 4-phenylpyrrolidin-3-yl)urea
• 1-(7-fluoro-1-methyl-3-phenylisoquinolin-4-yl)-3-((3S,4R)-4-(3- fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea
• 1-(3-cyanoisoquinolin-4-yl)-3-((3S,4R)-1-(2-methoxyethyl)-4- phenylpyrrolidin-3-yl)urea
• 1-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(3-phenyl-1- (piperazin-1-yl)isoquinolin-4-yl)urea
• 1-(1-cyano-7-fluoro-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
• 1 -(1 -(difluoromethyl)-3-phenylisoquinolin-4-yl)-3-((3S,4R)-4-(3- fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea
• 7-fluoro-4-(3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)ureido)-3-phenylisoquinoline-1-carboxylic acid
• 7-fluoro-4-(3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)ureido)-3-phenylisoquinoline-1-carboxamide
• 4-(3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)ureido)isoquinoline-3-carboxamide methyl 2-((7-fluoro-4-(3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin- 3-yl)ureido)-3-phenylisoquinolin-1-yl)(methyl)amino)acetate
2- ((7-fluoro-4-(3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)ureido)-3-phenylisoquinolin-1-yl)(methyl)amino)acetic acid
1- (7-fluoro-1-((2-hydroxyethyl)(methyl)amino)-3-phenylisoquinolin-4-yl)-
3- ((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
ethyl 2-((4-(3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3- yl)ureido)-3-phenylisoquinolin-7-yl)oxy)acetate
2- ((4-(3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)ureido)-3- phenylisoquinolin-7-yl)oxy)acetic acid
1-(7-(2-hydroxyethoxy)-3-phenylisoquinolin-4-yl)-3-((3S,4R)-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
1-(4-(benzyloxy)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(7-fluoro-1-methyl-
3- phenylisoquinolin-4-yl)urea
1-(7-fluoro-1-methyl-3-phenylisoquinolin-4-yl)-3-(4-hydroxy-1-(2- methoxyethyl)pyrrolidin-3-yl)urea
1-(7-fluoro-1-methyl-3-phenylisoquinolin-4-yl)-3-(4-hydroxy-1-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
1-(4-fluoro-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(7-fluoro-1- methyl-3-phenylisoquinolin-4-yl)urea or stereoisomers, tautomers, or pharmaceutically acceptable salts, isotopes, solvates, prodrugs or metabolites thereof.
PCT/IB2016/050328 2015-01-23 2016-01-22 Inhibitors of trka kinase WO2016116900A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BR112017015760-8A BR112017015760A2 (en) 2015-01-23 2016-01-22 trka kinase inhibitors
CN201680017646.8A CN107531589A (en) 2015-01-23 2016-01-22 Trka kinase inhibitors
EP16739869.2A EP3247692B1 (en) 2015-01-23 2016-01-22 Inhibitors of trka kinase
CA2974784A CA2974784A1 (en) 2015-01-23 2016-01-22 Inhibitors of trka kinase
JP2017557507A JP6706630B2 (en) 2015-01-23 2016-01-22 Inhibitor of TrkA kinase
US15/545,061 US10336723B2 (en) 2015-01-23 2016-01-22 Inhibitors of TrkA kinase
RU2017129757A RU2017129757A (en) 2015-01-23 2016-01-22 TRKA KINASE INHIBITORS
AU2016210544A AU2016210544B2 (en) 2015-01-23 2016-01-22 Inhibitors of TrkA kinase
AU2020223776A AU2020223776A1 (en) 2015-01-23 2020-08-28 Inhibitors of TrkA kinase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN362/CHE/2015 2015-01-23
IN362CH2015 2015-01-23

Publications (1)

Publication Number Publication Date
WO2016116900A1 true WO2016116900A1 (en) 2016-07-28

Family

ID=56416506

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/050328 WO2016116900A1 (en) 2015-01-23 2016-01-22 Inhibitors of trka kinase

Country Status (9)

Country Link
US (1) US10336723B2 (en)
EP (1) EP3247692B1 (en)
JP (1) JP6706630B2 (en)
CN (1) CN107531589A (en)
AU (2) AU2016210544B2 (en)
BR (1) BR112017015760A2 (en)
CA (1) CA2974784A1 (en)
RU (1) RU2017129757A (en)
WO (1) WO2016116900A1 (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106749098A (en) * 2016-12-07 2017-05-31 大连万福制药有限公司 A kind of friendly process for preparing dioxopromethazine hydrochloride as oxidant with oxygen
WO2017135399A1 (en) * 2016-02-04 2017-08-10 塩野義製薬株式会社 Nitrogen-containing heterocycle having trka inhibitory activity, and carbocyclic derivative
US9822069B2 (en) 2013-11-28 2017-11-21 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
WO2018079759A1 (en) * 2016-10-31 2018-05-03 塩野義製薬株式会社 Fused heterocycle having trka inhibitory activity and fused carbocycle derivative
US10160727B2 (en) 2014-08-06 2018-12-25 Shionogi & Co., Ltd. Heterocycle and carbocycle derivatives having TrkA inhibitory activity
WO2019054451A1 (en) * 2017-09-15 2019-03-21 持田製薬株式会社 Crystals of tetrahydronaphthyl urea derivative
US20190120823A1 (en) * 2017-08-22 2019-04-25 Scripps Health Methods of treating a neuroendocrine tumor
WO2020011227A1 (en) 2018-07-12 2020-01-16 南京明德新药研发有限公司 Pyrrolidinyl urea derivatives and application thereof in trka-related diseases
US10640495B2 (en) 2015-07-07 2020-05-05 Shionogi & Co., Ltd. Heterocycle derivatives having TrkA inhibitory activity
US10676431B2 (en) 2018-03-05 2020-06-09 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021139794A1 (en) 2020-01-10 2021-07-15 漳州片仔癀药业股份有限公司 Crystal form of pyrrolidinyl urea derivative and application thereof
WO2021139795A1 (en) 2020-01-10 2021-07-15 漳州片仔癀药业股份有限公司 Method for preparing pyrrolidinyl urea derivative
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US11149035B2 (en) 2017-06-13 2021-10-19 Glaxosmithkline Intellectual Property Dfvelopment Limited Chemical compounds as H—PGDS inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11780840B2 (en) 2020-07-02 2023-10-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108314648A (en) * 2018-04-12 2018-07-24 苏州康润医药有限公司 The synthetic method of the bromo- 7- fluorine isoquinolin of 4-
CN108947900B (en) * 2018-08-06 2021-07-30 河南大学 Method for synthesizing heterocyclic compound by photoinduced metal-free catalyzed carbon arylation cascade reaction
CN112979615A (en) * 2019-12-17 2021-06-18 上海医药集团股份有限公司 Quinazoline urea compound, preparation method, preparation intermediate, pharmaceutical composition and application thereof
CN115850480B (en) * 2022-09-23 2023-05-30 北京诺赛国际医学研究院 Preparation method of stem cell exosome and application of stem cell exosome in treatment of male erectile dysfunction

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026836A2 (en) * 2002-09-17 2004-04-01 Actelion Pharmaceuticals Ltd 1-pyridin-4-yl-urea derivatives
WO2005061540A2 (en) 2003-12-24 2005-07-07 Lay Line Genomics S.P.A. Method for the humanization of antibodies and humanized antibodies thereby obtained
EP1499607B1 (en) * 2001-12-04 2005-12-07 Actelion Pharmaceuticals Ltd. 4-(piperidyl- and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists
WO2006131952A1 (en) 2005-06-07 2006-12-14 Lay Line Genomics S.P.A. Novel analgesic treatment with prolonged effect
WO2008021924A1 (en) * 2006-08-09 2008-02-21 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EP1364212B1 (en) * 2001-03-02 2011-02-02 GPC Biotech AG Three hybrid assay system
WO2011147951A1 (en) 2010-05-28 2011-12-01 Prosidion Limited Cycloamino derivatives as gpr119 antagonists
WO2012125668A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2014052566A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014078378A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
AU2015200511A1 (en) 2008-10-22 2015-02-19 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
US20150336970A1 (en) 2010-05-20 2015-11-26 Array Biopharma Inc. Macrocyclic compounds as trk kinase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364212B1 (en) * 2001-03-02 2011-02-02 GPC Biotech AG Three hybrid assay system
EP1499607B1 (en) * 2001-12-04 2005-12-07 Actelion Pharmaceuticals Ltd. 4-(piperidyl- and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists
WO2004026836A2 (en) * 2002-09-17 2004-04-01 Actelion Pharmaceuticals Ltd 1-pyridin-4-yl-urea derivatives
WO2005061540A2 (en) 2003-12-24 2005-07-07 Lay Line Genomics S.P.A. Method for the humanization of antibodies and humanized antibodies thereby obtained
WO2006131952A1 (en) 2005-06-07 2006-12-14 Lay Line Genomics S.P.A. Novel analgesic treatment with prolonged effect
WO2008021924A1 (en) * 2006-08-09 2008-02-21 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
AU2015200511A1 (en) 2008-10-22 2015-02-19 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
US20150336970A1 (en) 2010-05-20 2015-11-26 Array Biopharma Inc. Macrocyclic compounds as trk kinase inhibitors
WO2011147951A1 (en) 2010-05-28 2011-12-01 Prosidion Limited Cycloamino derivatives as gpr119 antagonists
WO2012125668A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2014052566A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014078378A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors

Non-Patent Citations (42)

* Cited by examiner, † Cited by third party
Title
ACTA DERM VENEREOL, vol. 95, 2015, pages 542 - 548
ACTANEUROPATHOL., vol. 96, no. 5, November 1998 (1998-11-01), pages 495 - 501
ANESTHESIOLOGY, vol. 115, no. 1, July 2011 (2011-07-01), pages 189 - 204
ARCHIVES OF DERMATOLOGICAL RESEARCH, vol. 298, no. 1, 2006, pages 31 - 37
BJU INT., vol. 108, no. 2, July 2011 (2011-07-01), pages 248 - 51
BONE, vol. 26, no. 6, June 2000 (2000-06-01), pages 625 - 33
BRAIN RES., vol. 867, no. 1-2, 9 June 2000 (2000-06-09), pages 149 - 56
CANCER DISCOV., vol. 5, no. 10, October 2015 (2015-10-01), pages 1049 - 57
CANCER DISCOVERY, vol. 5, 1 January 2015 (2015-01-01), pages 25
CANCER LETT, vol. 169, 2001, pages 107 - 14
CANCER RES., vol. 62, no. 4, 15 February 2002 (2002-02-15), pages 986 - 9
CASTELLO, G ET AL.: "HCV-related hepatocellular carcinoma: From chronic inflammation to cancer.", CLINICAL IMMUNOLOGY, vol. 134, 2010, pages 237 - 250, XP055469313 *
CELL HOST MICROBE., vol. 1, no. 4, 14 June 2007 (2007-06-14), pages 251 - 61
CLIN CANCER RES, vol. 7, 2001, pages 2237 - 45
CLINAUTON RES, vol. 12, 2002, pages 120 - 32
DIABET MED., vol. 26, no. 12, December 2009 (2009-12-01), pages 1228 - 34
EIRO, N ET AL.: "Inflammation and cancer", WORLD JOUMAL OF GASTROINTESTINAL SURGERY, vol. 4, no. 3, 27 March 2012 (2012-03-27), pages 62 - 72, XP055469172 *
EUROPEAN UROLOGY, November 2014 (2014-11-01)
EXPERT OPIN. THER. PATENTS, vol. 24, no. 7, 2014, pages 731 - 744
EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 19, 2009, pages 305 - 19
EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 24, no. 7, 2014, pages 731 - 744
FIBROGENESIS TISSUE REPAIR, vol. 5, no. 1, 6 June 2012 (2012-06-06), pages S24
GUT, vol. 46, no. 5, 2000, pages 670 - 678
HUM REPROD., vol. 24, no. 4, April 2009 (2009-04-01), pages 827 - 34
J ALZHEIMERS DIS., vol. 40, no. 3, 2014, pages 605 - 617
J CLINLMMUNOL., vol. 31, no. 6, December 2011 (2011-12-01), pages 1010 - 1020
J NATL CANCER INST., vol. 108, no. 1, 12 November 2015 (2015-11-12)
J. CHEM. SOC., CHEM. COMMUN., 1985, pages 1566 - 1567
J. INVESTIGATIVE DERMATOLOGY, vol. 122, no. 3, 2004, pages 812 - 819
J. MED. CHEM., vol. 55, 2012, pages 8903 - 8925
JIMENEZ-ANDRADE, JM ET AL.: "Pathological Sprouting of Adult Nociceptors in Chronic Prostate Cancer-Induced Bone Pain.", THE JOURNAL OF NEUROSCIENCE, vol. 30, no. 44, 3 November 2010 (2010-11-03), pages 14649 - 14656, XP055469176 *
JOURNAL OF ORGANIC CHEMISTRY, vol. 57, 1992, pages 4404 - 4414
MARDY, S ET AL.: "Congenilal Insensitivity to Pain with Anhidrosis: Novel Mutations in the TRKA (NTRK1) Gene Encoding A High-Affinity Receptor for Nerve Growth Factor.", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 64, 1999, pages 1570 - 1579, XP002947154 *
MOL CELL BIOL., vol. 20, no. 23, December 2000 (2000-12-01), pages 8655 - 66
MOLECULES, vol. 20, no. 6, 2015, pages 10657 - 10688
N ENGL J MED., vol. 328, no. 12, 25 March 1993 (1993-03-25), pages 847 - 54
PHARMACOLOGY &THERAPEUTICS, vol. 117, no. 1, 2008, pages 52 - 76
REPROD SCI., vol. 18, no. 12, December 2011 (2011-12-01), pages 1202 - 10
TALAMAS, FX ET AL.: "Discovery of N-[4-[6-tert-Butyl-5-methoxy-8-(6-methoxy-2-oxo-1 H-pyridin-3-yl)-3-quinolyl]phenyl] methanesulfonamide (RG7109), a Potent Inhibitor of the Hepatitis C Virus NS5B Polymerase.", JOUMAL OF MEDICAL CHEMISTRY, vol. 57, no. 5, 13 March 2014 (2014-03-13), pages 1914 - 1931, XP055343623 *
THE JOURNAL OF UROLOGY, vol. 173, no. 3, 2005, pages 1016 - 21
UROLOGY, vol. 59, no. 4, April 2002 (2002-04-01), pages 603 - 8
WIESNER T ET AL.: "Kinase fusions are frequent in Spitz tumors and spitzoid melanomas.", NATURE COMMUNICATIONS, vol. 5, 2014, pages 3116, XP055406782 *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10464891B2 (en) 2013-11-28 2019-11-05 Kyorin Pharmaceuticals Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
US10696630B2 (en) 2013-11-28 2020-06-30 Kyorin Pharmaceuticals Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
US9822069B2 (en) 2013-11-28 2017-11-21 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
US10029983B2 (en) 2013-11-28 2018-07-24 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
US10252992B2 (en) 2013-11-28 2019-04-09 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
US11261155B2 (en) 2013-11-28 2022-03-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
US10160727B2 (en) 2014-08-06 2018-12-25 Shionogi & Co., Ltd. Heterocycle and carbocycle derivatives having TrkA inhibitory activity
US10532985B2 (en) 2014-08-06 2020-01-14 Shionogi & Co., Ltd. Heterocycle and carbocycle derivatives having TRKA inhibitory activity
US10640495B2 (en) 2015-07-07 2020-05-05 Shionogi & Co., Ltd. Heterocycle derivatives having TrkA inhibitory activity
US10781210B2 (en) 2016-02-04 2020-09-22 Shionogi & Co., Ltd. Nitrogen-containing heterocycle and carbocycle derivatives having TrkA inhibitory activity
US10533006B2 (en) 2016-02-04 2020-01-14 Shionogi & Co., Ltd. Nitrogen-containing heterocycle and carbocycle derivatives having TrkA inhibitory activity
WO2017135399A1 (en) * 2016-02-04 2017-08-10 塩野義製薬株式会社 Nitrogen-containing heterocycle having trka inhibitory activity, and carbocyclic derivative
US11008320B2 (en) 2016-02-04 2021-05-18 Shionogi & Co., Ltd. Nitrogen-containing heterocycle and carbocycle derivatives having TrkA inhibitory activity
WO2018079759A1 (en) * 2016-10-31 2018-05-03 塩野義製薬株式会社 Fused heterocycle having trka inhibitory activity and fused carbocycle derivative
CN106749098A (en) * 2016-12-07 2017-05-31 大连万福制药有限公司 A kind of friendly process for preparing dioxopromethazine hydrochloride as oxidant with oxygen
US11149035B2 (en) 2017-06-13 2021-10-19 Glaxosmithkline Intellectual Property Dfvelopment Limited Chemical compounds as H—PGDS inhibitors
US20190120823A1 (en) * 2017-08-22 2019-04-25 Scripps Health Methods of treating a neuroendocrine tumor
JPWO2019054451A1 (en) * 2017-09-15 2020-10-15 持田製薬株式会社 Crystals of tetrahydronaphthylurea derivative
WO2019054451A1 (en) * 2017-09-15 2019-03-21 持田製薬株式会社 Crystals of tetrahydronaphthyl urea derivative
JP7134983B2 (en) 2017-09-15 2022-09-12 持田製薬株式会社 Crystals of tetrahydronaphthyl urea derivatives
US11117861B2 (en) 2018-03-05 2021-09-14 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
US11708327B2 (en) 2018-03-05 2023-07-25 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
US10676431B2 (en) 2018-03-05 2020-06-09 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
WO2020011227A1 (en) 2018-07-12 2020-01-16 南京明德新药研发有限公司 Pyrrolidinyl urea derivatives and application thereof in trka-related diseases
US11932652B2 (en) 2018-07-12 2024-03-19 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Pyrrolidinyl urea derivatives and application thereof in TrkA-related diseases
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021139794A1 (en) 2020-01-10 2021-07-15 漳州片仔癀药业股份有限公司 Crystal form of pyrrolidinyl urea derivative and application thereof
WO2021139795A1 (en) 2020-01-10 2021-07-15 漳州片仔癀药业股份有限公司 Method for preparing pyrrolidinyl urea derivative
US11691965B2 (en) 2020-01-10 2023-07-04 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Method for preparing pyrrolidinyl urea derivative
US11708357B2 (en) 2020-01-10 2023-07-25 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Crystal form of pyrrolidinyl urea derivative and application thereof
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11780840B2 (en) 2020-07-02 2023-10-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors

Also Published As

Publication number Publication date
CN107531589A (en) 2018-01-02
RU2017129757A3 (en) 2019-06-06
AU2020223776A1 (en) 2020-10-01
US20180009781A1 (en) 2018-01-11
JP2018502930A (en) 2018-02-01
RU2017129757A (en) 2019-02-25
JP6706630B2 (en) 2020-06-10
CA2974784A1 (en) 2016-07-28
EP3247692A1 (en) 2017-11-29
EP3247692A4 (en) 2019-01-16
BR112017015760A2 (en) 2018-03-27
US10336723B2 (en) 2019-07-02
AU2016210544A1 (en) 2017-08-31
EP3247692B1 (en) 2022-09-07
AU2016210544B2 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
AU2016210544B2 (en) Inhibitors of TrkA kinase
JP6563623B1 (en) Pyridopyrimidinone CDK2 / 4/6 inhibitor
JP6482629B2 (en) N-pyrrolidinyl, N&#39;-pyrazolyl urea, thiourea, guanidine, and cyanoguanidine compounds as TRKA kinase inhibitors
CN109310690B (en) Isoquinolin-3-yl carboxamides, their preparation and their use
JP7023243B2 (en) Isoquinoline-3 yl-carboxamide and its preparation and method of use
JP6586104B2 (en) 5-Substituted indazole-3-carboxamides and methods for their preparation and use
AU2014272774B2 (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease
KR101877187B1 (en) Substituted dihydroisoquinolinone compounds
CN102015705B (en) Fused heterocyclic derivative and use thereof
JP2021520350A (en) BRM Targeted Compounds and Related Usage
CN110062758A (en) Two ring dihydro-pyrimidins-carboxamides derivatives as RHO- kinase inhibitor
JP7399848B2 (en) Inhibitors of Rho-related coiled-coil-containing protein kinases
AU2018312836B2 (en) Novel heterocyclic compounds as CDK8/19 inhibitors
EP2970260A1 (en) Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as ssao inhibitors
JP2017535536A (en) Carbazole derivatives
CN117062816A (en) Tricyclic-amide-bicyclic PRMT5 inhibitors
KR20200090636A (en) A pyrrolopyrimidine derivatives, and pharmaceutical composition for use in preventing or treating protein kinase related disease as an active ingredient
CN111655690B (en) Pyrazolopyridinone compounds
TW201300386A (en) 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives, preparation thereof and therapeutic use thereof
WO2019098211A1 (en) Annulated pyrazole derivative and medicinal use therefor
JP2019182805A (en) Fused pyrazole derivatives having linker site and pharmaceutical applications thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16739869

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017557507

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2974784

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017015760

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2016739869

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016210544

Country of ref document: AU

Date of ref document: 20160122

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112017015760

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170721